<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2F752A3-43CD-4ED6-9D9A-4059F81729EB"><gtr:id>E2F752A3-43CD-4ED6-9D9A-4059F81729EB</gtr:id><gtr:name>Edison Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A7C9204-3449-41D8-9C19-F3547150B67B"><gtr:id>9A7C9204-3449-41D8-9C19-F3547150B67B</gtr:id><gtr:name>Muscular Dystrophy UK</gtr:name><gtr:address><gtr:line1>61A Great Suffolk Street</gtr:line1><gtr:postCode>SE1 0BU</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1C6F835-8DA5-46B7-8126-6E733892FE0F"><gtr:id>A1C6F835-8DA5-46B7-8126-6E733892FE0F</gtr:id><gtr:name>AVI Biopharma, Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF"><gtr:id>C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF</gtr:id><gtr:name>University of Paris 6</gtr:name><gtr:address><gtr:line1>Bat 121</gtr:line1><gtr:line4>Paris</gtr:line4><gtr:postCode>F-75252</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BA9BFCD1-C860-4387-B150-BD302EFE4049"><gtr:id>BA9BFCD1-C860-4387-B150-BD302EFE4049</gtr:id><gtr:name>Free University of Berlin</gtr:name><gtr:address><gtr:line1>Kaiserswerther Str. 16-18</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FE65369-9DE6-4DDF-934F-F970C3CE6A81"><gtr:id>0FE65369-9DE6-4DDF-934F-F970C3CE6A81</gtr:id><gtr:name>Janus Developments</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/232FE897-4F2F-40BD-A92F-28CE006F8158"><gtr:id>232FE897-4F2F-40BD-A92F-28CE006F8158</gtr:id><gtr:name>San Raffaele del Monte Tabor Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE43EBFA-3FC9-44BC-B6FF-001F11664C46"><gtr:id>CE43EBFA-3FC9-44BC-B6FF-001F11664C46</gtr:id><gtr:name>Aarhus University</gtr:name><gtr:address><gtr:line1>Nordre Ringgade 1</gtr:line1><gtr:line4>Aarhus C</gtr:line4><gtr:line5>DK-8000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/618C6FA2-F2EB-4646-BB45-7927F09D69C4"><gtr:id>618C6FA2-F2EB-4646-BB45-7927F09D69C4</gtr:id><gtr:name>Helmholtz Zentrum M?nchen</gtr:name><gtr:address><gtr:line1>German Center f. Environmental Research</gtr:line1><gtr:line2>Ingolst?dter Landstr. 1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1AB05DA1-4DD6-4843-B416-D7D9441EBFFB"><gtr:id>1AB05DA1-4DD6-4843-B416-D7D9441EBFFB</gtr:id><gtr:name>Royal Veterinary College</gtr:name><gtr:address><gtr:line1>Royal College Street</gtr:line1><gtr:line2>Camden Town</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW1 0TU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D39EFE7-A4A8-4F9F-8BBA-D6265DA09CF2"><gtr:id>5D39EFE7-A4A8-4F9F-8BBA-D6265DA09CF2</gtr:id><gtr:name>Faculty of Biotechnology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2F752A3-43CD-4ED6-9D9A-4059F81729EB"><gtr:id>E2F752A3-43CD-4ED6-9D9A-4059F81729EB</gtr:id><gtr:name>Edison Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A7C9204-3449-41D8-9C19-F3547150B67B"><gtr:id>9A7C9204-3449-41D8-9C19-F3547150B67B</gtr:id><gtr:name>Muscular Dystrophy UK</gtr:name><gtr:address><gtr:line1>61A Great Suffolk Street</gtr:line1><gtr:postCode>SE1 0BU</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1C6F835-8DA5-46B7-8126-6E733892FE0F"><gtr:id>A1C6F835-8DA5-46B7-8126-6E733892FE0F</gtr:id><gtr:name>AVI Biopharma, Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF"><gtr:id>C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF</gtr:id><gtr:name>University of Paris 6</gtr:name><gtr:address><gtr:line1>Bat 121</gtr:line1><gtr:line4>Paris</gtr:line4><gtr:postCode>F-75252</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA9BFCD1-C860-4387-B150-BD302EFE4049"><gtr:id>BA9BFCD1-C860-4387-B150-BD302EFE4049</gtr:id><gtr:name>Free University of Berlin</gtr:name><gtr:address><gtr:line1>Kaiserswerther Str. 16-18</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FE65369-9DE6-4DDF-934F-F970C3CE6A81"><gtr:id>0FE65369-9DE6-4DDF-934F-F970C3CE6A81</gtr:id><gtr:name>Janus Developments</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/232FE897-4F2F-40BD-A92F-28CE006F8158"><gtr:id>232FE897-4F2F-40BD-A92F-28CE006F8158</gtr:id><gtr:name>San Raffaele del Monte Tabor Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE43EBFA-3FC9-44BC-B6FF-001F11664C46"><gtr:id>CE43EBFA-3FC9-44BC-B6FF-001F11664C46</gtr:id><gtr:name>Aarhus University</gtr:name><gtr:address><gtr:line1>Nordre Ringgade 1</gtr:line1><gtr:line4>Aarhus C</gtr:line4><gtr:line5>DK-8000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/618C6FA2-F2EB-4646-BB45-7927F09D69C4"><gtr:id>618C6FA2-F2EB-4646-BB45-7927F09D69C4</gtr:id><gtr:name>Helmholtz Zentrum M?nchen</gtr:name><gtr:address><gtr:line1>German Center f. Environmental Research</gtr:line1><gtr:line2>Ingolst?dter Landstr. 1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1AB05DA1-4DD6-4843-B416-D7D9441EBFFB"><gtr:id>1AB05DA1-4DD6-4843-B416-D7D9441EBFFB</gtr:id><gtr:name>Royal Veterinary College</gtr:name><gtr:address><gtr:line1>Royal College Street</gtr:line1><gtr:line2>Camden Town</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW1 0TU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D39EFE7-A4A8-4F9F-8BBA-D6265DA09CF2"><gtr:id>5D39EFE7-A4A8-4F9F-8BBA-D6265DA09CF2</gtr:id><gtr:name>Faculty of Biotechnology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/483D5886-D9B1-46DB-87FB-A90770EBBAA1"><gtr:id>483D5886-D9B1-46DB-87FB-A90770EBBAA1</gtr:id><gtr:firstName>Francesco</gtr:firstName><gtr:surname>Muntoni</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/002FC006-2518-458A-AB1F-FF4586FFE8D7"><gtr:id>002FC006-2518-458A-AB1F-FF4586FFE8D7</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Hanna</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C727E2B0-A636-4F29-9D0B-6D423A91FE19"><gtr:id>C727E2B0-A636-4F29-9D0B-6D423A91FE19</gtr:id><gtr:firstName>Doug</gtr:firstName><gtr:surname>Turnbull</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6A4534BA-ABC4-43A8-8811-4D6064526CBB"><gtr:id>6A4534BA-ABC4-43A8-8811-4D6064526CBB</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:surname>Bushby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/74F3B285-F862-4051-A76A-9A4272BB626C"><gtr:id>74F3B285-F862-4051-A76A-9A4272BB626C</gtr:id><gtr:firstName>Mary</gtr:firstName><gtr:otherNames>Margaret</gtr:otherNames><gtr:surname>Reilly</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000608%2F1"><gtr:id>2E127DAB-03BC-46B5-AB02-84D772CF7563</gtr:id><gtr:title>MICA: MRC Centre for Neuromuscular Diseases</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000608/1</gtr:grantReference><gtr:abstractText>Neuromuscular diseases (NMD) are an important group of disabling conditions affecting about 150,000 children and adults in the UK. They are caused by impairment of peripheral nerve and/or skeletal muscle function. Patients with these diseases develop muscle weakness and the severity can range from death in childhood or early adult life through to life long disability &amp;amp; dependence. Many patients also have heart and breathing muscle weakness which can add to disability and sometimes be fatal. These NMD conditions are commonly genetic and may run in families. They can also be acquired-for example through antibody attack as in &amp;quot;autoimmune&amp;quot; NMD or due to premature degeneration of muscle. Genetic examples include muscular dystrophy (~1 in 3500), Charcot Marie Tooth (CMT) neuropathy (~1 in 2500) and mitochondrial diseases (~1 in 5000). Acquired examples include chronic nerve inflammation (~1 in 1500) and a muscle degeneration/inflammation condition called inclusion body myositis (~1 in 10,000). 

It is clear that NMD represent an important unmet health burden for the nation. However, relative to other neurological diseases such as epilepsy and multiple sclerosis, NMD have received less attention by government and other UK funding bodies. This is despite the excellent clinical infrastructure provided by several large clinical neuromuscular centres and the nationally commissioned NHS funding for care and diagnosis of some NMD lead by MRC Centre PI's (eg congenital muscular dystrophy, channelopathies and mitochondrial diseases). Furthermore, there has been significant progress in NMD discovery science, frequently lead by internationally high profile UK clinicians and scientists, but translation of this scientific discovery into clear benefit for UK patients has been disappointing so far.

We set up this MRC Centre to develop ways to bridge this &amp;quot;translational gap&amp;quot; between scientific discovery and patient benefit. We identified six main reasons (obstacles) why scientific discoveries were not clearly benefiting patients. We developed specific core activities to overcome each obstacle. Most notably we found there was a lack of UK trials culture for these conditions. That means that there were not many trials happening, doctors treating patients did not think there was much that could be done, and patients were not being given the opportunity to get involved in the research &amp;amp; trials that were happening. By setting up key core activites, in just four years, we have shifted the situation towards a trial and experimental medicine culture in the UK. Key activities we developed &amp;amp; which are now valuable UK available resources:

1. Stratified cohorts: collections of patients eligible for entry into trials and research
2. Experimental trials support: a system of coordination and support to enable testing of new therapies in patients
3. Neuromuscular human cell biobank: collecting muscle cells from patients to test new therapies
4. MRI biomarker studies: using MRI scans to accurately measure muscles and assess if experimental treatments are working
5. Training programmes to train more young scientists to undertake trials and develop new therapies
6. Getting clinicians &amp;amp; animal scientists working closely together to work out which are the best cell &amp;amp; animal models on which to test new therapies

These core activities &amp;amp; our clinician scientist networks have resulted in a ten-fold increase in clinical trials &amp;amp; an even larger increase in patients entered into research cohorts. We now want to build on this success to embed a trials culture in UK practice.

In the UK there is no other centre that focuses on systematically linking discovery research to experimental medicine for NMD. This MRC Centre has lead the UK efforts in the last four years. The mission of a renewed MRC Centre is to achieve impact by translating science into experimental medicine &amp;amp; find treatments for adults &amp;amp; children with disabling/fatal neuromuscular diseases.</gtr:abstractText><gtr:technicalSummary>The Centre mission is to translate science into experimental medicine &amp;amp; new treatments for children &amp;amp; adults with neuromuscular diseases. 
We will:
1. Deliver new experimental medicine studies with clinical impact. 
2. Develop the core activities/resources that underpin translation including stratified cohorts, MRI biomarkers, neuromuscular biobank, preclinical models &amp;amp; capacity building PhD translational research training programmes.
3. Add value to major programmes of separately funded (&amp;gt;&amp;pound;60m) Centre PI discovery science. 
Specific technical objectives for the Centre: 
1. New experimental therapies: we will deliver a new experimental therapy study in each of five target diseases (muscular dystrophy, channelopathy, neuropathy, inclusion body myositis &amp;amp; mitochondrial disease).
2. Antisense therapy: we will target other dystrophin gene exons using different antisense chemistries &amp;amp; identify new disease targets.
3. Stem cell therapies: we will develop strategies to correct autologous DMD stem cells with a lentiviral vector &amp;amp; assess safety &amp;amp; efficacy using myogenic stem cells injected into a single human muscle. We will develop a safe efficient method to transduce stem cells for systemic delivery.
4. Exercise therapy: we will address key experimental questions in relation to the molecular basis of exercise benefit. We will asses safety &amp;amp; efficacy of exercise in dystrophy, inclusion body myositis, mitochondrial disease &amp;amp; neuropathy.
5. Discover new genes: we will use whole exome next generation DNA sequencing to identify new genes &amp;amp; therefore new therapy targets &amp;amp; new biomarkers in the five target diseases. 
6. Industry partnerships: we will build on &amp;amp; add additional successful industry links to 1) develop new experimental therapies eg new antisense chemistries 2) reprofile licensed drugs eg retigabine in muscle channelopathies &amp;amp; bezafibrate in mitochondrial disease and 3) use industry drug libraries to screen animal / biobank cell preclinical models.</gtr:technicalSummary><gtr:potentialImpactText>There are particular challenges faced in the field of NMD. Challenges apply across stakeholder groups, and impact in all of these areas will be achieved through the outputs of the MRC Neuromuscular Centre. 
The affected patients themselves and the patient organisations who represent them face uncertain access to diagnosis and care, have limited access to experimental clinical trials and the majority are without effective or curative therapies. The clinical and academic groups who work with NMD require resources (such as the MRC Centre biobank) and know-how to underpin delivery of care and translational research. The policy makers who determine care delivery in this area need information on which to base health recommendations. Industry is a recent partner in rare disease research, with industrial partners frequently lacking knowledge in the disease areas and perceiving that the field lacks &amp;quot;trial readiness&amp;quot;.
By targeting the needs of these distinct stakeholder groups, the MRC Centre will provide outputs which will promote health and wellbeing in this patient group as well as promoting UK international competitiveness in this research field. Strong relationships are already in place to ensure that impact can be maximized. These include key roles for the Centre PIs in patient organisations and patient organization involvement in research design and oversight; leading roles of the Centre PIs in clinical and academic organizations; identified key areas of liaison with the policy makers involved in rare disease public health decision making and many links to industry (as detailed in Pathway to Impact). 
Patients and patient organisations will benefit from the experimental medicine studies and increased trial activity, which is aimed at defining better therapeutic strategies. This will lead to the development of better strategies for diagnosis and treatment of these currently incurable disorders with ultimate impact on health, quality of life and societal benefit via greater participation of this patient group in their communities. Underpinning the experimental medicine activity of the Centre will be the development of stratified cohorts and natural history studies (as highlighted in the new MRC Stratified Medicine call), enabling personalized medicine and a much larger group of patients to contribute to experimental clinical studies and access standardized procedures for care and assessment. 
The extension of these studies to new collaborating clinical colleagues across the country by MRC Centre-designed studies continuing to achieve NIHR portfolio adoption will provide tools/resources to greater numbers of clinicians involved in delivery of NMD care while the expertise generated by the MRC Centre will be available for the current planning process for specialized commissioning and rare disease public health policy development. On the academic side, the availability of the resources of the MRC Centre, including the biobanks, stratified cohorts and experimental medicine know how will increase the UK competitiveness for the development of research in this area. 
Policy makers will have access to clearer and more harmonized guidance on the management of these patient groups which can be applied to healthcare planning both in the UK in the context of specialized commissioning and in the EU through its rare disease strategy. 
Stratified cohorts, research know-how and a strategic programme of preclinical research provide a conducive environment for increased industry engagement with the presence of trial expertise, ready access to rare patients and experimental resources. In addition to interaction with industry for the initiation of industry sponsored studies, the research programmes undertaken in the Centre will identify targets for new areas of industrial exploitation.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3161130</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pierre and Marie Curie University - Paris 6</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>UMR 787 (Institute of Myology)</gtr:department><gtr:description>MRI analyses in muscular dystrophy</gtr:description><gtr:id>3EFF52C8-2AF9-4CC9-871A-006C5B03CBA2</gtr:id><gtr:impact>PMID 19856446.</gtr:impact><gtr:outcomeId>hQBUuE1JHJx-1</gtr:outcomeId><gtr:partnerContribution>Expertise in MRI.</gtr:partnerContribution><gtr:piContribution>Clinical Fellow (Dr Penny Garood) undertook research to develop MRI scanning techniques, and performed clinical research into MRI applications.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>RDCRC Inherited Neuropathies Consortium</gtr:description><gtr:id>CDF69AF3-F146-4C1F-9451-A28E1A1E4D9E</gtr:id><gtr:impact>Two clinical research fellows in the UK have completed the training scheme. One clinical research fellow is currently on the scheme. 21 research fellows funded by non-NIHR sources have completed/are undergoing the programme.</gtr:impact><gtr:outcomeId>kVB6kaqCA9i-1</gtr:outcomeId><gtr:partnerContribution>International consortium for research into inherited neuropathies.</gtr:partnerContribution><gtr:piContribution>Provision of patient data, Fellowship training scheme. PI is Co-Director of the consortium.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Biozentrum Basel</gtr:department><gtr:description>Markus Ruegg Collaboration</gtr:description><gtr:id>6F7DDDF6-804C-4CAE-8862-AEDFE89C4679</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>PTRZkKKueBJ-1</gtr:outcomeId><gtr:partnerContribution>Provision of experise and materials</gtr:partnerContribution><gtr:piContribution>Exchange of biomaterials (plasmids and constructs)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Barcelona (UB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Natural History Study of Dysferlinopathy</gtr:description><gtr:id>35614CAC-ECE8-4CF6-BE93-402F49AD36F7</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>GWvUciHGJLw-2</gtr:outcomeId><gtr:partnerContribution>Coordination of trial, patient recruitment and data management.Patient recruitment and data analysis.</gtr:partnerContribution><gtr:piContribution>Coordination of the study, patient recruitment and data analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Kennedy's Disease Research</gtr:description><gtr:id>2E61B548-2DEC-4408-A57A-BE77905094FC</gtr:id><gtr:impact>Research donation; PhD student, three papers in preparation.
Multi-disciplinary - basic and clinical neuroscience.</gtr:impact><gtr:outcomeId>H8UDU99F1ZS-1</gtr:outcomeId><gtr:partnerContribution>Investigating the pathogenesis of Kennedy's disease in vivo and in vitro</gtr:partnerContribution><gtr:piContribution>Skills and clinical knowledge</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Raffaele Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>San Raffaele Scientific Institute (SRSI)</gtr:department><gtr:description>Notch and c-Jun signalling in Schwann cells</gtr:description><gtr:id>E7F4840D-6C91-4424-982A-5F3CBF63E498</gtr:id><gtr:impact>Two papers: PMID 19525946 and PMID 18490512.</gtr:impact><gtr:outcomeId>QTKQVvV5pnA-1</gtr:outcomeId><gtr:partnerContribution>The collaboration enabled us to generate mice without RBPj and c-June in Schwann cells. The collaborator provided us with Po-CRE mice.</gtr:partnerContribution><gtr:piContribution>We mated the Po-CRE mice with other mice and analysed the result.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Biotechnology</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Rudiger Rudolf Collaboration</gtr:description><gtr:id>C7AA14D2-419C-4FAC-BB4A-4D1964A6A5D2</gtr:id><gtr:impact>sympathetic innervation controls homeostatsis in health and disease Proac NAt academy science USA jan 2016 doi: 10.1073</gtr:impact><gtr:outcomeId>56d478888ef1f4.89612401-1</gtr:outcomeId><gtr:partnerContribution>linking sympathetic innovations of neuromuscular junctions to disease conditions</gtr:partnerContribution><gtr:piContribution>Investigation of sympathetic innovation of neuromuscular junctions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>IBM-Net</gtr:description><gtr:id>C7EA8D85-CD55-418F-B6B5-D11BB2863DB8</gtr:id><gtr:impact>Development of IBM-Net database.</gtr:impact><gtr:outcomeId>GLHaRvXBcQ8-2</gtr:outcomeId><gtr:partnerContribution>Addition of patient data to web-based cohort of IBM patients.Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients.</gtr:partnerContribution><gtr:piContribution>Addition of patient data to web-based cohort of IBM patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>David Beeson Collaboration</gtr:description><gtr:id>92BAF834-4EC6-4F8D-8E10-E56A4FA663D8</gtr:id><gtr:impact>Joint publication under consideration</gtr:impact><gtr:outcomeId>eSZeZqKLn6d-1</gtr:outcomeId><gtr:partnerContribution>Data analysis and sharing</gtr:partnerContribution><gtr:piContribution>Provision of samples and data for analysis of CMS</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Human Genetics</gtr:department><gtr:description>UK Heart Protection Trial</gtr:description><gtr:id>54AF16FC-0F8E-40C3-8D10-FB264F5BB7A8</gtr:id><gtr:impact>Contribution to the standards of care. 
PMID 19945913.</gtr:impact><gtr:outcomeId>nMqAqLZN4N1-1</gtr:outcomeId><gtr:partnerContribution>Clinical care and research.</gtr:partnerContribution><gtr:piContribution>Patient recruitment and data analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Establishing a Biobank for the MRC Centre for Neuromuscular Diseases</gtr:description><gtr:id>53EA7C83-BEA8-4AF7-AB61-F52B68205A4F</gtr:id><gtr:impact>The Dubowitz Neuromuscular Centre is now fully functional and CPA accredited. It is a valuable resource and a centre of excellence, proving a unique research infrastructure to the MRC Centre for Neuromuscular Diseases.</gtr:impact><gtr:outcomeId>874F8766B69-1</gtr:outcomeId><gtr:partnerContribution>Provided infrastructure and guidance to establish Biobank for neuromuscular disease. Facilitated relocation of the Dubowitz Neuromuscular Centre to Queen Square.</gtr:partnerContribution><gtr:piContribution>Provided facilities and staff support in form of Biobank Technician.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development GSK</gtr:department><gtr:description>GSK and Muscle MRI</gtr:description><gtr:id>7FC6C111-DB66-463B-B066-6BCEB01E1522</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>YGFFATfanMs-1</gtr:outcomeId><gtr:piContribution>Management of MRI Physicist working on muscle MRI project for two years.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shire Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Mexiletine and Myotonia Congenita</gtr:description><gtr:id>080D51C4-8C19-4E0E-BFC6-D4C2E675E192</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>izHMsQAC2ri-1</gtr:outcomeId><gtr:piContribution>Providing clinical information regarding the side effects of mexiletine in myotonia congenita cohort.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muscular Dystrophy UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Smart-Net</gtr:description><gtr:id>F9B4AD9D-5803-4549-ACC6-29A8B62AC698</gtr:id><gtr:impact>Continuing expansion of database.</gtr:impact><gtr:outcomeId>STjgktsxwT1-1</gtr:outcomeId><gtr:partnerContribution>Administrative support.</gtr:partnerContribution><gtr:piContribution>Prospective data collection for natural history study of hundreds of children with spinal muscular atrophy; coordination of 18 centres.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Muscle stem cells for therapies in muscular dystrophy</gtr:description><gtr:id>ACAAF879-F40F-4F94-BAA9-27A7C3E14B92</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>HVXE1q4QKUy-1</gtr:outcomeId><gtr:partnerContribution>Myogenic cell characterisation and lentiviral vector design.</gtr:partnerContribution><gtr:piContribution>Development of optimal dystrophin constructs for gene replacement.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neurology Service</gtr:department><gtr:description>IBM-Net</gtr:description><gtr:id>335D7F79-8A89-4904-96FE-FED5362681D2</gtr:id><gtr:impact>Development of IBM-Net database.</gtr:impact><gtr:outcomeId>GLHaRvXBcQ8-4</gtr:outcomeId><gtr:partnerContribution>Addition of patient data to web-based cohort of IBM patients.Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients.</gtr:partnerContribution><gtr:piContribution>Addition of patient data to web-based cohort of IBM patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Translational research in muscular dystrophy</gtr:description><gtr:id>BD0015C4-DF6F-466B-BCDC-1E5166806ABE</gtr:id><gtr:impact>Numerous publications, particularly PMID 20405137 and 20346669, 20562457.</gtr:impact><gtr:outcomeId>JWm3TLB7wjz-1</gtr:outcomeId><gtr:partnerContribution>Patient material, clinical data, molecular analyses.Patient material, clinical data, molecular analyses.</gtr:partnerContribution><gtr:piContribution>Patient material, clinical data, molecular analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Raffaele del Monte Tabor Foundation</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Cell therapy of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts</gtr:description><gtr:id>7D1F10B1-C051-406F-926E-D321A153901D</gtr:id><gtr:impact>.</gtr:impact><gtr:outcomeId>Dved398EyGg-1</gtr:outcomeId><gtr:partnerContribution>Clinical trial PI also a PI at the MRC Centre for Neuromuscular Diseases.</gtr:partnerContribution><gtr:piContribution>Quantitative analysis of patient biopsies before and after stem cell transplantation in this phase I/II clinical trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>Schwann cell deymelination</gtr:description><gtr:id>57F59561-F61B-4726-ACCE-161D1D0C7282</gtr:id><gtr:impact>Paper PMID 18490512.</gtr:impact><gtr:outcomeId>RR5z5F7zkC3-1</gtr:outcomeId><gtr:partnerContribution>The collaboration enabled us to study c-Jun function in vivo. The collaborator provided us with GM mice.</gtr:partnerContribution><gtr:piContribution>Our lab bred the mice and and analysed the progeny.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Free University of Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Medical School Berlin</gtr:department><gtr:description>PTRF-cavin in muscle disease</gtr:description><gtr:id>136822BB-1C3C-4421-BD61-C9F32048A76C</gtr:id><gtr:impact>PMID 20300641.</gtr:impact><gtr:outcomeId>eRwiB9jmSoy-1</gtr:outcomeId><gtr:partnerContribution>PTFR-cavin resources.</gtr:partnerContribution><gtr:piContribution>Patient material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences</gtr:department><gtr:description>Muscle stem cells in mitochondrial disease</gtr:description><gtr:id>AF19D3A6-918A-493D-904C-CCD95DC702E2</gtr:id><gtr:impact>Development of student's skill set. Publication in preparation.</gtr:impact><gtr:outcomeId>jNsRvPP6iDn-1</gtr:outcomeId><gtr:partnerContribution>Expertise in analysis of mitochondria.</gtr:partnerContribution><gtr:piContribution>Myoblast culture and analysis techniques.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Investigating novel TDP43 mutant mice</gtr:description><gtr:id>5C94B090-5874-49EE-81B4-D3EA646E4815</gtr:id><gtr:impact>One PhD student, two grants. 
Multidisciplinary - genetics and physiology.</gtr:impact><gtr:outcomeId>k2qGArzux9h-1</gtr:outcomeId><gtr:partnerContribution>Physiological phenotyping of mutant TDP43 mice.</gtr:partnerContribution><gtr:piContribution>Clinical expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Functional characterisation of novel mitochondrial disease genes</gtr:description><gtr:id>56513591-A892-4D59-A3B3-1626AF4F2ED8</gtr:id><gtr:impact>PMID 23993193</gtr:impact><gtr:outcomeId>td3hcRU6fAf-1</gtr:outcomeId><gtr:partnerContribution>Exome sequencing families with mitochondrial disorders.</gtr:partnerContribution><gtr:piContribution>Functional characterisation of novel mitochondrial disease genes.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Developing an In Vitro Model of Inclusion Body Myositis</gtr:description><gtr:id>BBD47437-42DC-4396-A721-98BB7475CA13</gtr:id><gtr:impact>ARC grant, one clinical research fellow, one PhD student, one paper in preparation. Clinical trial initiated. 
Multi-dispclinary - basic and clinical neuroscience.</gtr:impact><gtr:outcomeId>VjxFPazp5aL-1</gtr:outcomeId><gtr:partnerContribution>Developing an in vitro model of Inclusion Body Myositis</gtr:partnerContribution><gtr:piContribution>Imparting clinical knowledge and skills.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Veterinary College (RVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Veterinary Basic Sciences (VBS)</gtr:department><gtr:description>Stem cell function in the dystroglycanopathies</gtr:description><gtr:id>C28E038D-994C-40F8-8112-997160E3E48F</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>PieEzirGfoc-1</gtr:outcomeId><gtr:partnerContribution>Skills and knowledge.</gtr:partnerContribution><gtr:piContribution>Skills and knowledge imparted from team at Dubowitz Neuromuscular Centre, UCL Institute of Child Health.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>IBM-Net</gtr:description><gtr:id>341DACCD-118D-468D-B0C1-B88BFE48EBDB</gtr:id><gtr:impact>Development of IBM-Net database.</gtr:impact><gtr:outcomeId>GLHaRvXBcQ8-5</gtr:outcomeId><gtr:partnerContribution>Addition of patient data to web-based cohort of IBM patients.Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients.</gtr:partnerContribution><gtr:piContribution>Addition of patient data to web-based cohort of IBM patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NMD-CHIP</gtr:description><gtr:id>8B52F358-71B6-49AD-A0BF-0A5FF2C34B4D</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>jtcB96uyGZy-1</gtr:outcomeId><gtr:partnerContribution>By tracking the latest developments in NMD diagnostics, we have been able to analyse our patient cohorts for novel genes.</gtr:partnerContribution><gtr:piContribution>Development of diagnostic tests and reagents.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences Nottingham</gtr:department><gtr:description>New in vitro models for DMD using iPSC</gtr:description><gtr:id>30C7BEE8-3FED-495E-B75C-295384921253</gtr:id><gtr:impact>Joint grant applications (outstanding) and joint publications (Dick et al. 2010 and in preparation).</gtr:impact><gtr:outcomeId>XCcWQCgh96B-1</gtr:outcomeId><gtr:partnerContribution>The Nottingham group have provided us with iPSC cells and have trained our technician in their generation and maintenance.</gtr:partnerContribution><gtr:piContribution>By extending our collaborative links to a group working on iPSC we have gained valuable technological insights, unique experimental materials and access to a wider collaborative network. 
We have provided fibroblasts from dystrophic patients and technical support and expertise in analysing derived cardiomyocytes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Duisburg-Essen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Paediatric mitochondrial disease</gtr:description><gtr:id>23047ACD-DD77-4B01-A8F9-784398B793C1</gtr:id><gtr:impact>Two papers:
PMID 23430795
PMID 23814040</gtr:impact><gtr:outcomeId>kVvtDjB9KAo-1</gtr:outcomeId><gtr:partnerContribution>Supply of samples from paediatric patients with mitochondrial disease.</gtr:partnerContribution><gtr:piContribution>Analysis of samples to identify the cause of combined respiratory chain deficiency.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Veterinary College (RVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Veterinary Basic Sciences (VBS)</gtr:department><gtr:description>Therapeutic approaches in the dystroglycanopathies</gtr:description><gtr:id>A02FD322-5944-4C3A-9ED9-0A1743E52FCB</gtr:id><gtr:impact>None as yet.
Multidisciplinary - clinicians and basic scientists.</gtr:impact><gtr:outcomeId>iLKDzdNVoVe-1</gtr:outcomeId><gtr:partnerContribution>Skills and experience.</gtr:partnerContribution><gtr:piContribution>Skills and experience imparted from team at Dubowitz Neuromuscular Centre, UCL Institute of Child Health.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muscular Dystrophy UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Inclusion Body Myositis</gtr:description><gtr:id>EB2979E8-AD12-4E00-9334-67FA4B6F93C4</gtr:id><gtr:impact>One clinical research fellow working on IBM PhD project, jointly supervised by MRC Centre for Neuromuscular Diseases and University of Oxford.</gtr:impact><gtr:outcomeId>7D02E2EF549-2</gtr:outcomeId><gtr:partnerContribution>Sharing patient data and clinical knowledge.Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow.</gtr:partnerContribution><gtr:piContribution>Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow working on IBM PhD project.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Orphan &amp; Genetic Diseases Research Unit Pfizer</gtr:department><gtr:description>Evaluation of Biomarkers in DMD</gtr:description><gtr:id>A3648491-4A8E-4926-A47B-D57F419C0C87</gtr:id><gtr:impact>Further collaborative work in patient samples.</gtr:impact><gtr:outcomeId>nWDmw1sp6ZV-1</gtr:outcomeId><gtr:partnerContribution>Pfizer will shortly analyse the samples derived from our models for specific biomarkers.</gtr:partnerContribution><gtr:piContribution>We have provided mouse urine, tissue and myoblasts.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Human Genetics</gtr:department><gtr:description>National Neuromuscular Database</gtr:description><gtr:id>005EAC2D-E32C-4233-B008-E164B30A521D</gtr:id><gtr:impact>Growth and development of national neuromuscular database comprising data from four individual databases:
IBM-Net
Smart-Net
NorthStar
Congenital Muscular Dystrophy database</gtr:impact><gtr:outcomeId>emkTDvryZH2-3</gtr:outcomeId><gtr:partnerContribution>Contribution of data and joint management of database.Contribution of data and joint management of umbrella database.Contribution of data and joint management of umbrella database.</gtr:partnerContribution><gtr:piContribution>Contributing to and shared management of national neuromuscular database.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Translational research in muscular dystrophy</gtr:description><gtr:id>F41C7698-D2F7-406A-AF12-B850C02CA9B6</gtr:id><gtr:impact>Numerous publications, particularly PMID 20405137 and 20346669, 20562457.</gtr:impact><gtr:outcomeId>JWm3TLB7wjz-2</gtr:outcomeId><gtr:partnerContribution>Patient material, clinical data, molecular analyses.Patient material, clinical data, molecular analyses.</gtr:partnerContribution><gtr:piContribution>Patient material, clinical data, molecular analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>Translational research in mitochondrial disease</gtr:description><gtr:id>0537D32D-222A-4E69-88C7-1C3DB1F944D9</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>B257955467B-1</gtr:outcomeId><gtr:partnerContribution>Patient data, lab skills, sharing of clinical knowledge.</gtr:partnerContribution><gtr:piContribution>Patient data from mitochondrial patient cohort.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Centre for Human and Clinical Genetics</gtr:department><gtr:description>Annemieke Artsma-Rus Visiting Professorship</gtr:description><gtr:id>46E13B22-A5E9-4209-B97C-8C026FA12CC7</gtr:id><gtr:impact>Improved integration with networks and international collaborations such as the TREAT-NMD Alliance</gtr:impact><gtr:outcomeId>SK5HjaQ4ZZ3-1</gtr:outcomeId><gtr:partnerContribution>Prof. Aartsma-Rus is making a concerted contribution to the networking and scientific activities of the wider team</gtr:partnerContribution><gtr:piContribution>We provide working space and collaborative projects for Prof. Aartsma-Rus whi visits Newcastle regularly.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janus Developments</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Preclinical testing in SOD1 mice</gtr:description><gtr:id>B9E249C0-5F0A-472E-8991-FF7925E510CD</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>NvLJZYzTmdj-1</gtr:outcomeId><gtr:partnerContribution>Development strategy.</gtr:partnerContribution><gtr:piContribution>Undertaking a preclinical trial of a compound in a mouse model of ALS.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton University Hospitals NHS Trust (SUHT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>IBM-Net</gtr:description><gtr:id>2573192E-C054-4DA3-B9D7-F8928B67599B</gtr:id><gtr:impact>Development of IBM-Net database.</gtr:impact><gtr:outcomeId>GLHaRvXBcQ8-3</gtr:outcomeId><gtr:partnerContribution>Addition of patient data to web-based cohort of IBM patients.Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients.</gtr:partnerContribution><gtr:piContribution>Addition of patient data to web-based cohort of IBM patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences KCL</gtr:department><gtr:description>Schwann cell precursors and regeneration</gtr:description><gtr:id>8DEE1C01-F0F9-4543-9208-6F2FC6E42450</gtr:id><gtr:impact>One paper: PMID 18484102</gtr:impact><gtr:outcomeId>jpiaFgo4LMV-1</gtr:outcomeId><gtr:partnerContribution>The collaborator has enabled us to study regeneration in the spinal cord. The collaborator carried out operations on the spinal cord.</gtr:partnerContribution><gtr:piContribution>We provided Schwann cell precursors and analysed the results.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Gene Center Munich</gtr:department><gtr:description>Dystrophic Pig Collaboration</gtr:description><gtr:id>376F4CF6-7E69-40E6-8D22-93CFC91D5D61</gtr:id><gtr:impact>Publication (Pubmed ID: 23784375)</gtr:impact><gtr:outcomeId>VeW95o7QxPR-1</gtr:outcomeId><gtr:partnerContribution>Prof. Eckard Wolf has developed the pig breeding project and maintains the existing stocks. The collaboration is now moving forward to defining the next series of experiments to utilise the pig model.</gtr:partnerContribution><gtr:piContribution>We have provided advice on the project from the outset as well as some material support in the analysis phase.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Mitochondrial dysfunction in ALS</gtr:description><gtr:id>9F0B388B-93D8-4882-B0CF-36B103302916</gtr:id><gtr:impact>Two PhD students; one paper - Bisland et al 2009. 
Multidisciplinary - cellular physiology and confocal fluorescent imaging.</gtr:impact><gtr:outcomeId>XfUDi56xutN-1</gtr:outcomeId><gtr:partnerContribution>Primary cultures of muscles, astrocytes and motoneurons from transgenic mice.</gtr:partnerContribution><gtr:piContribution>Clinical knowledge.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular Medical Sciences Nottingham</gtr:department><gtr:description>iPSCs for modelling dystrophic cardiomyoctes</gtr:description><gtr:id>BAB467B9-C1C7-493E-A33A-85285FA5C284</gtr:id><gtr:impact>iPSCs derived and characterised. Publication in preparation.</gtr:impact><gtr:outcomeId>GDdcmALY6MJ-1</gtr:outcomeId><gtr:partnerContribution>Development of iPSC lines from DMD fibroblasts.</gtr:partnerContribution><gtr:piContribution>Derivation of patient fibroblasts, characterisation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Disease-causing mutant Hsp27 mutations</gtr:description><gtr:id>62FACBCA-0BAE-43CB-A984-878791DFBD63</gtr:id><gtr:impact>One PhD student and one clinical research fellow sponsored by Ipsen.
Multidisciplinary - basic and clinical neuroscience.</gtr:impact><gtr:outcomeId>Edt4p4x5byS-1</gtr:outcomeId><gtr:partnerContribution>Modelling the pathogenesis of mutant Hsp27-induced peripheral neuropathy.</gtr:partnerContribution><gtr:piContribution>Clinical expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rochester</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>FOR-DMD: a large-scale multi-centre trial of steroids in DMD</gtr:description><gtr:id>23835225-BEC0-4182-BD93-B7E28FE82806</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>616DA3A2DC0-1</gtr:outcomeId><gtr:partnerContribution>Coordination of trial, patient recruitment and data management</gtr:partnerContribution><gtr:piContribution>Patient recruitment and data analysis. Collecting and processing data, provision of our own patient data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Notch signalling in Schwann Cells</gtr:description><gtr:id>8D118EC0-FBC9-40A1-A8FF-ABD107829626</gtr:id><gtr:impact>One paper: PMID 19525946</gtr:impact><gtr:outcomeId>Sh4r683uoAb-1</gtr:outcomeId><gtr:partnerContribution>The collaboration enabled us to generate mice without RBPj in Schwann cells. The collaborator provided us with DhhCRE mice.</gtr:partnerContribution><gtr:piContribution>We mated the DhhCRE mice with other mice, and analysed the result.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>National Neuromuscular Database</gtr:description><gtr:id>4C83689C-7D1B-4C8F-84A4-12BA656B7E35</gtr:id><gtr:impact>Growth and development of national neuromuscular database comprising data from four individual databases:
IBM-Net
Smart-Net
NorthStar
Congenital Muscular Dystrophy database</gtr:impact><gtr:outcomeId>emkTDvryZH2-1</gtr:outcomeId><gtr:partnerContribution>Contribution of data and joint management of database.Contribution of data and joint management of umbrella database.Contribution of data and joint management of umbrella database.</gtr:partnerContribution><gtr:piContribution>Contributing to and shared management of national neuromuscular database.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>MRI in LGMD2I</gtr:description><gtr:id>B4D871AB-A1CB-4AE9-BE68-94B7450378D5</gtr:id><gtr:impact>Publication in preparation.</gtr:impact><gtr:outcomeId>FFcPwLjLLy4-1</gtr:outcomeId><gtr:partnerContribution>Expertise in functional analysis of muscle and MRI.</gtr:partnerContribution><gtr:piContribution>Clinical Fellow (Dr Tracy Willis) leading the Newcastle end of the collaboration. Provided patient recruitment resources and MRI scanning time.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>Inclusion Body Myositis</gtr:description><gtr:id>5F6C4771-A1B9-41C2-B87C-5244DEA2506F</gtr:id><gtr:impact>One clinical research fellow working on IBM PhD project, jointly supervised by MRC Centre for Neuromuscular Diseases and University of Oxford.</gtr:impact><gtr:outcomeId>7D02E2EF549-3</gtr:outcomeId><gtr:partnerContribution>Sharing patient data and clinical knowledge.Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow.</gtr:partnerContribution><gtr:piContribution>Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow working on IBM PhD project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AVI Biopharma, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Research and Development AVI Biopharma</gtr:department><gtr:description>Dose ranging study of AVI-4658 to induce dystrophin expression</gtr:description><gtr:id>E84F4109-AA9D-4ADA-A37A-6EE95FB4FCFC</gtr:id><gtr:impact>An intramuscular phase I/II clinical trial in seven DMD boys from October 2007-March 2009.</gtr:impact><gtr:outcomeId>PCTjBT75vQi-1</gtr:outcomeId><gtr:partnerContribution>Provided clinical grade study drug.</gtr:partnerContribution><gtr:piContribution>Study design; clinical, molecular and pathological assessment of DMD patients; Biobank. Clinical support for the trial, laboratory studies on the efficacy of the study drug.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Edison Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Edison and Mitochondrial Disease</gtr:description><gtr:id>398D7E50-3F68-46B1-8181-10FB68E3A85C</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>GEquEUfBvAs-1</gtr:outcomeId><gtr:piContribution>Running planned clinical drug trial for mitochondrial disease. Supervision of a Clinical Research Fellow for one year.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>SOD1 GFP Investigation</gtr:description><gtr:id>E8FE2757-7154-45B4-B8EF-65CFDA5D27E3</gtr:id><gtr:impact>PMID 20221404.</gtr:impact><gtr:outcomeId>kKKKSVqMQ14-2</gtr:outcomeId><gtr:partnerContribution>Resources and skills.Facilities and skills.</gtr:partnerContribution><gtr:piContribution>Providing mice and skills.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Brighton and Sussex Medical School</gtr:department><gtr:description>Investigating LOA mouse</gtr:description><gtr:id>AD055502-B8A9-4614-B4E7-3C3E2A2DCF4E</gtr:id><gtr:impact>PMID 20382740.</gtr:impact><gtr:outcomeId>DcDjDRgYYJo-1</gtr:outcomeId><gtr:partnerContribution>Specific skills, experience and facilities.</gtr:partnerContribution><gtr:piContribution>Providing mice and skills.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Inclusion Body Myositis</gtr:description><gtr:id>6A871DA8-2B91-4EA6-873B-930EA023F700</gtr:id><gtr:impact>One clinical research fellow working on IBM PhD project, jointly supervised by MRC Centre for Neuromuscular Diseases and University of Oxford.</gtr:impact><gtr:outcomeId>7D02E2EF549-4</gtr:outcomeId><gtr:partnerContribution>Sharing patient data and clinical knowledge.Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow.</gtr:partnerContribution><gtr:piContribution>Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow working on IBM PhD project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Functional characterisation of novel mitochondrial disease genes</gtr:description><gtr:id>D621BDF9-C773-416A-97AF-B6385BABE579</gtr:id><gtr:impact>PMID: 23929671</gtr:impact><gtr:outcomeId>Qms4j5eJ7cs-1</gtr:outcomeId><gtr:partnerContribution>Identification and characterisation of mitochondrial disease genes</gtr:partnerContribution><gtr:piContribution>Investigation of the role of FBXL4 in mitochondrial function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Identification and characterisation of CMS genes</gtr:description><gtr:id>F7F6F722-4997-4C5B-A280-615684151DC0</gtr:id><gtr:impact>Clinical paper submitted. Scientific paper in preparation.</gtr:impact><gtr:outcomeId>icH7ekX7kPz-2</gtr:outcomeId><gtr:partnerContribution>Large-scale mapping and sequencing resources.Patient material.</gtr:partnerContribution><gtr:piContribution>Patient material, consumables and personnel for gene analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>TREAT-NMD Alliance</gtr:description><gtr:id>AE0FBC51-FD1A-4CD7-B9C8-B981F383C7C1</gtr:id><gtr:impact>Meetings and conferences. Collaborative preparation of papers and briefing documents. Integration with patient organisations.</gtr:impact><gtr:outcomeId>qMm3qoKfzXk-1</gtr:outcomeId><gtr:partnerContribution>Contribution to the governance and activities of the network.</gtr:partnerContribution><gtr:piContribution>Following the success of the TREAT-NMD network of excellence, the TREAT-NMD Alliance has been formed as the continuing, sustainable network supporting translational research in neuromuscular diseases internationally. We have been tasked with coordination of the network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ETH Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Identification and characterisation of CMS genes</gtr:description><gtr:id>0966A22E-C04E-4419-97A4-532306944D40</gtr:id><gtr:impact>Clinical paper submitted. Scientific paper in preparation.</gtr:impact><gtr:outcomeId>icH7ekX7kPz-1</gtr:outcomeId><gtr:partnerContribution>Large-scale mapping and sequencing resources.Patient material.</gtr:partnerContribution><gtr:piContribution>Patient material, consumables and personnel for gene analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Senexis Ltd Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Inclusion Body Myositis</gtr:description><gtr:id>9B40025D-D638-4760-B091-F16A3EBC4F3B</gtr:id><gtr:impact>One clinical research fellow working on IBM PhD project, jointly supervised by MRC Centre for Neuromuscular Diseases and University of Oxford.</gtr:impact><gtr:outcomeId>7D02E2EF549-1</gtr:outcomeId><gtr:partnerContribution>Sharing patient data and clinical knowledge.Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow.</gtr:partnerContribution><gtr:piContribution>Sharing patient data and clinical knowledge. Joint supervision of one Clinical Research Fellow working on IBM PhD project.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>MRC SMA Grant</gtr:description><gtr:id>8A3331F5-83F3-44A3-BE42-4631801BBFFA</gtr:id><gtr:impact>PMID: 26506088; 26264577</gtr:impact><gtr:outcomeId>56b21899f26056.65802247-1</gtr:outcomeId><gtr:partnerContribution>novel backbones for the antisense</gtr:partnerContribution><gtr:piContribution>preclinical model of SMA; vascular defects; generation of a chronic model to explore window of intervention</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>SOD1 GFP Investigation</gtr:description><gtr:id>A1A5F324-B2AC-4E5E-9C25-14EF47869446</gtr:id><gtr:impact>PMID 20221404.</gtr:impact><gtr:outcomeId>kKKKSVqMQ14-1</gtr:outcomeId><gtr:partnerContribution>Resources and skills.Facilities and skills.</gtr:partnerContribution><gtr:piContribution>Providing mice and skills.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Studying new mouse models of ALS</gtr:description><gtr:id>F53B40F1-0598-46C8-B160-BE85607A406B</gtr:id><gtr:impact>One clinical research fellow. 
Multidisciplinary - genetics and physiology.</gtr:impact><gtr:outcomeId>oXTG8QFghus-1</gtr:outcomeId><gtr:partnerContribution>Phenotyping of mouse models of ALS.</gtr:partnerContribution><gtr:piContribution>Clinical expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>National Neuromuscular Database</gtr:description><gtr:id>CDE1DEAB-01D8-4603-A009-4C2CC07F0445</gtr:id><gtr:impact>Growth and development of national neuromuscular database comprising data from four individual databases:
IBM-Net
Smart-Net
NorthStar
Congenital Muscular Dystrophy database</gtr:impact><gtr:outcomeId>emkTDvryZH2-2</gtr:outcomeId><gtr:partnerContribution>Contribution of data and joint management of database.Contribution of data and joint management of umbrella database.Contribution of data and joint management of umbrella database.</gtr:partnerContribution><gtr:piContribution>Contributing to and shared management of national neuromuscular database.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Anne Dell Collaboration</gtr:description><gtr:id>A08ED862-78AA-41B6-9FC9-69625B9FD66F</gtr:id><gtr:impact>None to datge</gtr:impact><gtr:outcomeId>qbkdxKEiRbb-1</gtr:outcomeId><gtr:partnerContribution>Analysis of glyco-epitopes by proteomics</gtr:partnerContribution><gtr:piContribution>Provision of myoblast cells knocked down for Gfpt1</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Jackson Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Investigating Gars Mouse</gtr:description><gtr:id>26130B75-1983-487E-B5BD-E6040A882FF3</gtr:id><gtr:impact>PMID 19470612.</gtr:impact><gtr:outcomeId>KTbf7jg5e1h-1</gtr:outcomeId><gtr:partnerContribution>Specific skills, experience and mouse models.</gtr:partnerContribution><gtr:piContribution>Providing mice and skills.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>tRNA Modification</gtr:description><gtr:id>0761F733-DAB0-4E20-AF4D-4357B2DAD013</gtr:id><gtr:impact>Collaborative manuscript submitted (PLoS Genetics)</gtr:impact><gtr:outcomeId>mAaFEChS3MU-1</gtr:outcomeId><gtr:partnerContribution>Functional characterisation of tRNA modification in patient cells and tissues</gtr:partnerContribution><gtr:piContribution>Functional characterisation of novel mitochondrial disease proteins involved in tRNA modification</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>Studying a novel gene for motor neuron degeneration</gtr:description><gtr:id>9250FB2E-0688-4316-8D92-A91FF602DCA8</gtr:id><gtr:impact>Awarded a grant for &amp;pound;110,000 from the Motor Neuron Diseases Association for a PhD student.</gtr:impact><gtr:outcomeId>BNo5k1wYFj3-1</gtr:outcomeId><gtr:partnerContribution>The partnership has extended the research into new areas.</gtr:partnerContribution><gtr:piContribution>Providing new models for analysis of neurodegeneration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Zentrum M?nchen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Functional characterisation of novel mitochondrial disease genes</gtr:description><gtr:id>CF53DC72-CD2F-4E7C-80CD-71D6D6375617</gtr:id><gtr:impact>PMID: 23849775</gtr:impact><gtr:outcomeId>Sh6eJyjwTze-1</gtr:outcomeId><gtr:partnerContribution>Identification of novel disease genes associated with human complex I deficiency</gtr:partnerContribution><gtr:piContribution>Exome sequencing families with mitochondrial disorders</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Schwann cell dedifferentiation and regeneration</gtr:description><gtr:id>8B78AD89-5AAB-4E55-B1F4-A9B9F0501C9F</gtr:id><gtr:impact>No papers to date.</gtr:impact><gtr:outcomeId>Xb4rXzxmuUU-1</gtr:outcomeId><gtr:partnerContribution>The collaboration has enabled us to study regeneration in the facial nerve. The collaborator provided knowledge of the facial nerve.</gtr:partnerContribution><gtr:piContribution>We analysed the results.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Identifying causative genes and pathomechanisms in CMS</gtr:description><gtr:id>9CD3C318-CA29-43A1-8FD8-F46F902F6BB3</gtr:id><gtr:impact>Joint publications (Beeson et al 2006; Senderek et al. 2011) and grant applications.</gtr:impact><gtr:outcomeId>Y2P9NKnz16m-2</gtr:outcomeId><gtr:partnerContribution>Information regarding gene function in CMS has been made available to the Newcastle group. Collaborators provided samples, expertise and consumables.Information regarding gene function in CMS has been made available to the Newcastle group. Collaborators provided samples, expertise and consumables.</gtr:partnerContribution><gtr:piContribution>We have provided samples, expertise and consumables.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aix-Marseille University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Natural History Study of Dysferlinopathy</gtr:description><gtr:id>37BD327D-0D90-4301-B3A2-16FBA4096DE6</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>GWvUciHGJLw-1</gtr:outcomeId><gtr:partnerContribution>Coordination of trial, patient recruitment and data management.Patient recruitment and data analysis.</gtr:partnerContribution><gtr:piContribution>Coordination of the study, patient recruitment and data analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences</gtr:department><gtr:description>Analysis of cardiac function in mouse models of muscular dystrophy</gtr:description><gtr:id>DD7DF86D-7AD7-4E3F-8A11-12E653152FED</gtr:id><gtr:impact>PMID 19913415, 19233868 and 19259135.</gtr:impact><gtr:outcomeId>ScMoSZRfgh7-1</gtr:outcomeId><gtr:partnerContribution>Expertise in haemodynamic measurements of cardiac function in rodents. Expertise in MRI analysis.</gtr:partnerContribution><gtr:piContribution>Provision of the mouse colony, personnel and consumables for the analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>BBSRC Case Studentship: targeting axonal transport deficits</gtr:description><gtr:id>33BCBC84-4DBF-496B-9552-C3F237540912</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>jq6Q7BKnBeP-1</gtr:outcomeId><gtr:partnerContribution>Developing high throughput assay for testing agents that modify axonal transport.</gtr:partnerContribution><gtr:piContribution>Developing high throughput assay for testing agents that modify axonal transport, and in vivo testing of efficacy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muscular Dystrophy UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IBM-Net</gtr:description><gtr:id>E88D7FAF-2175-43EA-A78D-EB49CDBB1D0C</gtr:id><gtr:impact>Development of IBM-Net database.</gtr:impact><gtr:outcomeId>GLHaRvXBcQ8-1</gtr:outcomeId><gtr:partnerContribution>Addition of patient data to web-based cohort of IBM patients.Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients. Addition of patient data to web-based cohort of IBM patients.</gtr:partnerContribution><gtr:piContribution>Addition of patient data to web-based cohort of IBM patients.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>MRC SMA Grant</gtr:description><gtr:id>80F28A4F-11D8-434C-9AEC-2D1B134AFF51</gtr:id><gtr:impact>PMID: 26506088; 26264577</gtr:impact><gtr:outcomeId>56b21899f26056.65802247-2</gtr:outcomeId><gtr:partnerContribution>novel backbones for the antisense</gtr:partnerContribution><gtr:piContribution>preclinical model of SMA; vascular defects; generation of a chronic model to explore window of intervention</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muscular Dystrophy UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>North-Star</gtr:description><gtr:id>4C218389-912D-4573-8C21-20EBDC36D3E6</gtr:id><gtr:impact>Ongoing growth of database.</gtr:impact><gtr:outcomeId>rwQgEPAD7K6-1</gtr:outcomeId><gtr:partnerContribution>Administrative support.</gtr:partnerContribution><gtr:piContribution>Prospective data collection for natural history study of hundreds of children with Duchenne Muscular Dystrophy; coordination of 18 centres.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aarhus University</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Institute of Human Genetics</gtr:department><gtr:description>Identifying causative genes and pathomechanisms in CMS</gtr:description><gtr:id>6342529B-D935-4951-9E3E-314D7D0667F9</gtr:id><gtr:impact>Joint publications (Beeson et al 2006; Senderek et al. 2011) and grant applications.</gtr:impact><gtr:outcomeId>Y2P9NKnz16m-1</gtr:outcomeId><gtr:partnerContribution>Information regarding gene function in CMS has been made available to the Newcastle group. Collaborators provided samples, expertise and consumables.Information regarding gene function in CMS has been made available to the Newcastle group. Collaborators provided samples, expertise and consumables.</gtr:partnerContribution><gtr:piContribution>We have provided samples, expertise and consumables.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DMT RCPH Liverpool 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EEDD58B0-F7C0-4729-8001-AD1916422533</gtr:id><gtr:impact>Invited speaker at the annual RCPH conference in Liverpool</gtr:impact><gtr:outcomeId>58c7fba7f2df19.42907659</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcpch.ac.uk/sites/default/files/user158/RCPCH-2016-annual-conference-programme.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview on the use of animal models</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9269774E-B846-494E-B053-5F699CF045BE</gtr:id><gtr:impact>Radio interview on the use of animal models. National outreach, television news audience.

.</gtr:impact><gtr:outcomeId>KJ3FswEkrdY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMT book : A practical guide</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>022E4505-6C0E-4989-A593-EF85B661BA4A</gtr:id><gtr:impact>Input into CMT a practical guide for patients</gtr:impact><gtr:outcomeId>56deeeeee677d5.95538380</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B72A05BD-5924-4B42-9DE2-87B9B15484A7</gtr:id><gtr:impact>Advances in treatment in neuromuscular disorder. British Neuropathology Society, UCL Institute of Child Health, London UK, 4th March 2015</gtr:impact><gtr:outcomeId>56b22a93ef0808.20159912</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Developing Antisense Oligomers as a Genetic Therapy for Duchenne Muscular Dystrophy. Distinguished lecture: Frontiers in Neuroscience, American Academy of Neurology Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30F79184-D67E-4E0D-90F4-51D2177BA891</gtr:id><gtr:impact>22nd - 25th April - lecture on TIMP and MMP9 and miRNA and dystrophin, How AON entre muscle cells, Differences between dynamic in cardiac and skeletal muscle, Novel PPMO and Tryciclo DNA</gtr:impact><gtr:outcomeId>56dd5ae4eb9e49.18676771</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IvIg Patient Information Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CD4D27ED-CB84-4D46-B715-77211ED4D998</gtr:id><gtr:impact>The centre for neuromuscular diseases held the first IvIg patient information day on 29th March 2010 at Queen Square. Patients receiving IvIg and their families came from all over the UK to hear about different aspects of the treatment. Members of the multidisciplinary team at Queen Square were on hand to answer questions and explain the treatment and process. Patients also had the important opportunity to meet other families who were undergoing IvIg treatment.

A second day is planned for 2011.</gtr:impact><gtr:outcomeId>jeDDJRsFn9h</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMT patron invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6090EABC-ABE2-4C71-8217-5DF112F3CA9F</gtr:id><gtr:impact>Invite dplenary speaker</gtr:impact><gtr:outcomeId>56deef45d02e05.75411594</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Information Day 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF0E7DA2-333D-4F83-A826-F2003C8FE2E2</gtr:id><gtr:impact>Over 100 patients, families and their carers attended an all day meeting in October 2016. There were talks from professional practitioners, information stands and engagement activities as well as patient focus groups. There was also an informal evening event which offered patients and their families and carers an opportunity to interact with other people affected by mitochondrial disease.</gtr:impact><gtr:outcomeId>58c7d2b3c688a9.57928449</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.newcastle-mitochondria.com/patient-day-2016/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advances in treatment in neuromuscular disorder talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9B9F75CF-EAC3-43B0-8458-4ABAB4B45BCE</gtr:id><gtr:impact>Gave a lecture during organised British Neuropathology Society meeting at UCL Institute of Neurology.</gtr:impact><gtr:outcomeId>56dd5a4240ceb0.24505325</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Myositis Support Group Annual Meeting &amp; Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B558AC17-5256-4DD4-86BA-31DED9281AC1</gtr:id><gtr:impact>The last Conference was in Southampton, 15th July 2012. The next Conference will be in Oxford, 21st July 2013. We are usually asked to give an update about IBM research. We also participate in &amp;quot;open discussion sessions&amp;quot; with patients.


Our research group is regularly invited to attend the Myositis Support Group Annual Meeting &amp;amp; Conference. The &amp;quot;open discussion sessions&amp;quot; are particularly appreciated by patients.</gtr:impact><gtr:outcomeId>rTmyM6qe4qM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EMEA - TREAT-NMD meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>277E43E7-11BC-46DB-8C6B-FEDC5803117B</gtr:id><gtr:impact>Meeting at EMEA organised by me (but hosted at EMEA) to discuss personalised medicine for DMD

workshop report to published
20347306 Muntoni F (May, 2010) The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009., Neuromuscular disorders : NMD 20, 5, 355-62</gtr:impact><gtr:outcomeId>A243806D1A8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work Experience Placements for Year 12 Students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>724DE104-1F21-45D7-9F47-4A6CA568443E</gtr:id><gtr:impact>Three year 12 students, including one with a comparatively mild muscle disease, observed a series of experiments in the lab for a week.

The students felt informed and expressed improved enthusiasm for biomedical science</gtr:impact><gtr:outcomeId>QjsrhNMwTik</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IBM Patient Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>307D4218-8A00-4A84-846C-3BC717F7C58B</gtr:id><gtr:impact>10/12 trial subjects attended the meeting. Preliminary trial results were reported. Feedback from patients was extremely positive. Future research directions were discussed. A representative of the &amp;quot;Myositis Support Group&amp;quot; also attended the meeting.

Further engagement of patients on the IBM research conducted at the MRC Centre for Neuromuscular Diseases.</gtr:impact><gtr:outcomeId>PuKAvPX384U</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DMT NIHR Summer Camp Ashbridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>892D323F-3F5F-414E-8917-40A5E9C0EEC4</gtr:id><gtr:impact>Invited speaker at the NIHR Training Camp in Ashridgge</gtr:impact><gtr:outcomeId>58c7ff30721323.74215620</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Channelopathy Patient Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5ADFA483-0155-4CC1-9BD3-05B66F908465</gtr:id><gtr:impact>The centre for neuromuscular diseases held the first channelopathy patient education and information day on 23rd January 2010 at Queen Square. Channelopathy patients and their families came from across the UK to hear about different aspects of channelopathies including diagnosis, treatment and care. Members of the entire multidisciplinary channelopathy team at Queen Square were on hand to answer questions and explain the diagnostic process, care and treatment through practical demonstrations and posters. Patients also had the important opportunity to meet other families who were affected by channelopathies.

A second patient day is planned for 2011.</gtr:impact><gtr:outcomeId>Zo6k7ZxqcBA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination articles for advocacy groups magazines</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5629DAB6-D0E0-4D4E-B10E-07E687AFBF1F</gtr:id><gtr:impact>Articles and interviews published in Action Duchenne and in Muscular Dystrophy Campaign UK Charities. The same for Muscular Dystrophy Association USA, and for MDA Australia, and for Association Francaise Myopathies.

Patient queries, request of more infromation/ clarification. Contact with industry</gtr:impact><gtr:outcomeId>318B8AD2EF0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited as speaker for ABN and PNS of whcih I am president elect and president</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D7328579-ACD6-40BA-953B-EE20DDB2B2B6</gtr:id><gtr:impact>Regularly invited as a speaker to international conferences to talk on CMT. ICNMD, PNS, ABN in Perth, Chile etc</gtr:impact><gtr:outcomeId>56deefe2e79340.34440472</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DMT Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C83A03B9-BD68-4A31-96A3-E790187FCEB8</gtr:id><gtr:impact>invited speaker at the Wellcome Mitochondrial Medicine meeting at Hinxton Cambridge in May</gtr:impact><gtr:outcomeId>58c7fcb6462d33.28076911</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.globaleventslist.elsevier.com/events/2016/05/mitochondrial-medicine-developng-new-treatments-for-mitochondrial-disease/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Skipping Threapy for Duchenne Muscular Dystrophy. Paediatric American Association Meeting, San Diego, 25th-28th April 2015.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F52E7DE5-B71D-438B-AD26-B6A3219CA3B0</gtr:id><gtr:impact>there were approx.. 400 - 500 attendees. Our task as a group is to give an overview of the topic each has agreed to discuss where research has been, where it is going, and the potential impact for treatment of the pediatric population.</gtr:impact><gtr:outcomeId>56dd5b29d5ccd0.19529596</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle Mitochondrial Patient Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7974EA7C-4C1E-448A-8550-7CA1956FD4D8</gtr:id><gtr:impact>Presentation to patients and their families/carers about diagnosis of mitochondrial disease, and the impact of new genetic technologies.

Patient day to be repeated in 2014.</gtr:impact><gtr:outcomeId>gsxiwpyeF8H</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Modification of Splicing as a Therapeutic strategy for neuromuscular disorders.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8DCAF3FB-E944-4A29-8573-20BEE5E6A506</gtr:id><gtr:impact>International Experimental Medicine Conference. NIHR Biomedical Research Centre at UCLH and Institute of neurology, London 13th October 2015. International Experimental Medicine Conference at which Francesco Muntoni lectured on Modification of splicing as a therapeutic strategy for neuromuscular disorders</gtr:impact><gtr:outcomeId>56dd5bca0828b4.40910123</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMT Patient Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4752102B-C0E1-48FC-BA1F-D01A68608EB6</gtr:id><gtr:impact>A day of talks for the CMT patient population given by a multidisciplinary team with opportunity for questions and discussion.

Request for this annual patient day to continue in 2015.</gtr:impact><gtr:outcomeId>5460d2431c8123.70927022</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>parent organisation meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>319C3FEB-543C-4004-BCE3-EC243C24FDA3</gtr:id><gtr:impact>presentations by various scientists and laypersons associated with DMD

attendance of experts in the field of DMD</gtr:impact><gtr:outcomeId>E53ABBA52EB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMT UK AGM</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CD7DDA9-33A5-4191-94AE-0679B2940F37</gtr:id><gtr:impact>PI, the President of CMT UK was an invited speaker at the AGM, and facilitated a question and answer session with CMT patients attending the meeting.

As a result of this meeting, CMT UK made a contribution towards MRI scanning at the MRC Centre for Neuromuscular Diseases.</gtr:impact><gtr:outcomeId>FyByMXqt54J</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.cmt.org.uk</gtr:url><gtr:year>2007,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Science Festival 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C69F5F85-345E-42DC-A598-6D06F28FF89D</gtr:id><gtr:impact>A series of lab tours were arranged and the public introduced to our working environment

Many participants reported finding the tours of high interest.</gtr:impact><gtr:outcomeId>jsKnhE7vnVh</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://blogs.ncl.ac.uk/igmengagement/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDC Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F9CDD096-5A30-4288-833A-ACD3CAA03061</gtr:id><gtr:impact>About 50 patients and carers attended a series of talks outlining the various activities ongoing in Newcastle. This was followed by tours of the labs and a chance to meet various members of the team.

Feedback from patients, carers and fundraisers indicated that the day was well-received with many participants gaining substantial useful information.</gtr:impact><gtr:outcomeId>GDQWzFSRR95</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>6th Form Experience Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0F60A6A9-023C-4BC0-A104-67D62AB4882C</gtr:id><gtr:impact>50 pupils were invited to engage with researchers and tour the labs.

The schools reported that many pupils found the day interesting and felt motivated to pursue scientific careers.</gtr:impact><gtr:outcomeId>M8pABXEsgzD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://blogs.ncl.ac.uk/igmengagement/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Molecular Biomarkers for Duchenne Muscular Atrophy. European Medicine Agency (EMA) meeting, London, 29th April 2015.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D8152F06-6A2C-4D91-9134-8189AA96D2F5</gtr:id><gtr:impact>Full day EMA meeting in London to discuss Biomarkers in DMD</gtr:impact><gtr:outcomeId>56dd5b6fa69be3.01704651</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIH/FDA conference on antisense oligonucleotide therapies in neuromuscular disease, Washington September 27-28, 2010</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EB89963-451D-4B77-9843-6CA01F23ED4D</gtr:id><gtr:impact>attended by representatives from FDA, NIH, industry, academics and parent organisation involved in Antisense Oligonucleotide Therapies in Neuromuscular Disorders

Presented concluding remark lecture on 'Lessons on Development of AON drugs for Neuromuscular Disease'.</gtr:impact><gtr:outcomeId>WRsdpipSwaG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Science Festival  2013 - DMT</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EEADE852-5BD0-4F25-8620-A6785F67519A</gtr:id><gtr:impact>CBAV Director led a public discussion, chaired by the Head of Communications at the Wellcome Trust, about the new IVF technique to prevent mitochondrial disease. The technique has generated huge international media interest.


UK Government have approved publication of revised draft regulations allowing this research to go ahead.</gtr:impact><gtr:outcomeId>h4rNprgUcfX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Organisation Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D29EB760-8254-4D75-9831-112D47733F09</gtr:id><gtr:impact>The aim of these meetings is to inform patient organisations about the activities of the centre, and ensure that they can work with the centre to achieve our goal of treating neuromuscular disease.

The area leads give updates on education, imaging, the Biobank, animal models and clinical neuromuscular trials across the UK, followed by the opportunity for questions and discussion. Representatives from over ten patient organisations attended the meetings.



Two patient organisations have part-funded one non-clinical three-year PhD studentship each as a result of these meetings (one CMT project, and one IBM project).</gtr:impact><gtr:outcomeId>Pf6QzeNMEak</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CMT Patient Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EFE53E6A-22EA-428C-8593-0AA12AFBE0A1</gtr:id><gtr:impact>The centre for neuromuscular diseases held the first CMT patient education and information day in 2010. CMT patients and their families came from all over the UK to hear about different aspects of CMT including diagnosis, treatment and care. Members of the entire multidisciplinary CMT team at Queen Square were on hand to answer questions and explain the diagnostic process, care and treatment through practical demonstrations and posters. Patients also had the important opportunity to meet other families who were affected by CMT.

.</gtr:impact><gtr:outcomeId>CN8Yw5sek3V</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Young Science Writers Contest</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FBEF40AD-BC14-45C9-952D-1A9731680E44</gtr:id><gtr:impact>Over 150 pupils from local schools submitted short stories to the competition. The winners and runners up were invited to a formal prize-giving and they and their families invited to tour the labs.

The students engaged effectively with the task and many felt that their interest in science had increased.</gtr:impact><gtr:outcomeId>qpMYtMKKjZh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://blogs.ncl.ac.uk/igmengagement/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitochondrial Patient Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6A1F92F-1B8F-4BA6-A8A4-3DA1D79A8644</gtr:id><gtr:impact>The centre for neuromuscular diseases held the first mitochondrial patient education and information day on the 15th November 2008 at Queen Square. Mitochondrial patients and their families came from across the UK to hear about different aspects mitochondrial disease including diagnosis, treatment and care. Members of the entire multidisciplinary mitochondrial NCG team at Queen Square were on hand to answer questions and explain the diagnostic process, care and treatment through practical demonstrations and posters. Patients also had the important opportunity to meet other families who were affected by mitochondrial disease. The second mitochondrial patient organisation day took place on 25th November 2009. The University of Newcastle has also held two mitochondrial patient organisation days in 
4th July 2009 and on 24th June 2010.

A third mitochondrial patient day is planned for 2011.</gtr:impact><gtr:outcomeId>GnxtRh2Wczj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sci-Talk Writers and Scientists Collaboration</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FC92C4CB-441B-4976-92D0-70522FF1E0CC</gtr:id><gtr:impact>Several meetings between a group of artists/writers and members of the research team to explore potential collaborative efforts aimed at producing materials (books, videos and artwork) to engage younger audiences in science.

Active collaboration between individuals resulting in a grant application to the Wellcome Trust for humanities funding. The grant was well-received, but did not get funded.</gtr:impact><gtr:outcomeId>WGdgfWYt44f</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.scitalk.org.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pathogenesis and therapeutic window in chromosome 5 spinal muscular atrophy.  XVIII Scientific Convention, Telethon. Riva del Garda, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>47A1CA44-67C8-408A-BFD6-5678CE4AC48C</gtr:id><gtr:impact>Lecture at 3 day conference, Telethon, Riva del Garda</gtr:impact><gtr:outcomeId>56dd5a8ff07184.14617600</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>35658</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TREAT-NMD Operating Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>41A25118-6DD8-4E4F-B63A-FA04C62A11BF</gtr:id><gtr:outcomeId>546213c80e9660.17788991</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55337</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain imaging and cognition in boys with Duchenne muscular dystrophy</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>ED28AAB8-A929-47E5-B1F4-5BFF415ED0D5</gtr:id><gtr:outcomeId>56d5bf45c23189.24418243</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CMTUK MRI funding</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Charcot-Marie-Tooth Disease (CMT)</gtr:fundingOrg><gtr:id>4254FA88-A1FC-4C91-82F0-2C46082FFA4D</gtr:id><gtr:outcomeId>56deeb57224b22.51766201</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>116126</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research leadership funding</gtr:description><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:id>2D55513D-58F4-47F7-8A6E-9FCDCC8EC65D</gtr:id><gtr:outcomeId>ZsmDbTJ4WJi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>317000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society URF</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>26C17A4A-19E1-4F59-89F3-9DF53882DB24</gtr:id><gtr:outcomeId>56c454877c7bb3.08800891</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>641000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy mechanism evaluation</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CCF28A61-AE2E-41B5-B6C7-FD1F32089036</gtr:id><gtr:outcomeId>HunwZi7h7ZZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Building the Knowledge Base for Therapy Development in Duchenne Muscular Dystrophy</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>814D0F40-41D0-4C63-8525-7589CB925CF9</gtr:id><gtr:outcomeId>56d58144b92037.81072905</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCF Award</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>59510510-5E92-4ED0-8FFA-972EF732CC41</gtr:id><gtr:outcomeId>54622c66300ad5.69322803</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>282714</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Great Ormond Street Biomedical Research Centre</gtr:department><gtr:description>Matched funding for MRC Centre for Neuromuscular Diseases</gtr:description><gtr:fundingOrg>Great Ormond Street Hospital (GOSH)</gtr:fundingOrg><gtr:id>D703A806-6B62-4249-BF40-570A9035EEF0</gtr:id><gtr:outcomeId>oK6tVJKU71d</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Vascular abnormalities in Spinal Muscular Atrophy.</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:id>FB040C97-2FD4-4E7B-9164-2639A018B5A7</gtr:id><gtr:outcomeId>56dd565ef3dbe4.88836898</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>345000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Horizon 2020</gtr:department><gtr:description>Horizon2020 eNHANCE motor function in physically disabled people.</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>10421706-6898-4F18-A28E-3878FD0F1039</gtr:id><gtr:outcomeId>56dd55c1881099.36060667</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111225</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Studentship</gtr:description><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>1E543852-6861-46EB-B318-5BFB5092E147</gtr:id><gtr:outcomeId>on4EPqYPva1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Associates x2</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>6FB322D5-1279-44AF-AB64-3D2A02328F71</gtr:id><gtr:outcomeId>58a45808f2fbe0.26482064</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>177731</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:fundingOrg>Janus Developments</gtr:fundingOrg><gtr:id>681FD97C-B71E-433C-BF04-CD4F9E2D8D1D</gtr:id><gtr:outcomeId>bZiFvVt4vhd</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SMA Coordinator</gtr:description><gtr:fundingOrg>Jennifer Trust for Spinal Muscular Atrophy</gtr:fundingOrg><gtr:id>63E9C27B-A490-49AA-A79B-F9B66CA495BE</gtr:id><gtr:outcomeId>54622ad750b068.66047771</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>290000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Fellowship Enhancement</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>25599C87-86C2-45FA-97C0-CF8F9F6E3C71</gtr:id><gtr:outcomeId>rGpYthJ9bZi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Novartis Institutes for BioMedical Research (NIBR)</gtr:fundingOrg><gtr:id>C3FFD31A-6A7A-489D-AF42-B647AB4F320C</gtr:id><gtr:outcomeId>546237ff6b4803.64754928</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28571</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RARE - Best Practices</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>A6D743B8-0882-4BA6-A5AD-7CA11D00E1F8</gtr:id><gtr:outcomeId>5462139e8b3b31.52488667</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4194451</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F9BE7B0F-83D1-4171-86F9-3DAB55C0F2AE</gtr:id><gtr:outcomeId>546228192eb4d6.69917894</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>303704</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU-FP6 TREAT-NMD Network of Excellance in Neuromuscular diseases (co-investigator, 10m euros across 27 participants)</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>A6478BA2-5982-44FF-9AA7-E3529321702D</gtr:id><gtr:outcomeId>CRmArr74KQb0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9019</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>A6695A87-787B-440B-B90F-6AA56A8D8C3D</gtr:id><gtr:outcomeId>54622a7616d622.08399866</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Newcastle Healthcare Charity</gtr:department><gtr:description>Project grant - The importance of mitochondiral dysfunction in the pathogenesis of osteoporosis</gtr:description><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>9CB6F5D1-8E15-420B-AC11-3F35E70F672F</gtr:id><gtr:outcomeId>ig2M7e3RYa8</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88888</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project 3 - Accelerating the agenda for academic networking in post marketing surveillance for RD drug development</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Children's National Medical Centre</gtr:fundingOrg><gtr:id>4C52F7E7-09CC-41AB-A55B-3D288FA12623</gtr:id><gtr:outcomeId>56d584ff94adf6.75266301</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>194000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1BB3DC1F-5267-4692-95B5-BB26D59E0187</gtr:id><gtr:outcomeId>546233a1eccc99.16012296</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>355000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rare Disease Initiative</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3D3C4BF5-1EB5-44D4-8A1F-A6EA38ED8B1A</gtr:id><gtr:outcomeId>54622e221430e4.87849504</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>164119</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Adrenergic signalling and congenital myasthenic syndromes - ABN Fellowship</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>81B199D0-27F6-41AC-94ED-4D611DE30C8D</gtr:id><gtr:outcomeId>56d58210ee90a5.05488338</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111225</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>AAA2CFCB-9CFD-4B1D-9B0F-2D16F423E7BB</gtr:id><gtr:outcomeId>54622c92c24ad9.40166990</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1139280</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Starter Grant - consolidator</gtr:description><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>E5A03D3F-4B27-44AE-B199-05C2C0370661</gtr:id><gtr:outcomeId>54622852970eb9.78009355</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU Health Innovation</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>AC247E62-C489-459E-9763-7E97CB18742D</gtr:id><gtr:outcomeId>HPbraiSoQ7h</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>891000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>342FCA41-E542-4651-928A-0C5CE574A8B2</gtr:id><gtr:outcomeId>5462195e3b5905.00409198</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105143</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Second generation exon-skipping therapy combined with pharmacological inhibition of the sodium-hydrogen exchanger: effects on cardiac and skeletal muscle in a mouse model of DMD.</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Jesse's Journey</gtr:fundingOrg><gtr:id>EDD4C120-04A6-4542-9375-F52AEB90A86D</gtr:id><gtr:outcomeId>56d5beec0313c7.18263431</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TREAT-NMD Advisory Committee for Therapeutics</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>907D4AC0-88B3-486B-8AB5-F67D8B9C1535</gtr:id><gtr:outcomeId>56d58742b30a81.49565940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4A641666-82AB-4401-A082-FEBA5B358F58</gtr:id><gtr:outcomeId>546213ee800dc0.81449961</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EB880A7E-4576-47F7-A917-632B958E7EF3</gtr:id><gtr:outcomeId>Cj168PqtbZG</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464146</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4160166C-4D1B-4AF7-B2BD-21A56258FD1D</gtr:id><gtr:outcomeId>546227d4ac7007.45506234</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5960000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>FP7</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B2BEEC85-10C1-4B66-B74D-B26CEA5ADBEC</gtr:id><gtr:outcomeId>546212c5c3eb17.93384506</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8066</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>588DA762-E360-467C-A653-A3B11C9D1D77</gtr:id><gtr:outcomeId>54623584eaaf43.74078545</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Clinical Fellowship - 2nd renewal</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>167C57E3-8AE6-4230-A2FC-543B2B67FC86</gtr:id><gtr:outcomeId>jkppPG3WLbp</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61744</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Myotubular and Centronuclear Myopathy Patient Registry</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Myotubular Trust</gtr:fundingOrg><gtr:id>570752DB-2DFE-418A-8F2D-25F680DD790F</gtr:id><gtr:outcomeId>56d5832522d890.14509343</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>895068DC-5A24-47EF-91F7-FCB15FEC4A36</gtr:id><gtr:outcomeId>56c45098a8a203.89356117</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E2B254BD-DF56-4748-867F-28C330E56E50</gtr:id><gtr:outcomeId>546233d5393f28.94358896</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept Fund (co-investigator with Professor Hanns Lochm&amp;uuml;ller)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BEC61605-392C-4AAC-B93E-1EBB59C38695</gtr:id><gtr:outcomeId>56b878413e1452.86064984</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rare Diseases Translational Research Collaboration - DMD</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E4715A33-3E3A-4762-992C-5D52B928EF8D</gtr:id><gtr:outcomeId>546226fedb0248.22158957</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208314</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CSO Fellowship</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>72E32A47-A410-4521-93BB-90AB9860AB25</gtr:id><gtr:outcomeId>YdoQD9jeAHS</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>144849</gtr:amountPounds><gtr:country>South Africa, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council of South Africa (MRC)</gtr:fundingOrg><gtr:id>C1B96EBA-9535-4285-92A1-C42C57DC42BF</gtr:id><gtr:outcomeId>5462346dda53e1.33516181</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24547</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Peptide conjugated oligonucleotides for splice switching therapy of Spinal Muscular Atrophy</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BE093E40-8ADF-4B22-926D-B09C71EF9CD8</gtr:id><gtr:outcomeId>56d5bb65859203.63295759</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strengthening the neuromuscular junction as a new concept for the treatment of congenital myasthenic syndromes and motor neuropathies with synaptic dysfunction</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>AC19983F-AD66-46D6-8F61-C531042DDF8F</gtr:id><gtr:outcomeId>56d584a292af96.63437264</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6336817</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Centre renewal</gtr:description><gtr:end>2022-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>203105/Z/16/Z</gtr:fundingRef><gtr:id>611AE213-8482-4A64-8F1B-4CC4F8355A95</gtr:id><gtr:outcomeId>58c29bdeb02051.57023305</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18518</gtr:amountPounds><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DMD Liaison Post</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Duchenne Parent Project Holland</gtr:fundingOrg><gtr:id>480BD0B6-691C-4258-937B-4D8A5215FFDA</gtr:id><gtr:outcomeId>54621566559858.61762736</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>994155</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DD926E57-E461-4764-B500-1F3164045CC8</gtr:id><gtr:outcomeId>5462232b69dcb5.47395440</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>342971</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bridging Funding</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D806E205-594B-4466-9713-B120A5180798</gtr:id><gtr:outcomeId>54623781353949.79730531</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Starter Grant</gtr:description><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>1FB77A1F-8356-4AFD-AAF6-31C7F7156C56</gtr:id><gtr:outcomeId>GtDS4SbddoL</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>161319</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cardiomyocyte regeneration in non-ischaemic cardiomyopathy</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>1B7B538D-2BE5-4302-9E73-95D69A4124B5</gtr:id><gtr:outcomeId>56d5a0c6008829.32657812</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>2F5BB9F8-CB25-42CE-9B54-4CD957A287CB</gtr:id><gtr:outcomeId>5462383e561a05.78905621</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Clinical Fellowship - 2nd renewal</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C701F044-7DD1-4DD9-A556-89E2944960A8</gtr:id><gtr:outcomeId>546219130efc20.45051537</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>466205</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K018523/1</gtr:fundingRef><gtr:id>06A90D03-2FCE-4188-A6BC-1BEE2224C310</gtr:id><gtr:outcomeId>ne6Jp7xaZiZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>153755</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dr Michela Guglieri RCF Support</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>NHS England</gtr:fundingOrg><gtr:id>F981558C-B8C8-46E2-8EA3-9AB9769FAC31</gtr:id><gtr:outcomeId>56d5838589d788.66041606</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>8EC247D1-89D8-4FBB-A34C-93C53A18DB07</gtr:id><gtr:outcomeId>54622a9df07a36.81347406</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>212000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D1DF7CEE-62BD-462D-83AD-97F56F48B19B</gtr:id><gtr:outcomeId>56deeaea584541.02172427</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1008000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5EB8E1A9-BE19-4144-82CB-32962B895F0E</gtr:id><gtr:outcomeId>54622e8fa98a07.18549760</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>157489</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Newcastle Healthcare Charity</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>FCED939A-7BA2-49AC-AD49-6BB833DE7DF0</gtr:id><gtr:outcomeId>546237aee7c498.22712292</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>193000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Neuromics</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>659B1B6F-4459-49E0-BFA9-D3C2035BDEE6</gtr:id><gtr:outcomeId>NLv3FRzJSun</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99360</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Project grant - HSN1: exploring the role of 1-dSLs in the pathogenesis of the disease, and defining outcome measures for a clinical trial</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>EB98E301-12CF-4C33-B962-99742F94754A</gtr:id><gtr:outcomeId>jbySpwCNEVy</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-Doctoral Fellowship</gtr:description><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>9568D503-1F65-4243-A3D8-45ADC50E0F11</gtr:id><gtr:outcomeId>546221332125c8.84614897</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363060</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Rare Disease Translational Research Collaboration Postdoctoral Clinical Fellowship - Channelopathies</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E34BBA5A-83EF-4A92-B698-816EEF38456B</gtr:id><gtr:outcomeId>56dd6478562632.59392525</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>295743</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of cardiomyocyte senescence and cardiac regeneration in ageing</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>17A77EAF-64FF-435B-AE86-521006A974E2</gtr:id><gtr:outcomeId>56d5c0804232c3.92398110</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25002</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>Project grant - Treating mitochondrial dysfunction</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>194627B7-6FFB-46F6-A4D5-08B53BF41FD0</gtr:id><gtr:outcomeId>FgciHHgwUrZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Fast Track Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B8046A54-4B7E-48A7-B4B9-B0C0DB67568F</gtr:id><gtr:outcomeId>j5jMwwD68ft</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>197000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - Evaluating benefits of community-based aerobic training</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>2D28CFD2-E3F6-45BD-AEB1-26F780AF8DB0</gtr:id><gtr:outcomeId>nDbuFWfVMsd</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29507</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:id>E0B46202-BDB4-4CBA-8D7A-1E0D2A1F6FF0</gtr:id><gtr:outcomeId>5462148e580234.74071085</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Pathfinder (co-investigator with Professor Hanns Lochm&amp;uuml;ller)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EC784264-E7D8-4404-9091-03F36C3B1A45</gtr:id><gtr:outcomeId>56b8787b810d31.87691839</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1980000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Capabilities Call</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8709006D-7A96-49B5-9DE9-ACD8543B9789</gtr:id><gtr:outcomeId>546218b0403265.05300275</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1543444</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project grant: A randomised controlled trial of efficacy of heat shock protein upregulation in IBM</gtr:description><gtr:fundingOrg>Food and Drug Administration (FDA)</gtr:fundingOrg><gtr:id>62267374-CCDE-4657-AEC6-8AA11297C2EE</gtr:id><gtr:outcomeId>58a457b293f2b9.22814157</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Purchase of Embletta MPR PSG with ST+ proxy sleep recording device</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy Association</gtr:fundingOrg><gtr:id>3D23CEC1-699A-417A-8E86-0B769DFB68E3</gtr:id><gtr:outcomeId>56d582d9ae9640.26594054</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>730067</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8100CC2B-1FF5-4B71-9218-9053B64F9C3F</gtr:id><gtr:outcomeId>5462364155f3a1.14854209</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530404</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RD-ACTION Joint Action on EU wide rare diseases information databases</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F31F886F-F51F-4758-B1D4-739D5F3C3D8B</gtr:id><gtr:outcomeId>56d5862f060cb2.80304801</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>155213</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identifying HIBM patients - Ultragenyx</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Ultragenyx Pharmaceutical Inc</gtr:fundingOrg><gtr:id>911EBE01-2D94-4D33-85A6-9D28C6076592</gtr:id><gtr:outcomeId>56d5829a313a90.10025809</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>The Lily Foundation</gtr:fundingOrg><gtr:id>51DD1ED0-7EC8-4935-B537-1ACBFE972181</gtr:id><gtr:outcomeId>54622c3ddc01a1.68210898</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200243</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:id>CE24E25F-AB1A-4871-A5FD-F5B4438EEFEC</gtr:id><gtr:outcomeId>546220904ff159.68175377</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>577798</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>People Itn (Marie-Curie Action)</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>98D7E53D-F609-4BBD-9B56-3B1CEF30D216</gtr:id><gtr:outcomeId>54622893753370.19310169</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8571</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TREAT-NMD registry</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>University of La Rochelle</gtr:fundingOrg><gtr:id>0DBF0905-6465-45F1-ADE4-8B93C54784E4</gtr:id><gtr:outcomeId>56d581d0a772f5.50262632</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>197219</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novel biomarkers for mitochondrial disease</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>2709B8DC-C007-42BC-9FB4-FEBC18F4DB94</gtr:id><gtr:outcomeId>56dea14464e506.19688299</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Investigator Award</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>109915/Z/15/Z)</gtr:fundingRef><gtr:id>1149886B-D05E-42DB-962C-26B53F444BCC</gtr:id><gtr:outcomeId>56b877b07fd861.87859526</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192243</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - mitochondrial quality control pathways</gtr:description><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:id>3CB463DE-49EC-4C82-AD15-635216197E32</gtr:id><gtr:outcomeId>nTj9edTU3jC</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Proof of concept trial</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>5FB4AAF4-05E6-4A84-BED0-CB88AE9430C0</gtr:id><gtr:outcomeId>58a458898422b7.13275418</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH Rare Diseases Consortium Grant(USA)</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>National Cancer Institute (NCI)</gtr:fundingOrg><gtr:id>A558119C-730F-4189-8B60-5EA8CB6A81CE</gtr:id><gtr:outcomeId>5697c46ce3d289.94533549</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>286551</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Public Engagement Programme</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9D8999D7-701D-4842-AC4D-CA479314FBFE</gtr:id><gtr:outcomeId>5462367fa61460.93178315</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DMD Liaison Post</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Parent Project Muscular Dystrophy</gtr:fundingOrg><gtr:id>EA211B6A-AD8D-42A6-8AB6-DB48BACD3CAD</gtr:id><gtr:outcomeId>5462172e5de3e5.07095498</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>The Lily Foundation</gtr:fundingOrg><gtr:id>51887815-C034-4858-928C-8F689A7FA218</gtr:id><gtr:outcomeId>54622609500492.47097135</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>71441</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>9E26A215-830A-4114-9D82-C9B208BBF678</gtr:id><gtr:outcomeId>546235aba9a0c7.01738878</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>Malta, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Naarden Five Years Later. A global assessment of myotonic dystrophy registries, databases and cohorts.</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Marigold Foundation</gtr:fundingOrg><gtr:id>5EC35568-4FE8-4E42-9E09-81367413BFA2</gtr:id><gtr:outcomeId>56d5807d255026.11104095</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10826</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Patient Registry</gtr:description><gtr:fundingOrg>PTC Therapeutics</gtr:fundingOrg><gtr:id>939080B8-EE30-4819-B651-B01F1188CD54</gtr:id><gtr:outcomeId>54622b03a4d962.10753414</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of new Gene Therapy approaches for Spinal Muscular Atrophy.</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:id>E5DF5BED-98A8-4BFE-843A-83C00CD25BB2</gtr:id><gtr:outcomeId>56dd5929a7df82.61572824</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC - Strengthening the neuromuscular junction as a new concept for the treatment of congenital myasthenic syndromes and motor neuropathies with synaptic dysfunction</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3C128A11-3C70-4937-9E7D-BEAE9E7EB098</gtr:id><gtr:outcomeId>56d5845744f981.76176960</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>Bezafibrate to treat mitochondrial myopathy. Internal award.</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>092CBACE-F9E9-4126-8A7D-A1372A3C464A</gtr:id><gtr:outcomeId>56dea354a88221.86235612</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112665</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>e-Therapeutics</gtr:fundingOrg><gtr:id>7EA00C00-6681-4C12-8A92-9BD63204AEE2</gtr:id><gtr:outcomeId>546236da34ece6.35080167</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464146</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Periodic paralysis: from molecules to mice</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2EDFFDBA-8CFD-4D95-9D82-E8BBFDE2EEA7</gtr:id><gtr:outcomeId>56dd64cf418992.42436596</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>852000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>A385C66C-624E-417B-AF45-CB9DAF289786</gtr:id><gtr:outcomeId>54622ecb5af735.35905080</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>193000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Neuromics FP7f</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>598A9CF0-31E1-4D73-8DB5-FAC1C4236DFA</gtr:id><gtr:outcomeId>546226320f9e09.41160695</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Next generation MRI brain imaging platform for dementia research: from microstructure to function</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A34C918F-70E7-4D35-AD62-BEE9D4E1B72E</gtr:id><gtr:outcomeId>56d46c1ae89e23.22570605</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21230</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Validation of Serum Biomarkers for DMD</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>CD0521B5-534F-416B-8B3B-ADDDC1490FC5</gtr:id><gtr:outcomeId>56d5802994cc89.93255477</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13889</gtr:amountPounds><gtr:country>Colombia, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Cancer Institute</gtr:department><gtr:description>National Institute of Cancer collaboration - UK Myotonic Dystrophy Patient Registry</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Government of Colombia</gtr:fundingOrg><gtr:id>4954B486-4DCF-4163-A759-3D61DBF18730</gtr:id><gtr:outcomeId>56d57fa5c4c4d3.79525300</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99360</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8E400CAF-78F4-466A-B549-73D4F18F288C</gtr:id><gtr:outcomeId>546234e200e311.43353116</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Building the Knowledge Base for Therapy Development in Duchenne Muscular Dystrophy</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>C9DC984D-232E-4A0F-BD82-FD60B723D9D8</gtr:id><gtr:outcomeId>56d586c89456a1.39837337</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Disease progression in mitochondrial disease</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>DEDD7342-B549-459C-AB07-950042200618</gtr:id><gtr:outcomeId>56dea3fe877a07.48143538</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Brain Research Trust (BRT)</gtr:fundingOrg><gtr:id>A0360487-8476-4BD1-8112-1BB26E1FEBEE</gtr:id><gtr:outcomeId>gWptLXkeLcj</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2907201</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1990A801-EC4A-4B27-9669-74A4A672592E</gtr:id><gtr:outcomeId>54623707040b72.07820185</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55556</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - Monogenetic mitochondrial disorders</gtr:description><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>FEF6F7B2-4A4C-43C9-BAF5-AB7812F23648</gtr:id><gtr:outcomeId>rTEiDFCxZD2</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome SIMOA Equipment grant</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EA5B0148-0B63-4656-9EAE-A029B15E55B4</gtr:id><gtr:outcomeId>56c3117b95a141.40388327</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Ryan Stanford Appeal</gtr:fundingOrg><gtr:id>C932C4E1-4339-4F65-BE6C-812757711451</gtr:id><gtr:outcomeId>54622bdd413ae2.09884774</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Cure CMD (Congenital Muscular Dystrophies)</gtr:fundingOrg><gtr:id>EDC531FF-9371-4169-972E-978104BCD501</gtr:id><gtr:outcomeId>54622e51747ae3.25909003</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>493106</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Matched funding for MRC Centre for Neuromuscular Diseases</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>939E68EA-79B8-442A-9FB3-1A0EF3D513BC</gtr:id><gtr:outcomeId>VKJx1AfH2hA</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>891000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - high throughput genomics and transcriptions of the human development biology resource</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6C77A70B-6DD2-4CDE-A620-9FE8A587C7FE</gtr:id><gtr:outcomeId>eJLq7h3pndW</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88888</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project 3 - Accelerating the agenda for academic networking in post marketing surveillance for RD drug development</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Children's National Medical Centre</gtr:fundingOrg><gtr:id>CA43E092-5B0E-4B8E-A7C9-9026ABFD9F4F</gtr:id><gtr:outcomeId>5462182e83ff71.39759674</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>174944</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>3150DE59-D50F-4BD0-963D-8CEC74B85866</gtr:id><gtr:outcomeId>54622d2706f105.11629922</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>401333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Rare Disease Translational Research Collaboration Postdoctoral Clinical Fellowship - IBM</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8F60F4E6-27CB-4C79-AEB7-54F2EE148B93</gtr:id><gtr:outcomeId>56dd63d7092ab0.37941269</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200010</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCF Award</gtr:description><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>407D1AED-D5B7-4F93-BC67-BF59E7203984</gtr:id><gtr:outcomeId>546236b43ef844.14876689</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1832756</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU - Horizon 2020</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>9286EC77-5F68-45ED-BB8E-244E47CA5CC8</gtr:id><gtr:outcomeId>56c450418a88f5.70606366</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4194451</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Synaptopathies: genetics, biophysics and circuit mechanisms of paroxysmal neurological disorders</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DBAF5E12-0142-43B1-A613-FCF704DD8BB2</gtr:id><gtr:outcomeId>56dd665beb1f16.26437886</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Senior Investigator Award Renewal</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4F82C021-27F6-4C80-BE07-D44016921B54</gtr:id><gtr:outcomeId>56dea3a52454d6.47119181</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>139000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>BRC</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>173324F2-6712-4527-936A-FC7C4161691F</gtr:id><gtr:outcomeId>56deebd2d8bdc4.75872362</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>84644</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Advances in oligonucleotide-mediated exon skipping for DMD and related disorders - WP3</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>BD9E393B-B6BB-43FD-B0B1-B32931635FAC</gtr:id><gtr:outcomeId>56d5bafbcaae71.06665289</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>287000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Public Engagement Programme</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A83E49F4-1CEC-47B0-8AEF-998BEA913F82</gtr:id><gtr:outcomeId>54622bad366f73.87943295</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>101520</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE Studentship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>2EE78FA4-C3CF-4701-B54D-E85B3AAE9EFF</gtr:id><gtr:outcomeId>5462205e95d061.59984936</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>94600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DMD Programme Coordinator</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Duchenne UK</gtr:fundingOrg><gtr:id>168F2284-3B90-4CAE-A044-2073568FEBA0</gtr:id><gtr:outcomeId>56d5868a575bc2.62864923</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>576521</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>BIO-NMD consortium (Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of neuromuscular Disorders (PI))</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>7DFA5A61-25F7-4A98-B058-AA5CFC4E154C</gtr:id><gtr:outcomeId>ivnMaTmEzHo0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96360</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>ED4AC6D1-DE7A-4C40-BCC1-32C8F16E5771</gtr:id><gtr:outcomeId>546222ef0fcc00.41924109</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>264000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>SMA Trust</gtr:fundingOrg><gtr:id>856F047A-A557-4381-918F-8F89A52F2990</gtr:id><gtr:outcomeId>54622dc03b6240.42346235</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>342971</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant Extension - Centre for Brain Ageing and Vitality</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8BD2186B-31D6-49A0-B473-EC61921C3831</gtr:id><gtr:outcomeId>U2AT9LAYjj7</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7337845</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Controlling Abnormal Network Dynamics with Optogenetics (CANDO) - Full Application</gtr:description><gtr:end>2021-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E6F71D71-77E0-41B9-945B-BB9F2468E224</gtr:id><gtr:outcomeId>56d57f4ac06b55.81448593</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Repair of duplications in dystrophin using CRSIPR/ Cas9.</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>473B4F9A-D185-4DEE-95E1-51825048EE27</gtr:id><gtr:outcomeId>56dd58deeb11d7.79405639</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>School of Life and Medical Sciences</gtr:department><gtr:description>Capital Equipment Fund</gtr:description><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>7F594868-5F47-4877-AA34-BAA9C0D8FD60</gtr:id><gtr:outcomeId>54621cde2fbf77.22474517</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cochrane Neuromuscular Disease Group Quinquennial Renewal</gtr:description><gtr:fundingOrg>The Cochrane Collaboration</gtr:fundingOrg><gtr:id>9B9E2D01-FA78-470C-A9C5-61088339CFC3</gtr:id><gtr:outcomeId>54622b4329a8b1.00720623</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>153059</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Applications of MR imaging and spectroscopy techniques in neuromuscular disease: collaboration on outcome measures and pattern recognition for diagnostics and therapy development</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Dystonia Europe</gtr:fundingOrg><gtr:id>DD2AF4EE-FE7E-4D2A-A543-37806DDE61DD</gtr:id><gtr:outcomeId>56d59f2542dac5.01257398</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4472</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>INC research patient registry enquiry</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>INC Research</gtr:fundingOrg><gtr:id>55956F74-45A5-40BD-B9AF-34B52C801458</gtr:id><gtr:outcomeId>56d585a8bb73d1.64276145</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>498992</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 Health 2013 Innovation 1</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B7EC77E7-4005-4146-817B-1CC486445897</gtr:id><gtr:outcomeId>546219a72d4843.22621903</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhenoDM1Myotonic Dystrophy type 1 (DM1) deep phenotyping to improve delivery of personalised medicine</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>25064DB3-1724-4054-B724-4504B3366CE7</gtr:id><gtr:outcomeId>56d580bc850e11.45914815</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363060</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-Doctoral Fellowship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>5376A2F5-B711-4FFE-8DC1-B11D9F076C3D</gtr:id><gtr:outcomeId>5462275ce2eba7.32078602</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21373</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2CiC - Understanding the biology of ageing skeletal muscle in the oldest old</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>41DF8A22-84E3-4F5F-93F1-71DEF29475A2</gtr:id><gtr:outcomeId>56d587801976a9.03895379</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19444</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Charities MYO-SEQ</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>LGMD2i Research Fund</gtr:fundingOrg><gtr:id>5B065A6A-C73A-42F2-868C-2C5BE36FB7D7</gtr:id><gtr:outcomeId>56d5be923349e9.36510860</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107988</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>Project Grant - exercise training in sedentary subjects</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>90B92DD7-B41C-47AF-BABD-8927D7683CE4</gtr:id><gtr:outcomeId>Kn3zvD4dJpJ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199949</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ultragenyx MYO-SEQ</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Ultragenyx Pharmaceutical Inc</gtr:fundingOrg><gtr:id>F7F040E2-F582-44DF-9FD8-DEC1AB5A8C7F</gtr:id><gtr:outcomeId>56d5bc0d6d4ec0.22922106</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98428</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>NHS Service Support</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7D09FA3C-B8E4-4D50-AA6B-BC30FC5D450C</gtr:id><gtr:outcomeId>54623924c4f6e3.32907430</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>121333</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SMA prevalence data</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Biogen Idec</gtr:fundingOrg><gtr:id>7F7ECA2E-1B3F-4343-B0D5-E7A61BF34C15</gtr:id><gtr:outcomeId>56d58187ed7c74.26690118</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>892F7FF9-8EE7-44FB-BEF9-07EE9FC912A8</gtr:id><gtr:outcomeId>546226786806c8.39792704</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Charcot-Marie-Tooth Disease (CMT)</gtr:fundingOrg><gtr:id>50A03407-6160-44EE-8408-17627C3B44B1</gtr:id><gtr:outcomeId>546234b0160501.36572107</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72413</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Deep molecular phenotyping of myotonic dystrophy (DM1) hiPSC-cardiomyocytes to facilitate risk stratification and drug evaluation</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>9EEC498D-001D-4427-B377-BA2FCA1A4C3E</gtr:id><gtr:outcomeId>56d58107eae646.56672992</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25002</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>9127603D-7142-4756-BD8C-0FA2B71CA609</gtr:id><gtr:outcomeId>546237d73342b3.97611463</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35714</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>93D7B895-062F-449A-B18D-A3AD588CA4AC</gtr:id><gtr:outcomeId>54622a4a3a1850.76913498</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>129298</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHE1 inhibitors to treat Duchenne muscular dystrophy</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:id>2ECCAFD0-0C6C-478C-ABCC-2ECD5B5E71E3</gtr:id><gtr:outcomeId>56d5baacce0b28.93974886</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem cell function in dystroglyanopathies (co-investigator)</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>C6471F0A-47E2-4A7B-807C-60158FEE17DB</gtr:id><gtr:outcomeId>XnUiHQGkEUa0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>126000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of new genes responsible for congenital muscular dystrophies and congenital myopathies using diverse invivo and in vitro approaches (PI)</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>5DB529C8-A811-4DC2-A8F2-0605CAEBFE4D</gtr:id><gtr:outcomeId>inUcbaAbGm30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>233400</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Research Grant</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>101C99CA-FC36-4F86-9AE2-E8DAC440B168</gtr:id><gtr:outcomeId>546221a872c295.04794640</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - maximising the value of MRC Brain Banks: high-throughput genomic studies to enrich data available to the research community</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0CF8B818-6237-43F0-83CE-646EA98436E9</gtr:id><gtr:outcomeId>LnNEfTm28PT</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19565</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CiC : Developing an assay to measure SMN complex activity for the identification of SMA therapeutics.</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>22F33D1A-52ED-4BB5-9A26-4561D4422E7C</gtr:id><gtr:outcomeId>56d5825bd9c1a0.98496665</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50836</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Genethon</gtr:fundingOrg><gtr:id>07828A70-9BDC-40A9-8E17-C39D95F23AEC</gtr:id><gtr:outcomeId>54622f5c1ce5e6.62612963</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>282714</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Great Ormond Street Biomedical Research Centre</gtr:department><gtr:description>Matched Funding</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital (GOSH)</gtr:fundingOrg><gtr:id>03F5C3D2-D7BE-4A2B-AB22-76EA9092F2E1</gtr:id><gtr:outcomeId>546225d9048d88.70027837</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>493106</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Matched Funding</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7DA88C2E-831B-4D81-83B9-AB4B864ACEDC</gtr:id><gtr:outcomeId>5462259d480c59.81969354</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>DE0AE821-F059-4C79-9B04-9753087D6461</gtr:id><gtr:outcomeId>5462151a381b11.17308059</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DMD liaison post at TREAT-NMD office</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Parent Project Muscular Dystrophy</gtr:fundingOrg><gtr:id>EDD6D964-A51A-422A-AC19-B72CC32E1A0D</gtr:id><gtr:outcomeId>56d58552275298.30658137</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1980000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical research capabilities call. The Newcastle University Single Cell Functional Genomics Unit</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7E2283E2-3466-4A56-8ADD-5B3C6EAA9117</gtr:id><gtr:outcomeId>56dea0fdb9b6d4.17978654</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17561</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Physiotherapist</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>UK Clinical Research Network (UKCRN)</gtr:fundingOrg><gtr:id>4D3CA76E-9AF0-4932-A4D0-26FA453526C6</gtr:id><gtr:outcomeId>546233782848c0.03189019</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>401333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-Doctoral Fellowship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7034593B-62C0-4A67-B24F-8E4803C8E872</gtr:id><gtr:outcomeId>54622739a1c8f6.33695560</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172114</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Testosterone Therapy in DMD</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Duchenne Now</gtr:fundingOrg><gtr:id>616D06E4-6469-4EB4-A284-D5B56C9AA149</gtr:id><gtr:outcomeId>56d5c013c1e718.41454009</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rare Diseases Translational Research Collaboration - IBM</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7B57AA3C-14A0-407F-8577-17054E9A5700</gtr:id><gtr:outcomeId>546226dda12bc3.15393836</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13995</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer patient registry enquiry</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Pfizer Global R &amp; D</gtr:fundingOrg><gtr:id>C06E4372-51BE-41B4-92FE-4384ED29E17C</gtr:id><gtr:outcomeId>56d585ec0db669.19100052</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>71441</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Exosomes: a novel therapeutic approach for the treatment of dystrophinopathies</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>7A039445-9E1E-4F3D-BD66-7BA66BE2914E</gtr:id><gtr:outcomeId>56d5a07fca1a06.22863380</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72666</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>European Cooperation in Science and Technology (COST)</gtr:fundingOrg><gtr:id>F672AF59-9D10-4B21-91CB-0DCCFC9DC95B</gtr:id><gtr:outcomeId>546236156a11e8.38062728</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Research Trust/Sobell Foundation Award</gtr:description><gtr:fundingOrg>Brain Research Trust (BRT)</gtr:fundingOrg><gtr:id>2BD5BA16-A15D-4EA5-8638-5EDE5B9C3769</gtr:id><gtr:outcomeId>fnjzwstBAwb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40234</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Demonstrating state-of-the-art neurological MRI for patients with DBS equipment in situ consistent with new product-label MRI safety conditions</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medtronic</gtr:fundingOrg><gtr:id>8569565E-B0D8-4B66-9383-D3EDD76F323B</gtr:id><gtr:outcomeId>56d46c838fb5b0.10709040</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47077</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Faculty of Medical Sciences</gtr:department><gtr:description>Therapeutic Intervention Award</gtr:description><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>8371ECB6-8623-4329-BFA3-EB2AF06A16B8</gtr:id><gtr:outcomeId>54622cdc8451e2.91870626</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-Doctoral Fellowship</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>628D007D-2044-4F89-81B3-EC753FA3BBCC</gtr:id><gtr:outcomeId>546221611c45c0.33518298</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - Eve's curse: the art of mitochondrial disease</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3168A94A-2E27-400C-9543-D105326F6D92</gtr:id><gtr:outcomeId>bHcYt7cUbSu</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107929</gtr:amountPounds><gtr:country>Croatia, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genzyme MYO-SEQ (Straub)</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Genzyme Europe B.V.</gtr:fundingOrg><gtr:id>A9402853-ACB8-411F-9FD0-B7060DD1218E</gtr:id><gtr:outcomeId>56d5bcd95f52a4.46895451</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC research grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AF2F55E9-E7FB-4F46-B590-A0DE0C097846</gtr:id><gtr:outcomeId>56c454fc621af1.05298230</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>425000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Marie Curie Training Network</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>9E8D182C-71CD-4940-8386-253962C09501</gtr:id><gtr:outcomeId>BeY8m7jQxUQ</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59134</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>A30D381C-D328-4C3E-8A5E-FFA3BDC68646</gtr:id><gtr:outcomeId>5462333ec87b83.27522188</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - developing MRI as an outcome measure for CMT</gtr:description><gtr:fundingOrg>Charcot-Marie-Tooth Disease (CMT)</gtr:fundingOrg><gtr:id>4EAAD03F-9808-4B4A-AFBF-A107BFB1FB34</gtr:id><gtr:outcomeId>EnX1rFdjXkh</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75335</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MDC Clinical Trials Coordinator</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>302DE4B7-2BE3-4B5B-B9CC-B46ADAFA761C</gtr:id><gtr:outcomeId>546214ebdce9c7.43865803</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention provides a method for determining all the molecular causes of Inherited Neuromuscular Disorders comprising determining a number of copy number variation(s), and/or determining a number of point mutation(s) on a physiological sample comprising a genome of a subject.</gtr:description><gtr:grantRef>MR/K000608/1</gtr:grantRef><gtr:id>E4C12D25-4547-45DD-9089-92B1621737FC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56c460e2b81465.43632936</gtr:outcomeId><gtr:patentId>WO2014037526</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>2015. Nicolas levy et al.. In vitro Genetic Diagnostic of Inherited Neuromuscular Disorders</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Human Fertilisation and Embryology Authority Draft Consultation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7D5EAC67-996A-4A5E-B355-7D3B1C55A809</gtr:id><gtr:impact>&amp;quot;Following a public consultation by the HFEA, the UK Government have backed the pioneering IVF technique where faulty mitochondria are removed from an egg and replaced with mitochondria from a healthy donor to create the so-called '3-parent baby'.
http://www.newscientist.com/article/dn24230-warning-sounded-over-threeparent-ivf-safety.html 
 
This has resulted in a huge amount of media coverage:
http://www.bbc.co.uk/news/health-23079276
Scientists comment on mitochondrial replacement and evolution, as published in Science*
Thursday 19th September 2013
Roundup comments
Professor Doug Turnbull, Professor of Neurology and Director of the Wellcome Trust Centre for
Mitochondrial Research, Newcastle University, said:
&amp;quot;Like every new medical technique, mitochondrial replacement will carry some risks when first used to
treat patients. We welcome discussion of these and agree that families affected by mitochondrial disease
should be fully appraised of the best science, so they can judge uncertain risk from the procedure against
2
the known high risk of having a child with a devastating disease. They will also consider the likely benefits
of mitochondrial replacement, which we are pleased that the authors of this commentary acknowledge.
&amp;quot;We do not agree that the concerns raised by the authors have been overlooked, or that they present a
compelling argument against clinical use. The experiments they cite have methodological weaknesses that
limit their relevance to humans, or have been superseded by more exhaustive research.
&amp;quot;The suggestion that proofofprinciple experiments in macaques involved closelyrelated animals is
especially misleading. Data in the original paper report that the macaques involved in this work were
unrelated, with substantial differences between the mitochondrial genomes of these animals.
&amp;quot;The authors nonetheless make sensible suggestions about managing risk by matching donated
mitochondria to the mother's as closely as possible. This will often be simple to achieve and is already in
our plans.
&amp;quot;It is critical that all risks, however small, are independently assessed and weighed against probable
benefits before mitochondrial replacement is approved for clinical use. The proper forum for this
assessment will be the expert HFEA licence committees that decide whether the techniques are safe
enough to be offered to patients, should Parliament agree that they are ethically acceptable.&amp;quot;
Professor Robin LovellBadge, Head of Developmental Genetics, MRC National Institute for Medical
Research, said:
&amp;quot;The authors of the commentary highlight some interesting (although not novel) concepts to do with
evolution of mitochondrial DNA sequences and the obvious conflict present due to mitochondria being
inherited only from females, which means effectively that it is not in their &amp;quot;interest&amp;quot; to promote male
survival or fertility. However, this is almost certainly of little relevance within a freely interbreeding species
such as humans, and it is of even less relevance when talking about using &amp;quot;mitochondria replacement&amp;quot;
techniques to allow a few individual women to have healthy rather than desperately ill children.&amp;quot;
* 'Mitochondrial replacement, evolution, and the clinic' by Klaus Reinhardt et al. will be published in
Science at 19:00 UK time on Thursday 19 September 2013, which is also when the embargo will lift.
All our previous output on this subject can be seen at this weblink:
http://www.sciencemediacentre.org/tag/mitochondrialdna/
http://www.bbc.co.uk/news/health24158049
New Scientist (quotes Doug Turnbull)
http://www.newscientist.com/article/dn24230warningsoundedoverthreeparentivfsafety.
html#.UjwUrz82nm4
Times (quotes Robin LovellBadge and Doug Turnbull)
http://www.thetimes.co.uk/tto/health/news/article3874038.ece
3
Science AAAS (quotes Robin LovellBadge)
http://news.sciencemag.org/biology/2013/09/newcontroversyoverexperimentalivfmethod
Clips
BBC News (quotes Robin LovellBadge and Doug Turnbull)
http://www.bbc.co.uk/news/health24158049
19 September 2013 Last updated at 20:10
Warning of three-person IVF 'risks'
By James Gallagher Health and science reporter, BBC News
http://theconversation.com/viewpoints-the-promise-and-perils-of-three-parent-ivf-18402.&amp;quot;</gtr:impact><gtr:outcomeId>DGPXcrdeAEL</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HFEA public consultation</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>04665682-BCD2-430B-8C7E-EA8BD6B945C2</gtr:id><gtr:outcomeId>Jd8cbGS4gA6</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EMA meetings</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines for clinical trials in Duchenne Muscular Dystrophy</gtr:guidelineTitle><gtr:id>E330FFFA-72A8-4CF0-9B89-F20BC909A5BB</gtr:id><gtr:outcomeId>56b4aa81c1d7f8.45049083</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Natural history study of Hereditary Sensory Neuropathy type 1 secondary to SPTLC1 and SPTLC2 mutations. Open to recruitment. Funded by MRC Centre grant.</gtr:description><gtr:id>70FF0D33-1F26-49FA-AA3D-9AAD54629918</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546378c8c3bce4.10659896</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Natural history study of hereditary sensory neuropathy type 1</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Open to recruitment, funded by NIHR.</gtr:description><gtr:id>81E1E344-2BD3-4C4E-BB90-52ACF8B2AEF2</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546365e079a2c9.04909264</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Exploring the causes of falls and balance impariments in people with neuromuscular diseases</gtr:title><gtr:type>Therapeutic Intervention - Physical</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>clinical safety and biochemical efficacy of intravenously administered Eteplirsen in 19 DMD patients. The study drug was well tolerated with no drug related serious adverse events. The study drug is being further developed in the USA and funded by the drug company Sarepta Therapeutics.</gtr:description><gtr:id>34DDBAEE-7A65-4A0F-B422-CF2B83E2F8E1</gtr:id><gtr:impact>The study drug is being further developed in clinical trials in the USA at higher doses, to improve impact. Data is being anaysed for submission to FDA.</gtr:impact><gtr:outcomeId>C8AMNCRGFJd</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Eteplirsen</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/21784508</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Voluntary, multi-centre, multinational, observational programme for patients with LEMS disease and is intended to track the routine clinical outcomes of patients with LEMS over time. Funded by BioMarin Europe Ltd.</gtr:description><gtr:id>F9E390C4-AE24-4CDA-871F-7B017B6E81E8</gtr:id><gtr:impact>Registry in set-up phase.</gtr:impact><gtr:outcomeId>546370ef7c88a5.30667885</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>LEMS Disease Registry</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy)</gtr:description><gtr:id>D8271F2D-4CC3-476C-9E8D-F2AFA8BF8C0D</gtr:id><gtr:impact>The study is now being evaluated for definition of best treatment modality in DMD</gtr:impact><gtr:outcomeId>GRA2E2TDueU</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>DMD114349</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Prospective longitudinal study of the natural history and functional status of patients with MyoTubular Myopathy, in set-up phase. Funded by Institute of Myology.</gtr:description><gtr:id>1D51DC75-8BAE-46B5-9B42-FC8B81B8FD65</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>5463726234bb72.40523973</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Nat-His-MTM</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Closed to recruitment, results under evaluation.</gtr:description><gtr:id>D7FBCA3E-EDF9-497F-8946-DD60B5033237</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54636030da3da0.92242087</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>FOR-DMD</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>UK FSHD Patient Registry is a national registry for all people affected by facioscapulohumeral dystrophy living in England, Scotland, Wales and Northern Ireland, and was launched in May 2013. Open to recruitment. Funded by the Muscular Dystrophy Campaign and supported by the TREAT-NMD Alliance.</gtr:description><gtr:id>DE1AB807-AB51-4AB5-B31D-25B7B742D56B</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546373f6a20bd2.56186513</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>FSHD Registry</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Exercise trial open to recruitment.</gtr:description><gtr:id>DFA561A7-AE70-49B6-B3E0-A32F62A7EF9E</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54636419395c28.07953966</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Aerobic training in CMT and IBM</gtr:title><gtr:type>Therapeutic Intervention - Physical</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The international IBM Consortium Genetic Study. Open to recruitment (ongoing). Funded by the Medical Research Council.</gtr:description><gtr:id>F619AEC4-111B-429A-ACD2-D03454A20B3D</gtr:id><gtr:impact>None as yet. We expect to identify a number of IBM rare variants that cluster in disease associated genes.</gtr:impact><gtr:outcomeId>54637c603ca388.54016188</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>National register of patients with Kennedy's Disease (spinal and bulbar muscular atrophy). Open to recruitment. Funded by UCLH.</gtr:description><gtr:id>7B63C8D9-3CD1-4BE7-AE5F-805A8687E5AC</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546379f04fec71.80457714</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Kennedy's Disease - Study and Register</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Establish the first national clinical and research network names SMA REACH UK (SMA Research And Clinical Hub UK), to establish a national agreement on clinical and physiotherapy assessment and standards of care. Funded by SMA Trust.</gtr:description><gtr:id>88C1731E-4C51-408F-8D72-5DC99D540A3D</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54638361b1e817.23634624</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMA REACH UK</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Open for recruitment.</gtr:description><gtr:id>37909F3D-81C6-4835-99B1-D7E07F5E8CF0</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546360948d51b1.20537676</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMT C1100</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>An Open-Label study for previously treated Ataluren (PTC 124&amp;reg;) Patients with Nonsense mutations Dystrophinopathy</gtr:description><gtr:id>5C9404D2-AEDF-489F-9276-9E3381E5CA41</gtr:id><gtr:impact>The extension study of Ataluren aims to further explore the positive outcomes reported by patients on this medication.</gtr:impact><gtr:outcomeId>Q1azcDzRmmL</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>PTC 124 extension phase</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14900</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a new morpholino antisense oligomer to induce exon skipping of exon 53 in Duchenne muscular dystrophy boys
http://www.skip-nmd.eu/
First part was a phase I dose escalation study completed in January 2016. Now all children are in the phase II maintenance</gtr:description><gtr:id>783DB4E3-0444-49C3-B073-7E3F683B8C1B</gtr:id><gtr:impact>We hope this new morpholino antisense oligomer will obtain accelerated approval, in case we reach the primary endpoints</gtr:impact><gtr:outcomeId>58c80212f203a3.75118944</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SKIP NMD</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://www.skip-nmd.eu/</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>UK Myotonic Dystrophy Patient Registry is an online patient driven resource launched in May 2012. open to recruitment. Funded by the Myotonic Dystrophy Support Group.</gtr:description><gtr:id>1D2A62A6-F218-4DE9-816B-B5A7EB99C0B9</gtr:id><gtr:impact>Primary aim of the registry is to facilitate and accelerate the planning, design and recruitment of clinical research.</gtr:impact><gtr:outcomeId>5463821d620ad7.61696313</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>UK Myotonic Dystrophy Patient Registry</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Closed to recruitment - results under evaluation.</gtr:description><gtr:id>E2E749E2-7B31-4D2A-B0D1-FC38A20D24DB</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635fbe8d11f6.94544134</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>GSK Extension Study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Hereditary Inclusion Body Myopathy-Patient Monitoring Program (HIBM-PMP): A Registry and Prospective Observational Natural History Study to Assess HIBM Disease</gtr:description><gtr:id>AC11F0FD-50C9-4CCF-9FB2-7C09BD1E8D55</gtr:id><gtr:impact>The natural history study into HIBM aims to define a patient group for any future clinical trials and the expected disease course.</gtr:impact><gtr:outcomeId>re5BU8Z87GL</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>HIBM-PMP</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01784679</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Part of the TREAT-NMD Global SMA Registry, the UK SMA (Spinal Muscular Atrophy) Registry is for all aptients living in the UK and Ireland who are affected by all types of SMA. Ongoing recruitment. Funded by The Jennifer Trust for Spinal Muscular Atrophy.</gtr:description><gtr:id>EB9C49DE-E7A4-4B27-A592-81225A68B61C</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>5463819f22f711.87611776</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMA Registry</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) In Patients with Nonsense Mutation Dystrophinopathy.</gtr:description><gtr:id>5D81C705-EDD6-44A0-9D71-42D64C9401FC</gtr:id><gtr:impact>Improved understanding of the clinical profileof PTC124</gtr:impact><gtr:outcomeId>sb7HpDoTtCT</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>PTC124 trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14900</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Ongoing recruitment. Funded by ARC.</gtr:description><gtr:id>F9340A17-B258-4D62-8A42-8A4A3E8827AB</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54637fd583b4a6.13653508</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Identification of disease susceptibility genes associated with development and clinical characteristics of primary inflammatory muscle diseases, PM, DM and IBM</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Closed to recruitment, results under evaluation.</gtr:description><gtr:id>1E69540E-9036-43C1-906D-7BAE61C1C871</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635ffaa1be85.78868822</gtr:outcomeId><gtr:status>Closed</gtr:status><gtr:title>The PATH Study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Retrospective cohort study including patients from the National Hospital for Neurology, London UK, and the University Hospital of Rennes, France. Open to recruitment. Funded by UCL.</gtr:description><gtr:id>2128B761-A316-431C-9DC7-15E6C5F14049</gtr:id><gtr:impact>Objective is to determine biological factors in blood and CSF that could be predictive of severity of neuropathies associated with IgM anti-MAG antibodies. No impacts as yet.</gtr:impact><gtr:outcomeId>54637ef2b32241.30704180</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>A study of biological prognostic factors for IGM paraproteinemic anti-mag associated peripheral neuropathy</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>NIH funded study of corticosteroids in Duchenne muscular dystrophy. Duchenne muscular dystrophy: double-blind randomized trial to find optimum steroid regimen.</gtr:description><gtr:id>538D91AD-5B40-4131-956D-F2818CCBF7D6</gtr:id><gtr:impact>By defining the optimal steroid regime we aim to improve the care of DMD patients worlwide</gtr:impact><gtr:outcomeId>W1oYi2wq3bB</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>FOR-DMD</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN46102316</gtr:url></gtr:productOutput><gtr:productOutput><gtr:description>A registry and prospective observational natural history study to assess HIBM disease. Open to recruitment. Funded by Ultragenyx Pharmaceutical Inc. (USA).</gtr:description><gtr:id>DCB7EE1F-AE9B-46BF-81D0-1976A31F10C5</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546382f460de79.56777217</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GNE myopathy-disease monitoring programme (GNE-DMP)</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Translational research in Europe for the assessment and treatment of neuromuscular diseases (TREAT-NMD) international database in set-up phase. Funded by National Institutes of Health (NIH - USA).</gtr:description><gtr:id>83A622F0-F475-4983-8316-C5F2127A59BE</gtr:id><gtr:impact>None as yet - set up phase.</gtr:impact><gtr:outcomeId>5463716ee89d02.65012499</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CMT International Database</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Document with quantified measurements the natural history of Duchenne Muscular Dystrophy. Open to recruitment. Funded by AFM.</gtr:description><gtr:id>535A5199-3D7D-427A-B851-0DD4F5C2E1F5</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54637bc96f40c6.86981140</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AFM Natural History Study</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide versus placebo for the treatment of periodic paralysis. Closed to recruitment. Funded by National Institutes of Health (NIH - USA).</gtr:description><gtr:id>3D351D31-327F-491F-B90E-32852E64CF35</gtr:id><gtr:impact>Results in analysis.</gtr:impact><gtr:outcomeId>54636a78551f93.72760091</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>HYP HOP: Dicholorphenamide vs placebo for periodic paralysis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase IIa, double blind, exploratory, parallel clinical trial to assess the optimal dose of GSK2402968 for safety, tolerability, efficacy, in ambulant patients with DMD. Funded by GlaxoSmithKline.</gtr:description><gtr:id>EB0BFE24-4053-4C2B-BFDA-C4340CA0897E</gtr:id><gtr:impact>Paper in preparation.</gtr:impact><gtr:outcomeId>546369f88b5436.39320754</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>GSK/Prosensa clinical trial in DMD boys with study drug GSK2402968 (PRO051)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Charcot-Marie-Tooth Disease and related disorders: a natural history study. Open to recruitment. Funded by National Institutes of Health (NIH - USA).</gtr:description><gtr:id>45132447-22EE-4DBC-90B3-905C8D93260A</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546377bc0dd825.63852265</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CMT: A Natural History Study</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A phase I/IIa, open-label, escalating dose study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and clinical effects of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy</gtr:description><gtr:id>DABDDE41-E15F-4B63-92A8-74CB96DD083C</gtr:id><gtr:impact>The Prosensa trial aims to evaluate the exon-skipping compound PRO-045</gtr:impact><gtr:outcomeId>TTy4GpsDaSu</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Prosensa 045</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14391</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Clinical trial in set-up phase, funded by MRC Centre grant.</gtr:description><gtr:id>CEB89BEA-8495-4EEC-8588-D11B8B6676C2</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635ec06722c2.86790379</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Bumetanide in HypoPP</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A registry and prospective natural history study to assess HIBM disease. Currently recruiting. Funded by Ultragenyx.</gtr:description><gtr:id>5D884FFD-9F83-4D7D-9B3A-6EE8520F74CC</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54637cba559e45.41249083</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Hereditary Inclusion Body Myopathy - Patient Monitoring Program (HIBM-PMP)</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Open to recruitment, funded by Medical Research Council.</gtr:description><gtr:id>88D20CA7-90E6-400E-BDC8-2D94A0667DA1</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546366aae8de09.61906214</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Exercise and sarcopenia</gtr:title><gtr:type>Therapeutic Intervention - Physical</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>An open-label, multicenter, multinational, ascending dose study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeated biweekly infusions of neoGAA in na&amp;iuml;ve and alglucosidase alpha treated late-onset Pompe disease patients.</gtr:description><gtr:id>635EC5C7-3FBA-4664-A9A9-9EDB73B59CFB</gtr:id><gtr:impact>Improved treatment outcomes for Pompe disease patients</gtr:impact><gtr:outcomeId>KAyTpz7YF5b</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Pompe neoGAA trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=15467</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Clinical trial in set-up phase, funded by Novartis.</gtr:description><gtr:id>F0DB68D2-ECE6-4FCC-AA77-0DD7B311A39B</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635d1e768378.53234138</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Efficacy, safety and tolerability of BYM338 in sIBM</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase II, multicentre, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of Olesoxime (TRO19622) in 3-25 year old spinal Muscular Atrophy patients. Study completed. Funded by Association Francaise contre les Myopathies.</gtr:description><gtr:id>EA033745-54BA-47C6-9149-F40B34BC5D22</gtr:id><gtr:impact>Data in analysis.</gtr:impact><gtr:outcomeId>54636b250932b0.59001679</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Safety and efficacy of Olesoxime (TRO19622) in SMA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Follow up of the phase IIa RCT study concluded in 2012, this clinical trial is in set-up phase and is funded by FDA/Orphazyme (tbc).</gtr:description><gtr:id>E6C798BD-2FAC-4A6C-8737-4CEF4CBEF915</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635f3d5cb7d2.48924935</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>A phase IIb/III of Arimoclomol in IBM</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Natural history study to monitor the clinical and radiological course of upper limb muscle impairment in patients with DMD, potentially treatable with AAV-mediated exon 53 skipping. Open to recruitment. Funded by Genethon.</gtr:description><gtr:id>DD3D6065-6DB9-4C6D-A0A1-7FEED38FF9A9</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546380434abfc2.87932396</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Study of clinical and radiological changes in teenagers with Duchenne muscular dystrophy theoretically treatable with exon 53 skipping (Pre-U7)</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Jain Foundation natural history and clinical outcomes study of dysferlinopathy (limb-girdle muscular dystrophy type 2B)</gtr:description><gtr:id>497834D4-71C1-4616-B405-D90E42E3BDB7</gtr:id><gtr:impact>The natural history of LGMD2B has not been systematically studied. By understanding the disease course in a large, controlled population drawn from an international population we aim to provide a platform for testing of therapies.</gtr:impact><gtr:outcomeId>WnUhjBtbpS3</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>LGMD2B Natural History Study</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Open to recruitment, funded by the Medical Research Council.</gtr:description><gtr:id>C7B77A3D-D3B4-40B5-BFE8-168DEF4FF53E</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546366242f0007.34755959</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Physical activity and inclusion body myositis</gtr:title><gtr:type>Therapeutic Intervention - Physical</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Aim is to obtain a detailed and standardised database of clinical features, treatment and diagnostic electrophysiology, and collect a biobank with serum samples and DNA. Open to recruitment. Funded by Wellcome Trust/GBS Support Group.</gtr:description><gtr:id>AD3E701B-E625-47B6-BF7D-528A3971D898</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54637f85e29221.17541476</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>International GBS Outcome Study - IGOS</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>DMD Heart Protection Study: A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction</gtr:description><gtr:id>A9525BE6-A5A0-4BCC-9D93-1BDB185AFBDA</gtr:id><gtr:impact>This study is a double-blind, randomised, multi-centre, placebo-controlled trial. We wish to determine the effect of combined ACE-inhibitor (Perindopril) and beta-blocker (Bisoprolol) therapy in preventing the development of cardiomyopathy in 140 genetically characterised males with Duchenne Muscular Dystrophy (DMD) without echo-detectable left ventricular dysfunction, at five sites across the UK.</gtr:impact><gtr:outcomeId>HH4vV8UNkpA</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Heart Protection Study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN50395346</gtr:url></gtr:productOutput><gtr:productOutput><gtr:description>International registry for all persons affected by conditions caused by a mutation in the Fukutin-Related Protein (FKRP) gene, namely Limb Girdle Muscular Dystrophy type 2I. Open to recruitment. Funded by the LGMD2I Research Fund.</gtr:description><gtr:id>4A00C7B8-0FBB-4CAA-ACD5-72CBAFF63CBD</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546382815676d1.65258737</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Global FKRP Registry</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Clinical trial in set-up phase, funded by the Muscular Dystrophy Campaign.</gtr:description><gtr:id>8C06423E-AB64-423E-9D58-8EAEB48FF380</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635c9ea88118.31580723</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Valproate Sodium for McArdle Disease</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Clinical trial in set-up phase, funded by National Institutes of Health (NIH- USA).</gtr:description><gtr:id>74642B96-9C7B-489C-B2FA-3C00FAF88A15</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>54635c4b452d42.02100265</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TAPP</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Open to recruitment.</gtr:description><gtr:id>AA39F6C8-C8FF-4BCD-8E23-BC454D9A8A31</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546360d4c9ff98.34130414</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Safety and efficacy of neoGAA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Placebo controlled pilot study assessing safety, efficacy and tolerability of Arimoclomol in adult patients with sIBM. Funded by Arthritis Research UK and the Myositis Support Group.</gtr:description><gtr:id>9420B8DE-007A-4240-A72E-33B1858021D7</gtr:id><gtr:impact>Manuscript in preparation for publication. Follow up trial in set-up phase.</gtr:impact><gtr:outcomeId>5463696c057e56.78837373</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Arimoclomol for sporadic inclusion body myositis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Development of multiple patient registries as part of the wider networking effort (Myotonic dystrophy, FSHD, LGMD2I, etc.). This is also integrated with biobanking and clinical research activities.</gtr:description><gtr:id>4C5C4735-637C-4888-A244-D547828120D4</gtr:id><gtr:impact>Improved patient access to clinical researchers, improved integration with international networks and patient organisations.</gtr:impact><gtr:outcomeId>SqzHHrN4cdk</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Development of Registries and Biobanks</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type></gtr:productOutput><gtr:productOutput><gtr:description>AFM Funded: Outcome measures in Duchenne Muscular Dystrophy: a Natural History Study</gtr:description><gtr:id>FB3992D1-C154-402A-BBFA-A3A13807F2B2</gtr:id><gtr:impact>The AFM natural history study aims to refine patient and physician reported outcome measures in DMD trials.</gtr:impact><gtr:outcomeId>J37qNb6oNyX</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Duchenne Natural History Study</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A multicentre collaborative study on the clinical features, expression profiling, and quality of life of infantile onset fascioscapulohumeral muscular dystrophy. Set-up phase. Funded by NIH (USA).</gtr:description><gtr:id>18912C4E-4170-41AA-9645-6D41FA8D9066</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>5463738d2759d2.91047099</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>FSHD NH Study</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Consolidate and expand on previous work by collating clinical data and continuing to sequence candidate genes in patients suspected to have ion channel disorders. Open to recruitment. Funded by UCLH.</gtr:description><gtr:id>DAC0B0E8-05A7-467C-BA96-58EF8AD6C865</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54637b578f9979.63368286</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Investigation of Human Neurological Ion Channel Disorders</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Clinical trial in set-up phase, funded by Muscular Dystrophy Association (USA).</gtr:description><gtr:id>1E76F7A7-560A-4AE8-8C3D-D2EED10D28EA</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>54635e889d9e02.94043473</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HOP Study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Observational prolonged trial in myotonic dystrophy type 1 to improve quality of life standards, a target identification collaboration. Set-up phase. Funded by EU Seventh Framework Programme.</gtr:description><gtr:id>4AC2736C-7EF8-4EA0-B3B2-452AA044E6D8</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>546372be241b99.32225326</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>OPTIMISTIC</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We hold two strains carrying mutations in the Dysferlin gene, one naturally occuring in the SJL/J strain which has been bred onto C57BL/10, and the other a targeted mutation. The mutations both result in a very mild myopathy with late onset, compatible with the relatively mild phenotype of LGMD2B.</gtr:description><gtr:id>53953A89-BF52-4CCF-BBCD-E82C98CEB39A</gtr:id><gtr:impact>Understanding the regenerative defect in dysferlinopathy.</gtr:impact><gtr:outcomeId>546359242adb81.85160190</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LGMD2B: C57BL/10.SJL-Dysf, B6..129-Dysftm1Kcam</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Natural history data from mitochondrial patients</gtr:description><gtr:id>6AAB6CE0-349A-404D-A8FF-A1EFFC01F74D</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>MDyoqzYa8zB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mitochondrial cohort</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Natural history data from IBM patients.</gtr:description><gtr:id>D9F27B3C-38CB-4856-92A2-794C796243B6</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>Afb6oq5PWYg</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Inclusion Body Myositis cohort</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Techniques to assess the cardiac phenotype of mouse models of muscular dystrophy in vivo. This includes analysis of the heart structure and function using MRI and conductance catheter studies to define the pressure-volume relationship of the cardiac cycle in live animals.</gtr:description><gtr:id>56D53499-FB67-40C4-82F7-E421B33584C8</gtr:id><gtr:impact>Recent publications: Bauer et al. 2009, Bauer et al. 2010.</gtr:impact><gtr:outcomeId>QArS22w39Vo</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Analysis of cardiac function in mouse models</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>to quantify the amount of positive dystrophin fibres in tissue</gtr:description><gtr:id>5A9F514B-88C6-4196-BFE7-AC79A35678D2</gtr:id><gtr:impact>assists in the efficacy outcome of the clinical trial.
Peer reivewed publications.</gtr:impact><gtr:outcomeId>E08D6AB80E7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IHC quantitation</gtr:title><gtr:type>Antibody</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/25355828</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cDNA clones encoding either dysferlin or ANO5 have been inserted in frame with protein tags (myc tab, EGFP etc) for expression in cell culture.</gtr:description><gtr:id>A354AE0E-57A8-4DA5-8293-E35C14C3E5EA</gtr:id><gtr:impact>Material provided to other researchers in 2008, 2009, 2010 and 2011. 
Collaborative publications e.g. Hernandez-Deviez 2008 and Cacciottolo 2011.</gtr:impact><gtr:outcomeId>f5EMvRJpn5J</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Dysferlin and ANO5 constructs</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Natural history data from channelopathy patients</gtr:description><gtr:id>1E892DF4-1414-4B23-BB5C-47D467550DF5</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>dAkBbdqGeJg</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Channelopathy cohort</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The mdx model is the standard mammalian model for DMD with a nonsense mutation in exon 23 of the mouse dmd gene. Despite genetic homology with the human disease, mdx has a relatively mild myopathy. The human CMAH gene carries an inactivating deletion and humans do not sxpress this enzyme responsible for a specific sialytion of proteins and so human tissues do not express N-glycoylneuraminic acid (Neu5Gc), and abundant sialic acid derivative in non-human tissues. Expression of CMAH, and hence Neu5Gc, may be associated with protection from specific pathologies in non-human mammals, and the Cmah-/- mdx strain has a more severe, earlier onset myopathy than mdx.</gtr:description><gtr:id>06263C7A-88A2-42A5-A09D-B5FBE13D00A4</gtr:id><gtr:impact>Paper published PMID 20668298
Testing and validation of AON therapies in the mouse, especially with regard to improvements in cardiac function after treatment with PPMOs.</gtr:impact><gtr:outcomeId>54634d0d9032b6.82986933</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mdx/Cmah-/- Mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The 2005 CMT neuropathy score has been updated in 2010, and a paediatric version is also being produced. The scale is currently being validated.</gtr:description><gtr:id>0B31E323-B43D-436B-8BF3-C5484A00C2C4</gtr:id><gtr:impact>Reported in workshop report PMID 20850975.</gtr:impact><gtr:outcomeId>mhcFvSY3fxU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Reliability and validity of the CMT neuropathy score as a measure of disability</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20850975</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GM mice bred without Notch1 in Schwann cells</gtr:description><gtr:id>C7BDBE2F-75B9-4344-A4E7-793C099FCA75</gtr:id><gtr:impact>This mouse model has enabled us to study transdifferentiation and regeneration in the peripheral nervous system.</gtr:impact><gtr:outcomeId>f45EefXKGge</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GM mice without Notch1 in Schwann cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mangangese is a contrast agent in MRI which mimics calcium, and so shows increased contrast in muscular dystrophy where calcium is aberrantly elevated.</gtr:description><gtr:id>B7FE1E85-4203-477F-B344-6CC8775DD39E</gtr:id><gtr:impact>Not yet.</gtr:impact><gtr:outcomeId>ttnNmYT1Hkp</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Manganese-enhanced MRI (MEMRI)</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The Gfpt1 inducible knockout strain is derived from teh EUCOMM programme via the Neuromouse Consortium. The mouse strain has a Flp and Cre responsive targeted modification in exon 7 or the mouse Gfpt1 which can be used to generate either a LacZ expressing allele linked to the Gfpt1 promoter, or an Cre-inducible null allele for tissue-specific targeting.</gtr:description><gtr:id>4945E01A-708F-4B04-B9A3-1B498A0D4F4A</gtr:id><gtr:impact>The strain remains under development and there are no significant outputs yet.</gtr:impact><gtr:outcomeId>546359b6d7de15.65861931</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CMS: Gfpt1tm1a(EUCOMM(Wtsi</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Kennedy's Disease mouse model</gtr:description><gtr:id>3E752939-7516-405C-AC0F-08FAA0751592</gtr:id><gtr:impact>Paper to follow.</gtr:impact><gtr:outcomeId>54634c73cd9af5.58769925</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AR121 Mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA samples from Charcot Marie Tooth patients</gtr:description><gtr:id>FF597531-30E5-4AB6-A7D5-6E1B9396197A</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>kLzD39kwiNg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CMT DNA Bank</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A comprehensive MRI protocol which quantifies acute and chronic muscle pathology in the lower limbs of patients with neuromuscular diseases.</gtr:description><gtr:id>A434A6BD-527D-4A9A-B6AD-C683DF1E87D8</gtr:id><gtr:impact>Presentation of the data at international meetings including Peripheral Nerve Society meeting 2013. High impact journal articles submitted. Identifying sensitive outcome measures for clinical trials.</gtr:impact><gtr:outcomeId>TjKgz9sujB1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MRC Quantitative MRI Lower Limb Muscle Protocol</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New mouse models with mutations in genes known to be causative for neurogeneration in humans.</gtr:description><gtr:id>F7171E14-57E8-4B69-9470-69154ED2665F</gtr:id><gtr:impact>Presentations at meetings. Papers to follow.</gtr:impact><gtr:outcomeId>gyDcMek1T3U</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mutant Mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Methodology to assess the degree of hypertrophy induced by serum starvation. This is larger in dystrophic cardiomyocytes enabling selection for agents which may influence the cardiac phenotype in muscular dystrophy</gtr:description><gtr:id>0E0877A6-DB42-42D0-B394-0E3D4BFAAA1D</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>cbSwcbGEeFs</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cardiomyocyte hypertrophy assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Correlation of collagen VI immunofluorescence staining pattern with mutation and clinical presentation.</gtr:description><gtr:id>00561786-2992-409C-A50D-DC8C7851FA27</gtr:id><gtr:impact>Provided to other researchers in 200 and 2009.
Improvement in the diagnostic algorithm for Bethlem myopathy.</gtr:impact><gtr:outcomeId>hjhDLkae2n2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Collagen VI fibroblast IF assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Prospective data collection of natural history study of hundreds of children with Spinal Muscular Atrophy.</gtr:description><gtr:id>47A418C6-7D33-42EC-B28D-A252A5CAE0DA</gtr:id><gtr:impact>Continued growth of database.</gtr:impact><gtr:outcomeId>AjoEBqb183t</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Smart-Net</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Web-based database of patient information from IBM cohort.</gtr:description><gtr:id>E1DD7253-44EB-408A-9E47-016AC77C5D3B</gtr:id><gtr:impact>Continued growth of database.</gtr:impact><gtr:outcomeId>VHD2HHcsySk</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IBM-Net</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We correlated muscle MRI to histological findings in muscular dystrophy patients</gtr:description><gtr:id>6F039CB6-EFEE-4C12-AA2C-BABDDC0F00C3</gtr:id><gtr:impact>peer review publication</gtr:impact><gtr:outcomeId>9E513F86EE1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>muscle MRI</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/27649492</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA samples from Inclusion Body Myositis patients</gtr:description><gtr:id>74AAC5E1-D0FD-4774-8ADD-4AF50DA9FAA0</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>Lpx3bktFRC2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IBM DNA Bank</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GM mice bred without c-Jun in Schwann cells</gtr:description><gtr:id>5B8532D6-11D6-4D88-9764-2076663DAD72</gtr:id><gtr:impact>This mouse model has enabled us to study transdifferentiation and regeneration in the peripheral nervous system.</gtr:impact><gtr:outcomeId>gzieMphbhUB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GM mice without c-Jun in Schwann cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA samples from channelopathy patients</gtr:description><gtr:id>503110C4-50CB-4C61-A3E5-8B3B2307CA57</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>ZBoVkwk4gUx</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Channelopathy DNA Bank</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Prospective data collection for natural history study of hundreds of young adults with Duchenne Muscular Dystrophy; coordination of 18 centres.</gtr:description><gtr:id>F83B9314-86E3-4249-BA7C-5D905B35F66A</gtr:id><gtr:impact>Growth of national database.</gtr:impact><gtr:outcomeId>SPGRRpgSykJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Adult North-Star Database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Established core techniques for behavioural assessment of mouse models of neuromuscular disease e.g.:
Global behaviour
Morphology
Nerve and muscle function
Nerve function
Organ function
Biochemistry
Cellular function
Molecular biolody</gtr:description><gtr:id>A36D1870-BD05-40C5-9A33-C9311AE7CD05</gtr:id><gtr:impact>Publications: PMID 19470612, 18495669, 19913415.</gtr:impact><gtr:outcomeId>Y4sdNyuzCGV</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Standard battery for investigation of animal models of neuromuscular disease</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19470612</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GM mice bred without RBPj in Schwann cells.</gtr:description><gtr:id>A02242C7-E328-41F8-BC04-ABCACF4BB4C0</gtr:id><gtr:impact>This mouse model has enabled us to study transdifferentiation and regeneration in the peripheral nervous system.</gtr:impact><gtr:outcomeId>DPMHQZpn6zr</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GM mice without RBPj in Schwann cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Produced a minimal dataset for a CMT international database.</gtr:description><gtr:id>9D48B6C3-F52A-4A38-9B28-FEA9FB1D3B9B</gtr:id><gtr:impact>Published as workshop report in Neuromuscular Disorders PMID 20850975.</gtr:impact><gtr:outcomeId>jMj73tK3EJt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CMT International Database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20850975</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Myoblasts cell lines have been established on over 1000 patients as part of routine diagnostics in our centre. Patients are consented to provide this as a gift to research. Cell lines are used for basic research activity.</gtr:description><gtr:id>8C617BB4-38A4-4912-997B-403890CD099C</gtr:id><gtr:impact>Joint publication in Journal of Biological chemistry 2007 investigating mtiochondrial dysfunction in patients with mitochondrial diseases.</gtr:impact><gtr:outcomeId>p2gTPJ4Mng5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Biobank myoblast muscle cell lines</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>QTRAC is the patented technique developed by Professor Hugh Bostock in the Centre for Neuromuscular disease which allows reliable clinical evaluation of peripheral nerve excitability - so called nerve excitability testing. This has been adopted in a number of clinical neurophysiology units worldwide. We have published on this work eg Tomlinson et al Nerve excitability testing in episodic ataxia Brain in press PMID 21106501.</gtr:description><gtr:id>7118A4E2-E710-4349-AEC2-B53487AD349C</gtr:id><gtr:impact>PMIDs 21106501, 20095022, 19900504, 20715364.</gtr:impact><gtr:outcomeId>DK46mHc7F7o</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>QTRAC</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21106501</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Prospective data collection of natural history study of hundreds of children with Duchenne Muscular Dystrophy.</gtr:description><gtr:id>E5E0F193-E69F-47CE-A3BE-F542BA2925C7</gtr:id><gtr:impact>Ongoing collection of data; growth of database.</gtr:impact><gtr:outcomeId>B2x17BtgEYD</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>North-Star</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Natural history patient data</gtr:description><gtr:id>B1AEEF8F-F92F-4870-B036-FD8205A6E251</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>LWZgY2R6WuU</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CMT cohort</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DMD patients biological material (primary cell cultures)</gtr:description><gtr:id>6B79C4AE-7023-42D2-84EC-A01A862438B6</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>D7277EACADA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DMD patients</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/24920607</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The Sgcd-/- strain has an engineered null mutation in the delta sarcoglycan gene. In common with the human equivalent found in LGMD2F, the Sgcd-/- strain developes a dilated cardiomyopathy as well as myopathy. As such, this strain serves as a useful model for dilated cardiomyopathy as well as LGMD2F.</gtr:description><gtr:id>24F10AC7-8060-4F39-BBA4-DBAC71ADCF5C</gtr:id><gtr:impact>Testing of therapies aimed at modulating cardiac function, notably beta-blockers and ACE inhibitors.</gtr:impact><gtr:outcomeId>54634d467b2136.46273819</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LGMD2F: Sgcd-/-</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B7B1F2DC-AE50-4ADD-B557-3682F47F9706</gtr:id><gtr:title>Stiffness as a presenting symptom of an odd clinical condition caused by multiple sclerosis and myotonia congenita.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e8b42aebb2524f57d3833c5641664e8"><gtr:id>4e8b42aebb2524f57d3833c5641664e8</gtr:id><gtr:otherNames>Portaro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_22921319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F89DCB84-9BBF-4098-B31C-24968F7C7DA9</gtr:id><gtr:title>Tremor in Charcot-Marie-Tooth disease: No evidence of cerebellar dysfunction.</gtr:title><gtr:parentPublicationTitle>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f175735d8ce083c048d9ac312841f7d2"><gtr:id>f175735d8ce083c048d9ac312841f7d2</gtr:id><gtr:otherNames>Saifee TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1388-2457</gtr:issn><gtr:outcomeId>5697a81990f613.88317941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>580A11C4-E69D-4B77-9188-EEB4B6625205</gtr:id><gtr:title>Impaired quality of life in growth hormone-deficient adults is independent of the altered skeletal muscle oxidative metabolism found in conditions with peripheral fatigue.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a90a82436eee8eb4a9a25f757756064"><gtr:id>5a90a82436eee8eb4a9a25f757756064</gtr:id><gtr:otherNames>Sinha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5460bfab52b427.77371481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8E827B3-3315-452D-9AD5-622405914308</gtr:id><gtr:title>Cervical spinal cord compression complicating the clinical course of Charcot-Marie-Tooth type 1.</gtr:title><gtr:parentPublicationTitle>BMJ case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d9d2961fff00ec473e05c4efc293386"><gtr:id>0d9d2961fff00ec473e05c4efc293386</gtr:id><gtr:otherNames>Evans MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-790X</gtr:issn><gtr:outcomeId>5697a9069cd516.52517878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0CCDF9B-A410-4AF7-AD14-E0DE4C91581F</gtr:id><gtr:title>Mitochondrial pathology in progressive cerebellar ataxia.</gtr:title><gtr:parentPublicationTitle>Cerebellum &amp; ataxias</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c967a786847e7e5db1d802a30f49fbb9"><gtr:id>c967a786847e7e5db1d802a30f49fbb9</gtr:id><gtr:otherNames>Bargiela D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2053-8871</gtr:issn><gtr:outcomeId>56b4b3c68f00e1.86892651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD75193-F29C-4170-999F-49ACAD8ECE49</gtr:id><gtr:title>Bar Coding and Tracking in Pathology.</gtr:title><gtr:parentPublicationTitle>Surgical pathology clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1875-9157</gtr:issn><gtr:outcomeId>56dd62fd4d6144.26177456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF49112B-B505-4CE4-AB7E-474B1018DEE4</gtr:id><gtr:title>MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5697a9064eaf42.04677813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCDEC17D-1E91-4838-80EC-707D5B80EE8B</gtr:id><gtr:title>Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cffc962b932447a7204bc4603ea0b0cd"><gtr:id>cffc962b932447a7204bc4603ea0b0cd</gtr:id><gtr:otherNames>Uusimaa J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>pm_12934_24_23714749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13F40FD2-DF29-41D3-B55E-0EEDE3D03F46</gtr:id><gtr:title>The p.Ser107Leu in BICD2 is a mutation 'hot spot' causing distal spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40a020e11c4ea5657e5f2e6f3485cfd0"><gtr:id>40a020e11c4ea5657e5f2e6f3485cfd0</gtr:id><gtr:otherNames>Bansagi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b4b3c8280784.27187664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D09CC32-03C0-46A8-9763-E5667FC1941B</gtr:id><gtr:title>Optical control of muscle function by transplantation of stem cell-derived motor neurons in mice.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7209bea3e25ed7a2fc598e94195d920"><gtr:id>c7209bea3e25ed7a2fc598e94195d920</gtr:id><gtr:otherNames>Bryson JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5458f6ec22b865.77765049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D70CA954-5096-418C-B829-23D899FF0EE9</gtr:id><gtr:title>Congenital myasthenic syndrome and minicore-like myopathy with DOK7 mutation.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18692bc909f1f653c05eed67803ff70d"><gtr:id>18692bc909f1f653c05eed67803ff70d</gtr:id><gtr:otherNames>Lorenzoni PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23657916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4808E4E-00EF-4E3C-964B-DA5C0CB847B4</gtr:id><gtr:title>The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/decf7b210e7ff85027089c5e7f75ce3b"><gtr:id>decf7b210e7ff85027089c5e7f75ce3b</gtr:id><gtr:otherNames>McDonald CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23681930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>255C5539-69C0-4590-8D91-142888BA53EC</gtr:id><gtr:title>Induction of Anti-Hebbian LTP in CA1 Stratum Oriens Interneurons: Interactions between Group I Metabotropic Glutamate Receptors and M1 Muscarinic Receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1f054a23850a0fa11dfd04fb4f1335"><gtr:id>3f1f054a23850a0fa11dfd04fb4f1335</gtr:id><gtr:otherNames>Le Duigou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56b2118f746e87.28116175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D1E13C3-3183-480E-A2E2-4AB1C1329E06</gtr:id><gtr:title>Identification of KLHL41 Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline Myopathy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4380a494fa7083fd04e207ea48e8726f"><gtr:id>4380a494fa7083fd04e207ea48e8726f</gtr:id><gtr:otherNames>Gupta VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5460c3ac5e7948.39157683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F615AA85-9A70-41B2-9DB0-EC78917DDE4F</gtr:id><gtr:title>Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5afca19d2db41c572f0f172969c92bb2"><gtr:id>5afca19d2db41c572f0f172969c92bb2</gtr:id><gtr:otherNames>Novoselov SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_24023695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD50C363-CB6B-4F71-8CDB-7B786FBA3662</gtr:id><gtr:title>Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ade73ea2e70d7526d9f8069b3315b03"><gtr:id>0ade73ea2e70d7526d9f8069b3315b03</gtr:id><gtr:otherNames>Ravenscroft G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5460c4b88fff60.91319259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D64B82CC-0E04-4997-A622-4331C0A54220</gtr:id><gtr:title>Muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec2f27c03967b99bcc42479fd6b4820a"><gtr:id>ec2f27c03967b99bcc42479fd6b4820a</gtr:id><gtr:otherNames>Mercuri E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_12934_24_23465426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FCF0694-EB4C-4C77-AF4A-8313D5C42963</gtr:id><gtr:title>Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12cffd5a1b1a9a5423d7304520481af6"><gtr:id>12cffd5a1b1a9a5423d7304520481af6</gtr:id><gtr:otherNames>Vanhoutte EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b88831cb6857.12358854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A08A8618-4B2D-44E9-B771-29E5DBFBF2A3</gtr:id><gtr:title>Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/496c733d70b218462c7abdc86627d4cb"><gtr:id>496c733d70b218462c7abdc86627d4cb</gtr:id><gtr:otherNames>Malik B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>doi_55f9849843c35afd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F031BD76-0727-486A-BCEB-B765F515693D</gtr:id><gtr:title>Translational and regulatory challenges for exon skipping therapies.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f0682b259759dcbf352bf526183086e"><gtr:id>3f0682b259759dcbf352bf526183086e</gtr:id><gtr:otherNames>Aartsma-Rus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56d4742a62a919.54989482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39E75A0D-DC24-4EC0-B45A-CC8539D91FF3</gtr:id><gtr:title>CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d12bebfaa7e0b0345e19fd21ce4cd07"><gtr:id>3d12bebfaa7e0b0345e19fd21ce4cd07</gtr:id><gtr:otherNames>Fridman V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5697a76e60b607.75691818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D55C1370-B86B-4E05-9618-1CF870A8664F</gtr:id><gtr:title>The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5740d7dfacf41317fd1190662cfe9c79"><gtr:id>5740d7dfacf41317fd1190662cfe9c79</gtr:id><gtr:otherNames>Gang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56dd62fcaeb328.25912745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF228459-91EA-407A-A260-EED5D832AB25</gtr:id><gtr:title>Impulse conduction increases mitochondrial transport in adult mammalian peripheral nerves in vivo.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f470b9de1ef4c8355c84c83c595b04"><gtr:id>76f470b9de1ef4c8355c84c83c595b04</gtr:id><gtr:otherNames>Sajic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>5458d3c03cb445.76015160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEDD3F7B-13E7-490B-998B-35CF89A24E7A</gtr:id><gtr:title>Graphical modelling of molecular networks underlying sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5d2ace43ac20075ac8ea1ef8005d62"><gtr:id>7d5d2ace43ac20075ac8ea1ef8005d62</gtr:id><gtr:otherNames>Thorne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>pm_12934_24_23595110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFC48AAE-7A78-467D-A3D4-2BDD400CB4E7</gtr:id><gtr:title>SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3ff99924c8431a406c24561847715cd"><gtr:id>d3ff99924c8431a406c24561847715cd</gtr:id><gtr:otherNames>Hanisch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5460c9c395c332.12843875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BE31815-06E7-4DA1-B288-A3878C26449B</gtr:id><gtr:title>Longitudinal diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6a747d92dd7cf3b45f9d6ab049cf6bd"><gtr:id>f6a747d92dd7cf3b45f9d6ab049cf6bd</gtr:id><gtr:otherNames>Firbank MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>56c44f6230d653.79629193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF5ACD57-D865-4EDB-996B-CAF6E5765288</gtr:id><gtr:title>Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: Case studies of single gene mutations.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc03054e2224689b2c79afbbf3c3d9a"><gtr:id>abc03054e2224689b2c79afbbf3c3d9a</gtr:id><gtr:otherNames>Gilbert JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>56dd62ff55d073.06436880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C871749-4C6B-4DA6-AF06-40A9FC6372FE</gtr:id><gtr:title>Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b77449ecd226659758ab7bbc3bd8eab9"><gtr:id>b77449ecd226659758ab7bbc3bd8eab9</gtr:id><gtr:otherNames>Burki U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn><gtr:outcomeId>56d47a2a926bd1.11094769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96F83196-2BD3-41B1-B108-CBE608F6267C</gtr:id><gtr:title>MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7510162e96297e5cda1dc964e260b5c3"><gtr:id>7510162e96297e5cda1dc964e260b5c3</gtr:id><gtr:otherNames>Reza M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5a79d626d138c5.17147025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F77476-954B-4B0D-8E89-C3299E4854EF</gtr:id><gtr:title>Unique quadruple immunofluorescence assay demonstrates mitochondrial respiratory chain dysfunction in osteoblasts of aged and PolgA(-/-) mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01b8bbd659bc2658cd7e61b5045c08f9"><gtr:id>01b8bbd659bc2658cd7e61b5045c08f9</gtr:id><gtr:otherNames>Dobson PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58a711041f05c3.05354157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5800FF5D-B00D-45B1-911A-D99FDA15120E</gtr:id><gtr:title>Review: Central nervous system involvement in mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49556e9fdf0c03f1e42f752a9d5ca04e"><gtr:id>49556e9fdf0c03f1e42f752a9d5ca04e</gtr:id><gtr:otherNames>Lax NZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>58a7110592df48.90988521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF9374DF-2A50-4361-B979-FC32EC344E56</gtr:id><gtr:title>Approach to the diagnosis of congenital myopathies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee93c014dd428ed9c3eb8a3542af950a"><gtr:id>ee93c014dd428ed9c3eb8a3542af950a</gtr:id><gtr:otherNames>North KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c3ac39a3d5.68244270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D458F7B1-F1C4-4D9D-B5CE-3238C3A532E8</gtr:id><gtr:title>Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge.</gtr:title><gtr:parentPublicationTitle>BMJ case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e3c72c067d5420c1832edb91aeac661"><gtr:id>9e3c72c067d5420c1832edb91aeac661</gtr:id><gtr:otherNames>Sommerlad A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-790X</gtr:issn><gtr:outcomeId>56b888350e9e34.83547780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF25758C-7606-491D-BE25-D62BDA375A67</gtr:id><gtr:title>Simulated field maps for susceptibility artefact correction in interventional MRI.</gtr:title><gtr:parentPublicationTitle>International journal of computer assisted radiology and surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c016e06dab4e53dadb4143f2ea0e1316"><gtr:id>c016e06dab4e53dadb4143f2ea0e1316</gtr:id><gtr:otherNames>Kochan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1861-6410</gtr:issn><gtr:outcomeId>56c46677126488.98394749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA379467-9E13-49B6-8EEF-3BA5A9C20263</gtr:id><gtr:title>Neuronal oscillations: A physiological correlate for targeting mitochondrial dysfunction in neurodegenerative diseases?</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44222c78ec454beafd9c72ad49d6c46e"><gtr:id>44222c78ec454beafd9c72ad49d6c46e</gtr:id><gtr:otherNames>Chan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>56c46e03a3edf4.22773138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6992BE3D-4141-4A3E-B8F6-AE7A837164D8</gtr:id><gtr:title>The isolated carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e45ccf4556ac9f2fa83f02f213325f"><gtr:id>51e45ccf4556ac9f2fa83f02f213325f</gtr:id><gtr:otherNames>Perli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5460c9c41708b7.94109916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5CA3B77-589D-4E8D-88D1-45CEA7AE28C5</gtr:id><gtr:title>Long-term potentiation in hippocampal oriens interneurons: postsynaptic induction, presynaptic expression and evaluation of candidate retrograde factors.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae2a25850360f65ec63f35761b26fa8"><gtr:id>1ae2a25850360f65ec63f35761b26fa8</gtr:id><gtr:otherNames>Nicholson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>5460c0720a5078.31938721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A821AEA-DFD3-42FD-B30B-6BBFFF7446BC</gtr:id><gtr:title>Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>5460c072d72c35.05443996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17C5B77A-F1C0-40B2-9621-A1050495BDF1</gtr:id><gtr:title>Establishment of a human skeletal muscle-derived cell line: biochemical, cellular and electrophysiological characterization.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c8082802ec778386ca3cc5c516bf7e"><gtr:id>f5c8082802ec778386ca3cc5c516bf7e</gtr:id><gtr:otherNames>Rokach O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_12934_24_23905709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7536123-FBD4-4B7E-A965-95F2701C40B5</gtr:id><gtr:title>Quinine for muscle cramps.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e31898c3145fa391e5b057d7f853cc5"><gtr:id>8e31898c3145fa391e5b057d7f853cc5</gtr:id><gtr:otherNames>El-Tawil S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56b8883413f1b2.19520633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>228EA445-FD20-43CC-ABB8-6D7DC0A3B353</gtr:id><gtr:title>Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4f8402398c19e61034ee89eb516f487"><gtr:id>a4f8402398c19e61034ee89eb516f487</gtr:id><gtr:otherNames>Antony D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12934_24_23255504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C4033A-29DB-40F1-B7C7-8589376118C6</gtr:id><gtr:title>Editorial Note</gtr:title><gtr:parentPublicationTitle>Brain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/deb2105fe5437d266505d48371f2ea29"><gtr:id>deb2105fe5437d266505d48371f2ea29</gtr:id><gtr:otherNames>Kullmann D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460c06fecd866.14267317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78B65B99-DC58-43FE-9CF5-9279DE3DD1D4</gtr:id><gtr:title>Outcome measures in MMN revisited: further improvement needed.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/057eb5ef60f5f157fdb8058488d8e808"><gtr:id>057eb5ef60f5f157fdb8058488d8e808</gtr:id><gtr:otherNames>Pruppers MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b8883113ac98.43805358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0771F71B-E73E-4D0D-B008-9800A28E0CAB</gtr:id><gtr:title>Dissecting the mechanisms underlying the accumulation of mitochondrial DNA deletions in human skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5ae86333abda21d8f1ba8bb9a2bf897"><gtr:id>a5ae86333abda21d8f1ba8bb9a2bf897</gtr:id><gtr:otherNames>Campbell G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5460c9c3df23e0.39154658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB07BC42-B4BE-4620-8444-246F28368E6F</gtr:id><gtr:title>Differential Atrophy of Hippocampal Subfields: A Comparative Study of Dementia with Lewy Bodies and Alzheimer Disease.</gtr:title><gtr:parentPublicationTitle>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b296d4baeb1674602f1bfcb122dc45"><gtr:id>90b296d4baeb1674602f1bfcb122dc45</gtr:id><gtr:otherNames>Mak E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-7481</gtr:issn><gtr:outcomeId>56c3507c636737.67839962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B66F0E2B-BD7E-42E5-96F7-86EB4E3998BC</gtr:id><gtr:title>Inherited Neuropathies.</gtr:title><gtr:parentPublicationTitle>Seminars in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d12bebfaa7e0b0345e19fd21ce4cd07"><gtr:id>3d12bebfaa7e0b0345e19fd21ce4cd07</gtr:id><gtr:otherNames>Fridman V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0271-8235</gtr:issn><gtr:outcomeId>5697a8af737305.64924452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAAE0391-619C-4F27-AB7F-CE216C30CBD8</gtr:id><gtr:title>Nongenomic actions of progesterone and 17?-estradiol on the chloride conductance of skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c3b73138c4b8f4b2def0fdd8adbddd"><gtr:id>a7c3b73138c4b8f4b2def0fdd8adbddd</gtr:id><gtr:otherNames>Burge JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23625574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AD1B3F8-BA7B-4493-9F44-9ABC62D751A9</gtr:id><gtr:title>Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75880868018d92d0b7d54e2c82d1b2bc"><gtr:id>75880868018d92d0b7d54e2c82d1b2bc</gtr:id><gtr:otherNames>Liu YT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5460c561356382.87159152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5F0D421-0FC7-40D6-ADDA-61B4114F3BF7</gtr:id><gtr:title>Orthostatic intolerance is common in chronic disease--a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa82016345f415704bcfe5850a2f651"><gtr:id>afa82016345f415704bcfe5850a2f651</gtr:id><gtr:otherNames>Frith J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>5458f4cf24ba40.77972124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81CD86B5-9C93-401F-A169-33B2BF57ECBA</gtr:id><gtr:title>Exon skipping and gene transfer restore dystrophin expression in hiPSC-cardiomyocytes harbouring DMD mutations.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0a82c1753617d519e42ca31d6631d0a"><gtr:id>d0a82c1753617d519e42ca31d6631d0a</gtr:id><gtr:otherNames>Dick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>5460c18a30e750.53091266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B079105-EDFA-4073-A70A-DD7E14250B6A</gtr:id><gtr:title>Extraocular muscle atrophy and central nervous system involvement in chronic progressive external ophthalmoplegia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97b274883a1e43c32b7d3477aca9ca99"><gtr:id>97b274883a1e43c32b7d3477aca9ca99</gtr:id><gtr:otherNames>Yu-Wai-Man C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_24086434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8607B886-9264-4888-9A53-9E610388D4EE</gtr:id><gtr:title>Reactive oxygen species production and mitochondrial dysfunction in white blood cells are not valid biomarkers of ageing in the very old.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77bf9e20064f7d4720bea3c32e9352d3"><gtr:id>77bf9e20064f7d4720bea3c32e9352d3</gtr:id><gtr:otherNames>Wiley L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458bda6603ec3.36473758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC85FC51-B40E-40B4-AE5F-A2DA096FD8C5</gtr:id><gtr:title>Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23281026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E3043A1-6579-4989-9F50-28EB9C826090</gtr:id><gtr:title>Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ee6ba0f820764b5675e3c255fdb95a"><gtr:id>a4ee6ba0f820764b5675e3c255fdb95a</gtr:id><gtr:otherNames>Blakely EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12934_24_23696415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>457B91A1-10E8-4F93-BBBF-635A65B3CB56</gtr:id><gtr:title>Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cedfebe3b18145716da21165d7add4c6"><gtr:id>cedfebe3b18145716da21165d7add4c6</gtr:id><gtr:otherNames>Lynn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47427f0abf5.48301710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E96EE7C-0A8A-48AE-9830-67C3B10771D0</gtr:id><gtr:title>SGCE mutations cause psychiatric disorders: clinical and genetic characterization.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfb676b61584161f3525a4a662573280"><gtr:id>bfb676b61584161f3525a4a662573280</gtr:id><gtr:otherNames>Peall KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23365103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D11B4F-FC30-480F-9A4F-9A6593B7720F</gtr:id><gtr:title>Smartphone applications: A contemporary resource for dermatopathology.</gtr:title><gtr:parentPublicationTitle>Journal of pathology informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd62fe6a22b2.24562804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E354EA23-A0E5-4A5D-B4C5-1CFDFC74C422</gtr:id><gtr:title>Defining cardiac adaptations and safety of endurance training in patients with m.3243A&amp;gt;G-related mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de9c23bb73c8bb50f291bc66e670e46c"><gtr:id>de9c23bb73c8bb50f291bc66e670e46c</gtr:id><gtr:otherNames>Bates MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>pm_12934_24_23742928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBFA9E44-766F-4112-9B36-CD34947E4975</gtr:id><gtr:title>RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b3a98515dda0ce4f419ee1dee150db"><gtr:id>a8b3a98515dda0ce4f419ee1dee150db</gtr:id><gtr:otherNames>Jopson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56c3507c2372c6.63639607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3EBF0AD-1B90-4095-B35F-4F9D113BBE53</gtr:id><gtr:title>Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ade32be540517fb772d6b8c51f53d7fd"><gtr:id>ade32be540517fb772d6b8c51f53d7fd</gtr:id><gtr:otherNames>Nisar R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>56c3232e4b4ae6.53507013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFA919CA-2CB0-43E1-A6F7-9C1EFEE693AF</gtr:id><gtr:title>Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3cccc204cd9d3d87ee07e51f0dbaf3a"><gtr:id>b3cccc204cd9d3d87ee07e51f0dbaf3a</gtr:id><gtr:otherNames>Pienaar IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5460caad66c516.49560776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83435AE5-9CCB-4782-ABAD-5823E4ED6EC1</gtr:id><gtr:title>Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe424690789fe3b498adf4ad55c8999b"><gtr:id>fe424690789fe3b498adf4ad55c8999b</gtr:id><gtr:otherNames>Lu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b4be10dc0303.25212594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2C10E2D-6ADD-4B96-9A60-5D523F57B6B0</gtr:id><gtr:title>The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/decf7b210e7ff85027089c5e7f75ce3b"><gtr:id>decf7b210e7ff85027089c5e7f75ce3b</gtr:id><gtr:otherNames>McDonald CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23674289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A529A984-7FC6-4614-B48A-9B415107470F</gtr:id><gtr:title>ATP synthase deficiency due to TMEM70 mutation leads to ultrastructural mitochondrial degeneration and is amenable to treatment.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0fe295aa0422e6a50e86dc3492e525c"><gtr:id>a0fe295aa0422e6a50e86dc3492e525c</gtr:id><gtr:otherNames>Braczynski AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b4b3c76bef78.20393581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>251C06EF-A8E3-4807-AE77-F6FC25C7C050</gtr:id><gtr:title>Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc50ac584b098635298c4f9b4186740"><gtr:id>fbc50ac584b098635298c4f9b4186740</gtr:id><gtr:otherNames>Draak TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b88835b9bdd4.72286510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7777A9D4-B28E-4574-8065-4D72C58C1844</gtr:id><gtr:title>Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81c620967036980eced49aa8faaa9ade"><gtr:id>81c620967036980eced49aa8faaa9ade</gtr:id><gtr:otherNames>Mariot V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a79d6270a1e73.59355321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989EB1FB-75B1-487B-855A-B04BE90E5875</gtr:id><gtr:title>Collagen type VI myopathies.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9b0f561b62a035262b88eaabcd32f08"><gtr:id>e9b0f561b62a035262b88eaabcd32f08</gtr:id><gtr:otherNames>Bushby KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>56d4742a0459b5.76509005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0EF156A-9241-41B9-8BF1-316CC9488DEB</gtr:id><gtr:title>Subcortical connectivity in dementia with Lewy bodies and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b7c15b5f63e39c9265641f636eab249"><gtr:id>6b7c15b5f63e39c9265641f636eab249</gtr:id><gtr:otherNames>Kenny ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_12934_24_23846997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C7E8C3-C756-4EC5-9F6E-DB07B5C4005F</gtr:id><gtr:title>The urinary proteome and metabonome differ from normal in adults with mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebce6cf6481d3699fe4f10fc4e9b01c1"><gtr:id>ebce6cf6481d3699fe4f10fc4e9b01c1</gtr:id><gtr:otherNames>Hall AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>56dd62fae86cc7.20897236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65C1B7A0-A88E-4AAA-941D-3D1EF0513687</gtr:id><gtr:title>Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/460963d19821c9edb2c3c211bb56b03d"><gtr:id>460963d19821c9edb2c3c211bb56b03d</gtr:id><gtr:otherNames>Mayhew AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>pm_12934_24_23909763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D83CF07-5D4F-4DE9-B113-04F6DE9FEAEA</gtr:id><gtr:title>Near-identical segregation of mtDNA heteroplasmy in blood, muscle, urinary epithelium, and hair follicles in twins with optic atrophy, ptosis, and intractable epilepsy.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9324030e73eb3a5421a31ea80edbd26"><gtr:id>d9324030e73eb3a5421a31ea80edbd26</gtr:id><gtr:otherNames>Spyropoulos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_12934_24_24126373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC29064F-7232-4E62-9940-D4332082D529</gtr:id><gtr:title>Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe424690789fe3b498adf4ad55c8999b"><gtr:id>fe424690789fe3b498adf4ad55c8999b</gtr:id><gtr:otherNames>Lu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56b4be103dbf34.37532371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BA02A31-12BE-4DA4-920F-6223CF37B6D9</gtr:id><gtr:title>Brain. Editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c071099ee4.31472230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95E3ECA3-9BB3-4E89-8670-377450E1AB65</gtr:id><gtr:title>Guidelines on the diagnosis and management of Waldenstr&amp;ouml;m macroglobulinaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ba4af79c32f0451521aac6d2ece158"><gtr:id>14ba4af79c32f0451521aac6d2ece158</gtr:id><gtr:otherNames>Owen RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5460c2314fcc27.22275441</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A6DDA09-04E9-46FD-A0AA-71792F51C696</gtr:id><gtr:title>196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12cffd5a1b1a9a5423d7304520481af6"><gtr:id>12cffd5a1b1a9a5423d7304520481af6</gtr:id><gtr:otherNames>Vanhoutte EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c232575ad7.27628541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>145CDF25-B6E5-4151-A2A0-CE42858557B6</gtr:id><gtr:title>Chemotherapy-induced peripheral neurotoxicity: A critical analysis.</gtr:title><gtr:parentPublicationTitle>CA: a cancer journal for clinicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9e06be21bb19cb63cdc94aab4673f50"><gtr:id>e9e06be21bb19cb63cdc94aab4673f50</gtr:id><gtr:otherNames>Park Susanna B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_24178709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988C229B-6001-4F45-8074-C60C11F42C7A</gtr:id><gtr:title>Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision.</gtr:title><gtr:parentPublicationTitle>Physiotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/160705410ecce130708496fab5e137f2"><gtr:id>160705410ecce130708496fab5e137f2</gtr:id><gtr:otherNames>Hiscock A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-9406</gtr:issn><gtr:outcomeId>5460c560d81b08.43082169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D2FF56C-E69E-421E-AD66-ECE93401C2BD</gtr:id><gtr:title>Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>PLoS currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ebc2e2eeaa9e6dde429d1c5a758c485"><gtr:id>4ebc2e2eeaa9e6dde429d1c5a758c485</gtr:id><gtr:otherNames>Kinnett K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2157-3999</gtr:issn><gtr:outcomeId>56d4742892ef16.01148440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6325BA-C468-4F8C-8562-B315680DD46E</gtr:id><gtr:title>Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf5ff4a074de4b9c145950a2d78ce56"><gtr:id>4cf5ff4a074de4b9c145950a2d78ce56</gtr:id><gtr:otherNames>Rudnik-Sch?neborn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23284067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E84914C8-9BE7-4D93-BC53-A0CEEEC4FCC2</gtr:id><gtr:title>Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn><gtr:outcomeId>pm_12934_24_23916084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06EBBF2F-4FB0-4A42-A087-FAAE5E3D5552</gtr:id><gtr:title>Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ba4af79c32f0451521aac6d2ece158"><gtr:id>14ba4af79c32f0451521aac6d2ece158</gtr:id><gtr:otherNames>Owen RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56b888361fc945.16435303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5389D9FC-740F-487C-B978-C60BC57DB095</gtr:id><gtr:title>Steroids in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23856079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69322D8D-42A0-4C35-8432-DA7BF8F2E7E6</gtr:id><gtr:title>Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f12e72240b141ada6efdedc144629c0"><gtr:id>7f12e72240b141ada6efdedc144629c0</gtr:id><gtr:otherNames>Kawagashira Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>56b8883582b705.29840657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79204FE6-CCAB-4C29-86F4-5B470AD6723D</gtr:id><gtr:title>Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dc4ef98fb109882a350e079947eb003"><gtr:id>5dc4ef98fb109882a350e079947eb003</gtr:id><gtr:otherNames>Trivedi JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23771340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>260166ED-4CC6-4E1E-8155-89B33B11080B</gtr:id><gtr:title>Mitochondrial DNA deletions in muscle satellite cells: implications for therapies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b704140988a2c45c6d81ab167821ff"><gtr:id>47b704140988a2c45c6d81ab167821ff</gtr:id><gtr:otherNames>Spendiff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23847047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09CCFC7E-5F35-4443-8674-963E0B2ADCF6</gtr:id><gtr:title>Preventing the transmission of pathogenic mitochondrial DNA mutations: Can we achieve long-term benefits from germ-line gene transfer?</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f9d0997057465d16e0cbc9569506ae2"><gtr:id>8f9d0997057465d16e0cbc9569506ae2</gtr:id><gtr:otherNames>Samuels DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn><gtr:outcomeId>pm_12934_24_23297368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFF68A6-AFCD-476D-A8EE-EA3CFD8A502E</gtr:id><gtr:title>Two recurrent mutations are associated with GNE myopathy in the North of Britain.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92cf2dd7e98f0d1ff4c60ca219551d89"><gtr:id>92cf2dd7e98f0d1ff4c60ca219551d89</gtr:id><gtr:otherNames>Chaouch A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5458b815b62a52.40953977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFD8F6A3-BC22-4742-96A9-B01235916280</gtr:id><gtr:title>The role of the mitochondrial ribosome in human disease: searching for mutations in 12S mitochondrial rRNA with high disruptive potential.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a733e8310d6d7c83b8bb767da9873a8c"><gtr:id>a733e8310d6d7c83b8bb767da9873a8c</gtr:id><gtr:otherNames>Smith PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_24092330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAF72B0B-76E8-47DE-9693-C4738642DD13</gtr:id><gtr:title>Choline Kinase Beta-Related Muscular Dystrophy, Appearance of Muscle Involvement on Magnetic Resonance Imaging.</gtr:title><gtr:parentPublicationTitle>Pediatric neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d567982a3e015e2a717c0c11c0bdf52e"><gtr:id>d567982a3e015e2a717c0c11c0bdf52e</gtr:id><gtr:otherNames>De Goede C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0887-8994</gtr:issn><gtr:outcomeId>56b214a559c4f4.46953323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>963C1234-5BCC-492B-8498-48D9016C2580</gtr:id><gtr:title>Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5460c7e0738b51.59975201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0D2A9D0-6280-4643-B404-F3E9E7C87692</gtr:id><gtr:title>Quantitative MRI in muscular dystrophy: An indispensable trial endpoint?</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf878e42a37a7f62b5e7575b0a3a6e7"><gtr:id>bdf878e42a37a7f62b5e7575b0a3a6e7</gtr:id><gtr:otherNames>Hollingsworth KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5460bfab756fa4.43140168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC6DDE66-F38C-4B19-9C6C-336CCB942AA3</gtr:id><gtr:title>Distal weakness with respiratory insufficiency caused by the m.8344A &amp;gt; G &amp;quot;MERRF&amp;quot; mutation.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ee6ba0f820764b5675e3c255fdb95a"><gtr:id>a4ee6ba0f820764b5675e3c255fdb95a</gtr:id><gtr:otherNames>Blakely EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_540e151e15179736c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAEEECFB-FA76-4FF7-B5E5-5077222140AA</gtr:id><gtr:title>Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9abffe3d877c62e1432ee4a5b5d518a8"><gtr:id>9abffe3d877c62e1432ee4a5b5d518a8</gtr:id><gtr:otherNames>Bladen CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_24162038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26581253-F05E-4A18-B7B0-717553420A55</gtr:id><gtr:title>Frailty and mortality are not influenced by mitochondrial DNA haplotypes in the very old.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57147e8492ac173298e6d9f46d58302b"><gtr:id>57147e8492ac173298e6d9f46d58302b</gtr:id><gtr:otherNames>Collerton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5458cb0a226313.44770408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FF16E99-E1BE-4E02-B070-DF7650DE433C</gtr:id><gtr:title>Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4825c06e28e3e36da21434ee220cd097"><gtr:id>4825c06e28e3e36da21434ee220cd097</gtr:id><gtr:otherNames>Burke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23219351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F0B12BE-52C0-4D99-8BAE-B36AD9B8206A</gtr:id><gtr:title>Mitochondrial and inflammatory changes in sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbb354db3fe15f02e9119f525c22a31a"><gtr:id>dbb354db3fe15f02e9119f525c22a31a</gtr:id><gtr:otherNames>Rygiel KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>doi_55f984984666c55b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D2BBC8-264E-4C9D-BA1B-CB800E6E1713</gtr:id><gtr:title>Brain. Editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c0712f3178.77912956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E06B711A-80F2-485E-91F1-26FE10A34D3C</gtr:id><gtr:title>Neuromuscular Junction Formation in Tissue-Engineered Skeletal Muscle Augments Contractile Function and Improves Cytoskeletal Organization.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59e4f9ab20508aca72cbe749d135a464"><gtr:id>59e4f9ab20508aca72cbe749d135a464</gtr:id><gtr:otherNames>Martin NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>56c459b0689e91.47394522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB899802-A722-41C1-8AAC-C0DF237CE64C</gtr:id><gtr:title>The Role of the Protein Quality Control System in SBMA.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1970f0467c0bfb6fcc09671fc7ea6e52"><gtr:id>1970f0467c0bfb6fcc09671fc7ea6e52</gtr:id><gtr:otherNames>Rusmini P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn><gtr:outcomeId>56b4be1148faa6.59915966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E5CD548-7100-40A7-9677-6957FE7DEF00</gtr:id><gtr:title>Cerebellar learning distinguishes inflammatory neuropathy with and without tremor.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/933c853b6f0a20d8ccf3cf131cf4bc87"><gtr:id>933c853b6f0a20d8ccf3cf131cf4bc87</gtr:id><gtr:otherNames>Schwingenschuh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23596070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDAA2F21-586C-4FEC-B65E-8F3FD145E074</gtr:id><gtr:title>Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/906dfc026476c7e73e3c62ebff83fa85"><gtr:id>906dfc026476c7e73e3c62ebff83fa85</gtr:id><gtr:otherNames>Suetterlin KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56dd63000d3397.05144446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB6ADBA-307A-4290-91FC-CB262284CF3C</gtr:id><gtr:title>Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f2ffce8c02a4b6b0bbc58401abe540a"><gtr:id>3f2ffce8c02a4b6b0bbc58401abe540a</gtr:id><gtr:otherNames>Almalki A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_12934_24_24161539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19D3FAF-1720-4F5A-B92C-B267DE0F7672</gtr:id><gtr:title>Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8088f2d6e90105cd78b127c6516c9f"><gtr:id>2e8088f2d6e90105cd78b127c6516c9f</gtr:id><gtr:otherNames>Tucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5460c561cd0c63.06239997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3303132A-E892-4CF9-B1D7-07BB782E67C0</gtr:id><gtr:title>Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bd5b62cb431ce02e16df69703d0c6da"><gtr:id>7bd5b62cb431ce02e16df69703d0c6da</gtr:id><gtr:otherNames>Schabh?ttl M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5460c561a58b80.46334251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>256A5D5C-C1BF-442E-85C7-C95FEF364863</gtr:id><gtr:title>Muscular dystrophy with large mitochondria associated with mutations in the CHKB gene in three British patients: extending the clinical and pathological phenotype.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca5ab435a4e9976a086607c68acec298"><gtr:id>ca5ab435a4e9976a086607c68acec298</gtr:id><gtr:otherNames>Quinlivan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23692895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B124A07-C7C3-4484-9547-FEF2CADC7450</gtr:id><gtr:title>Longitudinal testing of visual perception in dementia with Lewy bodies and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>International journal of geriatric psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63046a5d0262bebc3218dc4eeae94210"><gtr:id>63046a5d0262bebc3218dc4eeae94210</gtr:id><gtr:otherNames>Wood JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-6230</gtr:issn><gtr:outcomeId>pm_12934_24_22821711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B5DD597-CD0F-4010-93ED-C13CA3BFC75F</gtr:id><gtr:title>195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4eb81bbb3690423e60cdda19f99b6b39"><gtr:id>4eb81bbb3690423e60cdda19f99b6b39</gtr:id><gtr:otherNames>Ellis JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23791627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B62E0804-78B1-43F8-9655-B937D0E485D4</gtr:id><gtr:title>Mosaicism for dominant collagen 6 mutations as a cause for intrafamilial phenotypic variability.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba387105d226ca2d980c0d2f6e8911e4"><gtr:id>ba387105d226ca2d980c0d2f6e8911e4</gtr:id><gtr:otherNames>Donkervoort S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>56b214a9083781.93075271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C54E37E7-EFFC-4792-A7FD-53CC2B154094</gtr:id><gtr:title>Quantitative quadruple-label immunofluorescence of mitochondrial and cytoplasmic proteins in single neurons from human midbrain tissue.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/255f14bfe5038a10c88615ffcedb9000"><gtr:id>255f14bfe5038a10c88615ffcedb9000</gtr:id><gtr:otherNames>Gr?newald A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>5460c9c3bbef19.93708199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7141AFCE-1E6C-472C-89A0-D18B53E98D37</gtr:id><gtr:title>Homozygous mutation incausing distal vacuolar myopathy and motor neuropathy.</gtr:title><gtr:parentPublicationTitle>Neurology. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d1503307a90897a52487453a039bddd"><gtr:id>1d1503307a90897a52487453a039bddd</gtr:id><gtr:otherNames>Bugiardini E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2376-7839</gtr:issn><gtr:outcomeId>5a79d626a1c493.14022811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65F0026E-FC0C-4404-9D6F-39DE2D446A70</gtr:id><gtr:title>Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d650d10593bac5fd741f0c8a365fc160"><gtr:id>d650d10593bac5fd741f0c8a365fc160</gtr:id><gtr:otherNames>Rothwell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56dd62ff7e1517.54997565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E46C91CC-5F22-4F7F-A0B2-9C4DA80BBE12</gtr:id><gtr:title>Cardiomyopathies due to homoplasmic mitochondrial tRNA mutations: morphologic and molecular features.</gtr:title><gtr:parentPublicationTitle>Human pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebed1cd795e0af5789caf713577a49fc"><gtr:id>ebed1cd795e0af5789caf713577a49fc</gtr:id><gtr:otherNames>Giordano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0046-8177</gtr:issn><gtr:outcomeId>pm_12934_24_23332932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E71807D-17E6-428C-9679-356CDFED63FD</gtr:id><gtr:title>Chemical-genetic attenuation of focal neocortical seizures.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e71c4ba694ccab7ce7b6754c5c8856a6"><gtr:id>e71c4ba694ccab7ce7b6754c5c8856a6</gtr:id><gtr:otherNames>K?tzel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460c070c150a3.03435374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC999B4-07CC-47E5-89EC-A944C89FE2E4</gtr:id><gtr:title>Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79450e4524dd6bf57d1eea3282e0deab"><gtr:id>79450e4524dd6bf57d1eea3282e0deab</gtr:id><gtr:otherNames>Sommerville EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5a5f5577cfc704.99990620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2EACB81-D808-43D8-8B24-FAE5517779FC</gtr:id><gtr:title>Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1161dceb49b9031cc5693146e0b920cb"><gtr:id>1161dceb49b9031cc5693146e0b920cb</gtr:id><gtr:otherNames>Lunn MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460c23176c5a6.32585746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53BE879F-9B97-44C2-A383-F4D452ABD12F</gtr:id><gtr:title>Dll4 and PDGF-BB convert committed skeletal myoblasts to pericytes without erasing their myogenic memory.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fae8d7e266f179c0d9d26bcf9ebf219"><gtr:id>3fae8d7e266f179c0d9d26bcf9ebf219</gtr:id><gtr:otherNames>Cappellari O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>pm_12934_24_23477786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>456F3A4E-9705-4212-8B87-E898ABB10301</gtr:id><gtr:title>Ongoing developments in sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Current rheumatology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/973fa2ad4c5615dcdcf432bf2cfb16da"><gtr:id>973fa2ad4c5615dcdcf432bf2cfb16da</gtr:id><gtr:otherNames>Machado PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-3774</gtr:issn><gtr:outcomeId>56b4be0fa54b60.81376707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BA20D0D-F98E-4FF5-8D85-CBC7673133B3</gtr:id><gtr:title>NDUFS8-related Complex I Deficiency Extends Phenotype from &amp;quot;PEO Plus&amp;quot; to Leigh Syndrome.</gtr:title><gtr:parentPublicationTitle>JIMD reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3b9089a043ed6fa458b831e348da7a"><gtr:id>af3b9089a043ed6fa458b831e348da7a</gtr:id><gtr:otherNames>Marina AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2192-8304</gtr:issn><gtr:outcomeId>pm_12934_24_23430795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54255693-CCD0-49EC-B940-E8A4613D3066</gtr:id><gtr:title>Genetic advances in sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Current opinion in rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5740d7dfacf41317fd1190662cfe9c79"><gtr:id>5740d7dfacf41317fd1190662cfe9c79</gtr:id><gtr:otherNames>Gang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1040-8711</gtr:issn><gtr:outcomeId>56dd62ff370a98.35750148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9E759E8-A4EE-4E7D-88EB-F70935AF5ACC</gtr:id><gtr:title>Early-onset cataracts, spastic paraparesis, and ataxia caused by a novel mitochondrial tRNAGlu (MT-TE) gene mutation causing severe complex I deficiency: a clinical, molecular, and neuropathologic study.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49556e9fdf0c03f1e42f752a9d5ca04e"><gtr:id>49556e9fdf0c03f1e42f752a9d5ca04e</gtr:id><gtr:otherNames>Lax NZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>pm_12934_24_23334599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>121E1F66-D81F-47C9-B112-D2F9D053F27D</gtr:id><gtr:title>Reliability and accuracy of skeletal muscle imaging in limb-girdle muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23905174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3614AF4A-008A-4AC0-BF1B-CBC4A93665A3</gtr:id><gtr:title>Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5675e598928c0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B7EF0E9-FA0E-4651-B75F-9B99573EE495</gtr:id><gtr:title>Calcium signaling as a mediator of cell energy demand and a trigger to cell death.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc79e1d48037f448518ef7526da50f0"><gtr:id>fbc79e1d48037f448518ef7526da50f0</gtr:id><gtr:otherNames>Bhosale G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>56c32874b9c794.74985802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>202470F7-2084-4BAF-8D20-46D9C5350BC7</gtr:id><gtr:title>Nanoscale-targeted patch-clamp recordings of functional presynaptic ion channels.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c74f2f031a8194794fe50f22d63d5c"><gtr:id>f5c74f2f031a8194794fe50f22d63d5c</gtr:id><gtr:otherNames>Novak P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_12934_24_24050398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9D85E01-7C35-4C05-9C0E-FAF8F231C97D</gtr:id><gtr:title>Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.</gtr:title><gtr:parentPublicationTitle>Neuromolecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7276d1e256346a632b0a5edf660a0b74"><gtr:id>7276d1e256346a632b0a5edf660a0b74</gtr:id><gtr:otherNames>Cregg R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-1084</gtr:issn><gtr:outcomeId>5460c232a1e3c1.23135414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60B01323-D70C-4D36-B75F-09AF0211B61E</gtr:id><gtr:title>SCP2 mutations and neurodegeneration with brain iron accumulation.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b4b3c6bed127.57784865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>134B3E48-E686-4284-B239-80D8FC90F371</gtr:id><gtr:title>Mitochondrial DNA sequence characteristics modulate the size of the genetic bottleneck.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99fcf07122666dd23e6cca7816fda75"><gtr:id>d99fcf07122666dd23e6cca7816fda75</gtr:id><gtr:otherNames>Wilson IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56c313ce097563.37577189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C3DCA7E-4B3F-4E64-8E91-83750A790206</gtr:id><gtr:title>In vivo assessment of muscle membrane properties in myotonic dystrophy.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63da48f6092092665f886cfef88e3860"><gtr:id>63da48f6092092665f886cfef88e3860</gtr:id><gtr:otherNames>Tan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>56dd630114c150.80428892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7484E131-08CB-459A-9D9F-35D779F656CF</gtr:id><gtr:title>Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd605107fd4c3c0c17a163afbaead00d"><gtr:id>dd605107fd4c3c0c17a163afbaead00d</gtr:id><gtr:otherNames>Herbert MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56dd62fceb36e3.56466664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06A30144-0F52-4835-A431-A9E459B16186</gtr:id><gtr:title>Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification.</gtr:title><gtr:parentPublicationTitle>SpringerPlus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2193-1801</gtr:issn><gtr:outcomeId>56dd62feb971c7.12900440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B3FF09-5481-4FAA-8E12-BCBF61EEFCBE</gtr:id><gtr:title>SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfb676b61584161f3525a4a662573280"><gtr:id>bfb676b61584161f3525a4a662573280</gtr:id><gtr:otherNames>Peall KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5458bb0b893811.58051023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4018D8-4F57-4C24-827B-E948234EA046</gtr:id><gtr:title>A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability--a pharmacogenetic transcranial magnetic stimulation study.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e9f5f1fb509e920c4fc58537faa76f"><gtr:id>a9e9f5f1fb509e920c4fc58537faa76f</gtr:id><gtr:otherNames>Menzler K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5460c7e09c7885.49391717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ECB4BC6-D08A-48FF-890B-77D856269287</gtr:id><gtr:title>International Charter of principles for sharing bio-specimens and data.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0dcfa39fd70702a2e03c6746adecee3"><gtr:id>c0dcfa39fd70702a2e03c6746adecee3</gtr:id><gtr:otherNames>Mascalzoni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>56d47b0e2a4873.62597391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C9CB15-032D-4A5A-A26A-9332125BF821</gtr:id><gtr:title>The effect of the muscle environment on the regenerative capacity of human skeletal muscle stem cells.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e84e3707839d90302345838b73f672b7"><gtr:id>e84e3707839d90302345838b73f672b7</gtr:id><gtr:otherNames>Meng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn><gtr:outcomeId>56b2139188d690.69366387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95AAA942-9BEA-4D0E-9EA4-6E5B1AD29141</gtr:id><gtr:title>Improving recognition of Duchenne muscular dystrophy: a retrospective case note review.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32c353d8432d4cf58c5717523703ef6c"><gtr:id>32c353d8432d4cf58c5717523703ef6c</gtr:id><gtr:otherNames>van Ruiten HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>56d47429c5e535.67603177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C58484A-ACBD-40A7-9F88-611199583C6D</gtr:id><gtr:title>Sequencing analysis of the spinal bulbar muscular atrophy CAG expansion reveals absence of repeat interruptions.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_12934_24_24041967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>007E8051-D9D3-405B-AF72-BCC4871D7D1E</gtr:id><gtr:title>Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/365ff300e2e52c02bd4f9ddb9d00cffe"><gtr:id>365ff300e2e52c02bd4f9ddb9d00cffe</gtr:id><gtr:otherNames>Gallenm?ller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c189d5b175.76620384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>078BB7FF-2DEF-4A98-8AF3-2D633DEAAA03</gtr:id><gtr:title>Titinopathy in a Canadian family sharing the British founder haplotype.</gtr:title><gtr:parentPublicationTitle>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0317-1671</gtr:issn><gtr:outcomeId>5458c7e7405b27.12797352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EEF0142-B499-4BF9-9EE7-2A7691B8D4DB</gtr:id><gtr:title>Recent mitochondrial DNA mutations increase the risk of developing common late-onset human diseases.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_540e151e151863b40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4F20DC6-56E7-4AA6-86C0-B36B48927B88</gtr:id><gtr:title>Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2eb898e5d34b317af133a25b9b5673d"><gtr:id>e2eb898e5d34b317af133a25b9b5673d</gtr:id><gtr:otherNames>Klymiuk N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23784375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD1E171A-F641-4CC1-8D4C-7EDB9E873F31</gtr:id><gtr:title>[Myology and ethnic minorities: all roads lead to the Roma].</gtr:title><gtr:parentPublicationTitle>Medecine sciences : M/S</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a04a2d5da3a8501817d3ca5dda1783de"><gtr:id>a04a2d5da3a8501817d3ca5dda1783de</gtr:id><gtr:otherNames>Urtizberea JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0767-0974</gtr:issn><gtr:outcomeId>56d47b0d9be3c9.55974223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB464FCF-149F-4FD4-9AC3-E6E2E4BEB7B0</gtr:id><gtr:title>Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers.</gtr:title><gtr:parentPublicationTitle>European heart journal cardiovascular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de9c23bb73c8bb50f291bc66e670e46c"><gtr:id>de9c23bb73c8bb50f291bc66e670e46c</gtr:id><gtr:otherNames>Bates MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2047-2404</gtr:issn><gtr:outcomeId>5458f56e5e21c3.89307241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C8D245-DFFA-48F8-8AA1-2126307B91B1</gtr:id><gtr:title>Future needs in peripheral neuropathy outcome measures.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ca357d87f4d45554ae7b2d975d3883b"><gtr:id>1ca357d87f4d45554ae7b2d975d3883b</gtr:id><gtr:otherNames>Van den Bergh PY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b8883144ef61.28059488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41F41689-771E-4882-AD52-468F84A7C56A</gtr:id><gtr:title>Exome sequencing identifies DYNC2H1 mutations as a common cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major polydactyly, renal or retinal involvement.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5291fcb060e2e3e91e1c34ce57879614"><gtr:id>5291fcb060e2e3e91e1c34ce57879614</gtr:id><gtr:otherNames>Schmidts M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>pm_12934_24_23456818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC132909-6AD6-4C69-8441-EF48EABBF17B</gtr:id><gtr:title>Mitochondrial IF1 preserves cristae structure to limit apoptotic cell death signaling.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/432a93a0abc1c455d7acbe3bdeeae1de"><gtr:id>432a93a0abc1c455d7acbe3bdeeae1de</gtr:id><gtr:otherNames>Faccenda D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_12934_24_23907134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C072590-AA69-4730-87BD-666F3338BED1</gtr:id><gtr:title>The UK10K project identifies rare variants in health and disease.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de52d61bcdd816885d202f38d31b1db"><gtr:id>0de52d61bcdd816885d202f38d31b1db</gtr:id><gtr:otherNames>UK10K Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56b214a5dfeee0.77683484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F3CDD2D-D618-4AC3-9BFD-078320336481</gtr:id><gtr:title>Mitochondrial disease in adults: what's old and what's new?</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1f4b7c0cf2741f213eff19fe22e37f"><gtr:id>fe1f4b7c0cf2741f213eff19fe22e37f</gtr:id><gtr:otherNames>Chinnery PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>56d470e7974619.96900236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B8012D8-554F-4F7C-B238-AA6EA97BFBF7</gtr:id><gtr:title>Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06cafa9846d93795ff1a2d7d7ee1b3c"><gtr:id>d06cafa9846d93795ff1a2d7d7ee1b3c</gtr:id><gtr:otherNames>Mazzone E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c3abbd2647.99085536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C09F368-D9E7-4BCC-9DB2-413BA6C50550</gtr:id><gtr:title>Epigenetic changes as a common trigger of muscle weakness in congenital myopathies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c8082802ec778386ca3cc5c516bf7e"><gtr:id>f5c8082802ec778386ca3cc5c516bf7e</gtr:id><gtr:otherNames>Rokach O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b214a70193c9.40590222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7655036D-BE29-4FE7-AD09-72625A7C58D9</gtr:id><gtr:title>Chloride channels in myotonia congenita assessed by velocity recovery cycles.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63da48f6092092665f886cfef88e3860"><gtr:id>63da48f6092092665f886cfef88e3860</gtr:id><gtr:otherNames>Tan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_24037712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDEEDEAF-809D-4380-8B8B-B79A804DDC2A</gtr:id><gtr:title>Bilateral paediatric optic neuropathy precipitated by vitamin B12 deficiency and a novel mitochondrial DNA mutation.</gtr:title><gtr:parentPublicationTitle>International ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f84f97b35f82fe950fadc32cbad436a"><gtr:id>2f84f97b35f82fe950fadc32cbad436a</gtr:id><gtr:otherNames>Jalil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-5701</gtr:issn><gtr:outcomeId>pm_12934_24_23572439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17A4A1B1-5BB8-46BF-9E7F-A225DECFC367</gtr:id><gtr:title>Collagen VI regulates satellite cell self-renewal and muscle regeneration.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f195ba155a3cf0f1e709391a0a676add"><gtr:id>f195ba155a3cf0f1e709391a0a676add</gtr:id><gtr:otherNames>Urciuolo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_12934_24_23743995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95490264-BD21-4857-8AEE-876D1BCF8774</gtr:id><gtr:title>204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27dda599429392390ec6f5655af4e714"><gtr:id>27dda599429392390ec6f5655af4e714</gtr:id><gtr:otherNames>Ferlini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47b0e579d57.71272107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE4CEB73-30FC-4639-A2BB-4BDF3B703BF1</gtr:id><gtr:title>Mutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathies.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ce5407a074f94dc51098c4e90a01f0e"><gtr:id>3ce5407a074f94dc51098c4e90a01f0e</gtr:id><gtr:otherNames>Marttila M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>5460c0c0e08d18.28937328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DEAA97E-3AB7-4B6F-9256-93FE76409DAC</gtr:id><gtr:title>Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23349320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>948A552C-3B60-489D-AD63-7AB1C726CA31</gtr:id><gtr:title>Assessment of ventricular function in mouse models of muscular dystrophy: a comparison of MRI with conductance catheter.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9d500eb6414ab3cf12e1887a7027e58"><gtr:id>d9d500eb6414ab3cf12e1887a7027e58</gtr:id><gtr:otherNames>Blain AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47a2acc7440.89549334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73F3A8A3-93A9-4C61-86DE-AE896E7BE0D8</gtr:id><gtr:title>A multi-center comparison of diagnostic methods for the biochemical evaluation of suspected mitochondrial disorders.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f29e2bd68fd6445e0ae296ba7a11dfb0"><gtr:id>f29e2bd68fd6445e0ae296ba7a11dfb0</gtr:id><gtr:otherNames>Rodenburg RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>pm_12934_24_23164799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EC0D362-A8BE-44B1-9443-900092321127</gtr:id><gtr:title>Accurate mitochondrial DNA sequencing using off-target reads provides a single test to identify pathogenic point mutations.</gtr:title><gtr:parentPublicationTitle>Genetics in medicine : official journal of the American College of Medical Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17b1972d3507f836480ade3288e49dc0"><gtr:id>17b1972d3507f836480ade3288e49dc0</gtr:id><gtr:otherNames>Griffin HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1098-3600</gtr:issn><gtr:outcomeId>5458bb0c0ec679.81163669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>772A476D-5176-4423-AA87-252B7647B743</gtr:id><gtr:title>Deep resequencing of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d470ea5c42e1.57383759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01F436C4-5583-4151-9CA4-9EB02E29BDAE</gtr:id><gtr:title>The Safety of Using Body-Transmit MRI in Patients with Implanted Deep Brain Stimulation Devices.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edeb3314dd5cdca2bdfe15a9221d0c8f"><gtr:id>edeb3314dd5cdca2bdfe15a9221d0c8f</gtr:id><gtr:otherNames>Kahan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c466773ee4a1.41816924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDAE164F-0AD8-41EF-8D36-FD898850BD7F</gtr:id><gtr:title>Enhanced reticulospinal output in patients with (REEP1) hereditary spastic paraplegia type 31.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c21fdfe87d806c02934f304730fc0da9"><gtr:id>c21fdfe87d806c02934f304730fc0da9</gtr:id><gtr:otherNames>Fisher KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5458c7e8926a73.33150982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E71F7A73-C3BD-4CBE-B721-3D17C9C8E90C</gtr:id><gtr:title>Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23810313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FDC113F-2F78-492E-956F-0197F2DCA323</gtr:id><gtr:title>Genotype/phenotype correlations in AARS-related neuropathy in a cohort of patients from the United Kingdom and Ireland.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40a020e11c4ea5657e5f2e6f3485cfd0"><gtr:id>40a020e11c4ea5657e5f2e6f3485cfd0</gtr:id><gtr:otherNames>Bansagi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56b4b3c7e77554.17279212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C809E7F1-DFDE-476C-A09C-A53EA929775C</gtr:id><gtr:title>Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458bda6110c11.97445729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89885B74-660B-4AD1-AB0E-BF85F034FAB2</gtr:id><gtr:title>CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb7de9e0bdbda47bf81b86f2720f04e3"><gtr:id>bb7de9e0bdbda47bf81b86f2720f04e3</gtr:id><gtr:otherNames>Scalco RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>58a4551c6bd2d7.49455852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F88EAD-23E2-4DB3-A6D0-848C92FA31CA</gtr:id><gtr:title>Separating NADH and NADPH fluorescence in live cells and tissues using FLIM.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c5e15d00b7fc6f2a4d8c41e3eb45e46"><gtr:id>6c5e15d00b7fc6f2a4d8c41e3eb45e46</gtr:id><gtr:otherNames>Blacker TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5458d3bfdf7ee5.29227837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD4CC64-BCF4-443D-A3F9-3507D0DC37EB</gtr:id><gtr:title>Somatic mtDNA variation is an important component of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ff3ff830765b467e00bb85c41d92c6"><gtr:id>72ff3ff830765b467e00bb85c41d92c6</gtr:id><gtr:otherNames>Coxhead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d470e7d6d763.47493056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40DE1237-3C75-4C45-AAE2-61B7DA9BCD72</gtr:id><gtr:title>The presence of highly disruptive 16S rRNA mutations in clinical samples indicates a wider role for mutations of the mitochondrial ribosome in human disease.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19cd9eac194029b31fc778c6567229da"><gtr:id>19cd9eac194029b31fc778c6567229da</gtr:id><gtr:otherNames>Elson JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>56c3208e6a7d23.47099939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFDC06F3-DA7D-4244-A4A8-A506C94EE9B1</gtr:id><gtr:title>Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc407e71218096589121f3b1463eb434"><gtr:id>cc407e71218096589121f3b1463eb434</gtr:id><gtr:otherNames>Mitrpant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460c4b8e4c784.14139636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07EAE7C3-2FDF-45E7-B2E7-DD27508E72DC</gtr:id><gtr:title>Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the a-e subunit interface.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f022b8687d82dc8df9d836a488d074d"><gtr:id>8f022b8687d82dc8df9d836a488d074d</gtr:id><gtr:otherNames>Webster R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c0c06c97d4.14065190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F1A8F5B-EDD1-4186-BC9C-E79D45B1FF20</gtr:id><gtr:title>One complex world of mitochondrial parkinsonism.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1f4b7c0cf2741f213eff19fe22e37f"><gtr:id>fe1f4b7c0cf2741f213eff19fe22e37f</gtr:id><gtr:otherNames>Chinnery PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23884808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43A5882E-F2C8-4476-AE68-B9F2E574F7AB</gtr:id><gtr:title>Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebed1cd795e0af5789caf713577a49fc"><gtr:id>ebed1cd795e0af5789caf713577a49fc</gtr:id><gtr:otherNames>Giordano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458c7e8461bc7.13990600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B49584B5-50EF-4252-AF2C-CC01DAD71065</gtr:id><gtr:title>ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf93ecbab15b08ce52d70b1af9453dc"><gtr:id>baf93ecbab15b08ce52d70b1af9453dc</gtr:id><gtr:otherNames>Cirak S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23288328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25B11356-B968-40F6-A4D0-11F23596E26C</gtr:id><gtr:title>Asymmetric sensory ganglionopathy: a case series.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae39de5efdba634a7472ce916fd122a3"><gtr:id>ae39de5efdba634a7472ce916fd122a3</gtr:id><gtr:otherNames>Marquez-Infante C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23744601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97296373-DBD7-4960-B839-C6551C404049</gtr:id><gtr:title>Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells.</gtr:title><gtr:parentPublicationTitle>Neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fcbe089751d63ca9d3cd02742981ed6"><gtr:id>6fcbe089751d63ca9d3cd02742981ed6</gtr:id><gtr:otherNames>Lin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1522-8517</gtr:issn><gtr:outcomeId>58a7110534fed1.76034125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A4BAA29-54BA-4EFA-863F-D6DC05040B4C</gtr:id><gtr:title>HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ab95560c5f1e023382cb34f11fcc3c"><gtr:id>d4ab95560c5f1e023382cb34f11fcc3c</gtr:id><gtr:otherNames>Guedes-Dias P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56c32874152143.30212729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF22464E-F16E-4CB3-BDDF-30B12D5FDB3F</gtr:id><gtr:title>Thymectomy: role in the treatment of myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5460c072b1c485.91383503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5A2AF8B-9E5C-401E-AC56-CAC8F57C2B76</gtr:id><gtr:title>Investigating the quantitative fidelity of prospectively undersampled chemical shift imaging in muscular dystrophy with compressed sensing and parallel imaging reconstruction.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf878e42a37a7f62b5e7575b0a3a6e7"><gtr:id>bdf878e42a37a7f62b5e7575b0a3a6e7</gtr:id><gtr:otherNames>Hollingsworth KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>5460bfabc29b51.34032138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45E57F1C-00D1-4DBB-9DBA-B8D15D2E6F68</gtr:id><gtr:title>Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23486992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C13CE00F-6717-46A5-812F-E6187498C5CA</gtr:id><gtr:title>Multiparameter MR imaging in the 6-OPRI variant of inherited prion disease.</gtr:title><gtr:parentPublicationTitle>AJNR. American journal of neuroradiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f043ed1cf2c55a840962d924232b9925"><gtr:id>f043ed1cf2c55a840962d924232b9925</gtr:id><gtr:otherNames>De Vita E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-6108</gtr:issn><gtr:outcomeId>pm_12934_24_23538406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79DFDF15-B4CA-4FE4-AA82-3B45989C012D</gtr:id><gtr:title>Regulation of mitochondrial morphogenesis by annexin A6.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59fabd98617d4d976a32769910c88583"><gtr:id>59fabd98617d4d976a32769910c88583</gtr:id><gtr:otherNames>Chlystun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458f4cecc7ef7.23696045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D38EE93C-B6F9-4860-887A-FBC633F71250</gtr:id><gtr:title>RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beab6a180a6190f432224107cc2d56fb"><gtr:id>beab6a180a6190f432224107cc2d56fb</gtr:id><gtr:otherNames>Illingworth MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c3ab46b8b5.75688067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCDD3D18-D69D-4B31-A110-76F04C3761A5</gtr:id><gtr:title>An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c33d500813.40259233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7014CC9D-719D-4C4E-8F67-C4062E339465</gtr:id><gtr:title>A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5c596058f4e99b11d3fe3dbd4f968f"><gtr:id>5f5c596058f4e99b11d3fe3dbd4f968f</gtr:id><gtr:otherNames>Sumner CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5458f6eb7bbaa9.17970320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73426894-43BB-420D-B7B9-5A66A805E50D</gtr:id><gtr:title>Early-onset leukoencephalopathy due to a homozygous missense mutation in the DARS2 gene.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular probes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b46a059d17a7e6e21fea65a261eb2d3"><gtr:id>5b46a059d17a7e6e21fea65a261eb2d3</gtr:id><gtr:otherNames>K?hler C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0890-8508</gtr:issn><gtr:outcomeId>56b4b3c7bbe1c2.87442868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>768E7B1B-B3E6-4E85-9589-2EF5AB54262D</gtr:id><gtr:title>Nebulin (NEB) mutations in a childhood onset distal myopathy with rods and cores uncovered by next generation sequencing.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002dc518113cfcd49df817b7f8935a46"><gtr:id>002dc518113cfcd49df817b7f8935a46</gtr:id><gtr:otherNames>Scoto M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>pm_12934_24_23443021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F54A35D3-CDD1-4F59-878F-A09127642E02</gtr:id><gtr:title>Mutations in SCN4A: a rare but treatable cause of recurrent life-threatening laryngospasm.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4c8a906803b3f7e1e43ff1b33c9a50e"><gtr:id>e4c8a906803b3f7e1e43ff1b33c9a50e</gtr:id><gtr:otherNames>Singh RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>56dd62fb466b68.57311152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B1CD45C-B1BE-4C13-A5E1-EA4C0ED4AF4F</gtr:id><gtr:title>Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae312a95b658688d9e502f838b047b75"><gtr:id>ae312a95b658688d9e502f838b047b75</gtr:id><gtr:otherNames>Corrochano S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b4be10003eb1.51921943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95015DE8-817D-4EB8-BD6B-B3DC227C2A5C</gtr:id><gtr:title>Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b4be11d1f362.21342087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20940CE2-C6DA-4C10-A63F-202D21A2BB8D</gtr:id><gtr:title>Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86694d88fb2c9bb553f0bfcfc3584548"><gtr:id>86694d88fb2c9bb553f0bfcfc3584548</gtr:id><gtr:otherNames>Graves TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_540e151e15164644c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7AA64B-B801-48D2-BE3B-6AD1EE3B399A</gtr:id><gtr:title>Incidence of carpal tunnel syndrome in adult patients with mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>pm_12934_24_23521646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F616319E-915D-4488-B241-6C4F5CE7C0BF</gtr:id><gtr:title>The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.</gtr:title><gtr:parentPublicationTitle>Human gene therapy. Clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45ff27fe5d0c78d850418ff8ef1d2b4f"><gtr:id>45ff27fe5d0c78d850418ff8ef1d2b4f</gtr:id><gtr:otherNames>Aiuti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2324-8637</gtr:issn><gtr:outcomeId>pm_12934_24_23862696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F02FF93-32D9-4D81-9595-CA43B8144B63</gtr:id><gtr:title>FUS is not dysregulated by the spinal bulbar muscular atrophy androgen receptor polyglutamine repeat expansion.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>WRqiTFq4TMi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D058A99-5492-4C88-AF99-07DB9EE16816</gtr:id><gtr:title>The importance of genetic diagnosis for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f0682b259759dcbf352bf526183086e"><gtr:id>3f0682b259759dcbf352bf526183086e</gtr:id><gtr:otherNames>Aartsma-Rus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>56d4742699b502.65956136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63D9B4AF-AC0F-421D-B032-F243E88FE7F0</gtr:id><gtr:title>New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cc6cc5027a071fd69e434cd23fde824"><gtr:id>4cc6cc5027a071fd69e434cd23fde824</gtr:id><gtr:otherNames>Ben Salem S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_12934_24_23746477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E612E925-E20B-411C-9563-2D5F6CEBD123</gtr:id><gtr:title>The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56b214a79206e5.86547754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C36731D-0EB0-416B-8CD8-8B373A813EE1</gtr:id><gtr:title>Cerebral vascular control is associated with skeletal muscle pH in chronic fatigue syndrome patients both at rest and during dynamic stimulation.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9386a94264cea756975b82feb62f963e"><gtr:id>9386a94264cea756975b82feb62f963e</gtr:id><gtr:otherNames>He J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>pm_12934_24_24179772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD2D4333-F238-4A7B-B957-7034474686C1</gtr:id><gtr:title>Mouse regenerating myofibers detected as false-positive donor myofibers with anti-human spectrin.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8457cdf0b8e97c1e66478931df0aa55e"><gtr:id>8457cdf0b8e97c1e66478931df0aa55e</gtr:id><gtr:otherNames>Rozkalne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>5460c33d9b9b25.05217864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>885121C5-DD1C-47FA-B060-88EC90EC0691</gtr:id><gtr:title>MFN2 deletion of exons 7 and 8: founder mutation in the UK population.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/230c6ae6cfa4b1a456b4b475e336d4da"><gtr:id>230c6ae6cfa4b1a456b4b475e336d4da</gtr:id><gtr:otherNames>Carr AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5697a8aee36137.66588073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB39BA3-9777-4181-BAFA-7935E41F152C</gtr:id><gtr:title>Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9846543db4183f5f0ccf80c6f934e416"><gtr:id>9846543db4183f5f0ccf80c6f934e416</gtr:id><gtr:otherNames>Yarnall AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5458c7e7bd96f2.42719927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5BA6355-9335-4904-9490-383B04EFCDAB</gtr:id><gtr:title>Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4f96e57c98d99f1463f4f7aa486d7f2"><gtr:id>d4f96e57c98d99f1463f4f7aa486d7f2</gtr:id><gtr:otherNames>Hodkinson JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>56b888327b92f1.33320950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96D8F59A-8852-45CA-8EE7-0115F619D2EB</gtr:id><gtr:title>WEIGHT LOSS, ENCEPHALOPATHY, URINARY DIFFICULTIES AND NUMB FEET IN A NIGERIAN MAN</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12bd802931db2c434b281e1bc64f66fc"><gtr:id>12bd802931db2c434b281e1bc64f66fc</gtr:id><gtr:otherNames>McColgan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_24108911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ECCA248-11AA-4623-B78E-CDA5E021B6E9</gtr:id><gtr:title>Multisystem fatal infantile disease caused by a novel homozygous EARS2 mutation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6ab13390a03bb47cc0c9895a3246407"><gtr:id>d6ab13390a03bb47cc0c9895a3246407</gtr:id><gtr:otherNames>Talim B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23008233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0E8DC9F-D809-4024-B8F1-EAE822B46BB4</gtr:id><gtr:title>Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f290ce49002164ad6a7d750e1563a856"><gtr:id>f290ce49002164ad6a7d750e1563a856</gtr:id><gtr:otherNames>Zhou H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b213913b9d41.62462494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57AAE959-66E5-4C1D-85B4-D60C1E2F568E</gtr:id><gtr:title>Fibronectin is a serum biomarker for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb2ce25240733782b73ade82f78a135"><gtr:id>ccb2ce25240733782b73ade82f78a135</gtr:id><gtr:otherNames>Cynthia Martin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>5460c18a066497.87024178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19E8E820-88D5-4135-95BE-659EDCF18607</gtr:id><gtr:title>GNE myopathy in Roma patients homozygous for the p.I618T founder mutation.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4deabfd981c11e2fb8d5ef0d09b862c4"><gtr:id>4deabfd981c11e2fb8d5ef0d09b862c4</gtr:id><gtr:otherNames>Chamova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47b0f5aee76.17589896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C796D633-D66F-4A39-A744-2BBCD143B2B0</gtr:id><gtr:title>Increased yield of exome sequencing by off-target mitochondrial DNA analysis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67ce09e20d856408a7b59f5c51db18c8"><gtr:id>67ce09e20d856408a7b59f5c51db18c8</gtr:id><gtr:otherNames>Griffin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56d470e9cdac34.44268096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5F4672B-1528-4FE4-B50B-58C4EFDE64E0</gtr:id><gtr:title>Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c1fd83bc7b48a76e311e696eeefba08"><gtr:id>4c1fd83bc7b48a76e311e696eeefba08</gtr:id><gtr:otherNames>Figueroa-Bonaparte S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d474290b6728.49906459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE68CC11-F1B4-456B-8FE1-D891A7E7C5DE</gtr:id><gtr:title>Familial childhood-onset progressive cerebellar syndrome associated with themutation.</gtr:title><gtr:parentPublicationTitle>Neurology. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/159c8c7cefbd596fac1d4f5555aa91ee"><gtr:id>159c8c7cefbd596fac1d4f5555aa91ee</gtr:id><gtr:otherNames>Jaffer F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2376-7839</gtr:issn><gtr:outcomeId>5a79d6257d7cf0.47814683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6097BC30-C58B-487E-9762-797DC637D5FB</gtr:id><gtr:title>A Unique Gene Regulatory Network Resets the Human Germline Epigenome for Development.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a30a61dfcdde776359e0abf990694f5"><gtr:id>2a30a61dfcdde776359e0abf990694f5</gtr:id><gtr:otherNames>Tang WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>56d470e89fd8b1.94356609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47D76E13-1A9E-450F-A758-2DC89AC730E0</gtr:id><gtr:title>Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/475d877ceec760cc4db02f32a29b38b3"><gtr:id>475d877ceec760cc4db02f32a29b38b3</gtr:id><gtr:otherNames>Osellame LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5458f4cea64860.71191269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A79D776A-0F2B-41EC-80AC-AA8375DDF92B</gtr:id><gtr:title>Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(&amp;copy;) ).</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12cffd5a1b1a9a5423d7304520481af6"><gtr:id>12cffd5a1b1a9a5423d7304520481af6</gtr:id><gtr:otherNames>Vanhoutte EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5697a906240074.90812062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA4F1484-C293-4DF7-979E-79BE7F00D364</gtr:id><gtr:title>210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27-29 March, 2015, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2742c7bce92a458ae386d5d1290110a"><gtr:id>c2742c7bce92a458ae386d5d1290110a</gtr:id><gtr:otherNames>Pennuto M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b4be111f4574.06881445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49DDED84-36C4-4D1A-A5E6-3411D437649F</gtr:id><gtr:title>Elusive sources of variability of dystrophin rescue by exon skipping.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ac96cd9e34d64362b76465e66d0b39f"><gtr:id>2ac96cd9e34d64362b76465e66d0b39f</gtr:id><gtr:otherNames>Vila MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn><gtr:outcomeId>56d47a29bce7b1.75694605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01B33341-0822-4969-B109-CD98ADC2CC23</gtr:id><gtr:title>Epilepsy in adults with mitochondrial disease: A cohort study.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56b4b3c6ebcc85.05732896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>355C21EB-D0D2-49C7-967B-C78EF6773721</gtr:id><gtr:title>Neuromuscular diseases: progress in gene discovery drives diagnostics and therapeutics.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56dd62fbe91129.46775044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>393C7739-A97B-47B2-A146-0CA6C6F4FFDC</gtr:id><gtr:title>Effects of Community Exercise Therapy on Metabolic, Brain, Physical, and Cognitive Function Following Stroke: A Randomized Controlled Pilot Trial.</gtr:title><gtr:parentPublicationTitle>Neurorehabilitation and neural repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e2426c44a837df45de1eaa2d36cdcb"><gtr:id>54e2426c44a837df45de1eaa2d36cdcb</gtr:id><gtr:otherNames>Moore SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1545-9683</gtr:issn><gtr:outcomeId>56c3507bb9ead1.69588413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12B57CBC-D503-4A2F-8143-438BDE96458C</gtr:id><gtr:title>Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4993366aa454f0f4e4b624bfd08b8e"><gtr:id>be4993366aa454f0f4e4b624bfd08b8e</gtr:id><gtr:otherNames>Wojtal D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56b214a51cb7e6.02849618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC25C02-AA35-4001-AC70-FE23C8C73692</gtr:id><gtr:title>Mitochondrial donation--how many women could benefit?</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56c3232fbf2e18.72583842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDD8EDB3-12AD-4513-BACC-5568DD319633</gtr:id><gtr:title>Investigating complex I deficiency in Purkinje cells and synapses in patients with mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ac9010b8fd67e4b517628ed4d73c5ab"><gtr:id>7ac9010b8fd67e4b517628ed4d73c5ab</gtr:id><gtr:otherNames>Chrysostomou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>57c01a111932a4.21292692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85B77744-F157-48B7-AD31-C12D6D686834</gtr:id><gtr:title>Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c19598be474cb49282eca984c7b19308"><gtr:id>c19598be474cb49282eca984c7b19308</gtr:id><gtr:otherNames>Daud D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56b4b3c854db36.95167571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CACF9F3-FDA3-4638-81E8-733B36FE51D7</gtr:id><gtr:title>A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f290ce49002164ad6a7d750e1563a856"><gtr:id>f290ce49002164ad6a7d750e1563a856</gtr:id><gtr:otherNames>Zhou H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>pm_12934_24_23339722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>878EA3BC-CF7A-419F-B5FA-427115E57B86</gtr:id><gtr:title>Becker and Duchenne muscular dystrophy: a two-way information process for therapies.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e066b01550c96ebd55c22ce477282b8"><gtr:id>3e066b01550c96ebd55c22ce477282b8</gtr:id><gtr:otherNames>Lochm?ller H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23695496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37ECD9F4-035C-41E6-92D1-AADD1471F90B</gtr:id><gtr:title>Auditory tracts identified with combined fMRI and diffusion tractography.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf2844b4f86468a34b4a76af45c7f9d4"><gtr:id>cf2844b4f86468a34b4a76af45c7f9d4</gtr:id><gtr:otherNames>Javad F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>pm_12934_24_24051357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6435945F-59FB-45D2-AF36-F697352A0EA6</gtr:id><gtr:title>Monitoring mitochondrial dynamics and complex I dysfunction in neurons: implications for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32fec412bacca7631826c0b2e5a78e7d"><gtr:id>32fec412bacca7631826c0b2e5a78e7d</gtr:id><gtr:otherNames>Simcox EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>5460caad8c1345.68130197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C6FA46-F64D-48AA-8267-55F6807877E9</gtr:id><gtr:title>Psycho-organic symptoms as early manifestation of adult onset POMT1-related limb girdle muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/516941d665eafcda950fa1dcd52bdfaf"><gtr:id>516941d665eafcda950fa1dcd52bdfaf</gtr:id><gtr:otherNames>Haberlova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5458b815105f84.11540197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C209F1D-49B2-47E5-A379-2573B39B9593</gtr:id><gtr:title>Tracks through the genome to physiological events.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e77a0f67ec5c73e987a7c8fa2e5cd8d"><gtr:id>8e77a0f67ec5c73e987a7c8fa2e5cd8d</gtr:id><gtr:otherNames>Lipscombe D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>56c455a4312042.43581174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4519BE6D-AB65-4029-8E88-2669654A11AC</gtr:id><gtr:title>Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af9e69a068edc2cb7e99e7652ac29072"><gtr:id>af9e69a068edc2cb7e99e7652ac29072</gtr:id><gtr:otherNames>Gess B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5697a90672e888.92292671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AB75444-0E64-46F7-AF79-AE8F0A6A2AF2</gtr:id><gtr:title>Initial development and validation of a mitochondrial disease quality of life scale.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19cd9eac194029b31fc778c6567229da"><gtr:id>19cd9eac194029b31fc778c6567229da</gtr:id><gtr:otherNames>Elson JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5458f56e3237d5.30723704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4085707-91F8-49A7-99BA-933F3E079A00</gtr:id><gtr:title>Mitochondrial DNA mutations in ageing and disease: implications for HIV?</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5458bda565d096.53964783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>005E4456-DEC7-4F80-9BF6-FA2D547D5729</gtr:id><gtr:title>Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bd786794a7beca0f215d6892dc90419"><gtr:id>3bd786794a7beca0f215d6892dc90419</gtr:id><gtr:otherNames>Thelwall PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_12934_24_23624251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA2EB47F-2CDE-44D1-882F-B5F7C3421257</gtr:id><gtr:title>Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>56b214a6237184.14591860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11F643CE-28E9-4190-9292-FD107371579C</gtr:id><gtr:title>Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1062071ceef968d1655c044e58e060e1"><gtr:id>1062071ceef968d1655c044e58e060e1</gtr:id><gtr:otherNames>Meilleur KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b214a8cc2e29.09934978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D2F0C8-6123-4B7D-9AFD-F7021F5B6E2E</gtr:id><gtr:title>Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37f48950ac754a3c97a85fecf4e1d7e4"><gtr:id>37f48950ac754a3c97a85fecf4e1d7e4</gtr:id><gtr:otherNames>Coenen-Stass AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d47b0ee2f823.19355348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE42250D-8F63-4534-AF25-8D2B3C8ED4F4</gtr:id><gtr:title>Update in inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Current opinion in rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ec459bbc79239f24d8fa0c4e80ceb2e"><gtr:id>4ec459bbc79239f24d8fa0c4e80ceb2e</gtr:id><gtr:otherNames>Machado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-8711</gtr:issn><gtr:outcomeId>pm_12934_24_24067381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7E41E32-19B6-4042-A2DD-7B6C6199C4B3</gtr:id><gtr:title>Uncertainty increases pain: evidence for a novel mechanism of pain modulation involving the periaqueductal gray.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae9b33a45388f93617b6055666cec5f6"><gtr:id>ae9b33a45388f93617b6055666cec5f6</gtr:id><gtr:otherNames>Yoshida W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_12934_24_23536078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22E82B8D-02CD-4D77-BB65-BE02ADB2E36F</gtr:id><gtr:title>Is overwork weakness relevant in Charcot-Marie-Tooth disease?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5523874169f71a476541373c881cf885"><gtr:id>5523874169f71a476541373c881cf885</gtr:id><gtr:otherNames>Piscosquito G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5460bfac1d3468.17879396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EADFC7CC-FB08-4E48-8446-F436EACEAC72</gtr:id><gtr:title>A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/311b04aa4c17b316103c9775174f68e9"><gtr:id>311b04aa4c17b316103c9775174f68e9</gtr:id><gtr:otherNames>Ricketts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458f6eba14138.17671515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>350D4491-E887-478F-8B1C-2931347D2EC0</gtr:id><gtr:title>Gait impairment precedes clinical symptoms in spinocerebellar ataxia type 6.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3bd44a7d00b8c6e3ccfc12e946d79fb"><gtr:id>b3bd44a7d00b8c6e3ccfc12e946d79fb</gtr:id><gtr:otherNames>Rochester L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5458c7e86a8810.43063842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8902949F-FA9B-4AB1-AF85-B072A210FBCB</gtr:id><gtr:title>MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a828975445f59e015c12e690bf2e4db"><gtr:id>2a828975445f59e015c12e690bf2e4db</gtr:id><gtr:otherNames>Baruffini E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12934_24_23929671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BEE53FA-A163-4EDE-9333-A0CE03E16794</gtr:id><gtr:title>Bar Coding and Tracking in Pathology.</gtr:title><gtr:parentPublicationTitle>Clinics in laboratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-2712</gtr:issn><gtr:outcomeId>56dd63013a92b4.84249738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5B81415-0BF3-4358-92B3-79D774F6D696</gtr:id><gtr:title>Magnetic Resonance Spectroscopy for Traumatic Brain Injury.</gtr:title><gtr:parentPublicationTitle>Topics in magnetic resonance imaging : TMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feede094cf46aec5a873800b8a3b1463"><gtr:id>feede094cf46aec5a873800b8a3b1463</gtr:id><gtr:otherNames>Croall I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0899-3459</gtr:issn><gtr:outcomeId>56c3507c9b8358.02536766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4B5385D-2D31-42B1-8666-E012341F5220</gtr:id><gtr:title>Targeted Molecular Therapies for SBMA.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2693983ce6ed9fdb8a9b72f88c5a93d"><gtr:id>c2693983ce6ed9fdb8a9b72f88c5a93d</gtr:id><gtr:otherNames>Rinaldi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn><gtr:outcomeId>56b4be11770d48.63536915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BB4525E-32DB-45F8-86C9-F26F5ED90C60</gtr:id><gtr:title>CIDP: mimics and chameleons.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f55ceadf977d2873038f3f132c83fda"><gtr:id>1f55ceadf977d2873038f3f132c83fda</gtr:id><gtr:otherNames>Neligan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>5460c2309e8ff9.08687290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90A0AC17-5947-42DB-9F87-95FB68D182B5</gtr:id><gtr:title>Brain iron takes off: a new propeller protein links neurodegeneration with autophagy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23674487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69D91F76-4246-46E3-A4B3-6B1998C8FA49</gtr:id><gtr:title>Dose calculation for electron therapy using an improved LBR method.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a68b16e92a9362ad62cbe9625d1fbbea"><gtr:id>a68b16e92a9362ad62cbe9625d1fbbea</gtr:id><gtr:otherNames>Gebreamlak WT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5458ca43c950b2.95883811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80E1689-6D0D-4B82-8968-D047C4EDC715</gtr:id><gtr:title>A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a11ab480408d1d18f144a13a091cbb75"><gtr:id>a11ab480408d1d18f144a13a091cbb75</gtr:id><gtr:otherNames>Habbout K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56dd6300351b47.70025020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ACE2934-4626-4583-B8A7-A3C1440E9466</gtr:id><gtr:title>Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: &amp;quot;translating&amp;quot; the translational.</gtr:title><gtr:parentPublicationTitle>PLoS currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4ddf96f03c4b1d183c1afa7fac13f33"><gtr:id>b4ddf96f03c4b1d183c1afa7fac13f33</gtr:id><gtr:otherNames>McCormack P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-3999</gtr:issn><gtr:outcomeId>pm_12934_24_23330068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A486CA71-5CF6-43EF-B4E2-A98D12820B5C</gtr:id><gtr:title>Structural modeling of tissue-specific mitochondrial alanyl-tRNA synthetase (AARS2) defects predicts differential effects on aminoacylation.</gtr:title><gtr:parentPublicationTitle>Frontiers in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3814fc62e9cde7d7219e4f2ee635c7da"><gtr:id>3814fc62e9cde7d7219e4f2ee635c7da</gtr:id><gtr:otherNames>Euro L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-8021</gtr:issn><gtr:outcomeId>56b4b3c97b21b3.68757163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92B7F976-76B8-43AE-B352-FF4A9F33A446</gtr:id><gtr:title>Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ba297a1edd6970078cb545704ad890"><gtr:id>79ba297a1edd6970078cb545704ad890</gtr:id><gtr:otherNames>Foley AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_540e151e15158fb3f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D8AAB19-1F1D-4901-B4C4-D200EAA47D45</gtr:id><gtr:title>Mitochondrial disorders: disease mechanisms and therapeutic approaches.</gtr:title><gtr:parentPublicationTitle>Discovery medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26500bfd7d1fca1c1e02bc26eba7c99a"><gtr:id>26500bfd7d1fca1c1e02bc26eba7c99a</gtr:id><gtr:otherNames>Poole OV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1539-6509</gtr:issn><gtr:outcomeId>56dd62ffde7581.55789543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E01F05D3-F432-4292-AC31-B92FD34C7A27</gtr:id><gtr:title>Mutations in APOPT1, encoding a mitochondrial protein, cause cavitating leukoencephalopathy with cytochrome c oxidase deficiency.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99d8c6ccf94c3c67c4711ae04e433e07"><gtr:id>99d8c6ccf94c3c67c4711ae04e433e07</gtr:id><gtr:otherNames>Melchionda L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5460c9c36b0df6.87855078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D35D4C9-70B3-4C65-971C-06158D380F42</gtr:id><gtr:title>Adult care for Duchenne muscular dystrophy in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82f3f1ff420153814bc3aa407bed051"><gtr:id>f82f3f1ff420153814bc3aa407bed051</gtr:id><gtr:otherNames>Rodger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d474272fa523.52021687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0DBF3AD-6FE2-44BE-BD12-B63276DC8BC0</gtr:id><gtr:title>Reply: 'Behr syndrome' with OPA1 compound heterozygote mutations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56d470ea2d0b59.86279946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54EFDFCD-5253-4538-9231-C045535492E6</gtr:id><gtr:title>A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10f1de102ebbd3fe3d4488973e4ef456"><gtr:id>10f1de102ebbd3fe3d4488973e4ef456</gtr:id><gtr:otherNames>L?seth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_23329375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97F72CAF-4280-4254-B8A5-6D79F8A7D936</gtr:id><gtr:title>PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/283f8a435ef41eee4e7e46052d6323b6"><gtr:id>283f8a435ef41eee4e7e46052d6323b6</gtr:id><gtr:otherNames>Nobbio L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c5615b52f2.28914695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F49CF43-8AC9-40A6-BBC8-BDBBB8A67F7F</gtr:id><gtr:title>Brain editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c070720875.82899316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD29311-C063-4FA1-8459-B2DDEDCEF14B</gtr:id><gtr:title>Charcot-Marie-Tooth disease type 2C and scapuloperoneal muscular atrophy overlap syndrome in a patient with the R232C TRPV4 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0141d4dc212d3dc1de00d97ceee75f7"><gtr:id>a0141d4dc212d3dc1de00d97ceee75f7</gtr:id><gtr:otherNames>Koutsis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5697a81a7a3288.14192622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40498C03-B46A-4427-9D76-468A26489F2F</gtr:id><gtr:title>Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56d470e86fba98.79247465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC20BEE2-8753-41CC-8D23-64789E469846</gtr:id><gtr:title>Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc1e6261a073e8c97bb04481b8202a"><gtr:id>a3bc1e6261a073e8c97bb04481b8202a</gtr:id><gtr:otherNames>Taylor RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>pm_540e151e1519d8057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55B44AC0-40DD-4C30-939D-9E50B0AE4EFD</gtr:id><gtr:title>Autoimmune synaptopathies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6837a62e3d7c04b652a506c6ef070db6"><gtr:id>6837a62e3d7c04b652a506c6ef070db6</gtr:id><gtr:otherNames>Crisp SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>56b2118ed44b42.41729275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7337C288-82BB-4690-89FC-CFB250277F35</gtr:id><gtr:title>Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>56b214a6c7b864.58114213</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C609966-7F27-471A-A887-AC03BF4419DD</gtr:id><gtr:title>Obstructive sleep apnoea, restless leg syndrome and Charcot-Marie-tooth disease type 1: important associations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4732af7ef6ff3beb803fd47a10bc7e3f"><gtr:id>4732af7ef6ff3beb803fd47a10bc7e3f</gtr:id><gtr:otherNames>Reilly MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23757421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09E55C7B-ADE2-4A65-8E35-CF0B4DAA3B05</gtr:id><gtr:title>Brain editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c071b2c545.68810163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49F6A07D-F2C7-45AE-BED5-7A88E8B5C89D</gtr:id><gtr:title>Mutations in the collagen XII gene define a new form of extracellular matrix-related myopathy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ccd588457e2b396fae242688b972e96"><gtr:id>6ccd588457e2b396fae242688b972e96</gtr:id><gtr:otherNames>Hicks D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5458b814dd2e20.35780984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C6E4A33-A749-421E-8744-0F9FAA7B24BC</gtr:id><gtr:title>Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e200f814262dac4d6b88ac30584c047"><gtr:id>8e200f814262dac4d6b88ac30584c047</gtr:id><gtr:otherNames>Rossor AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>doi_55f9849843e7b77c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16C219C1-CF52-44A4-A5D0-248EA142A8E3</gtr:id><gtr:title>Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in adult hematological malignancy patients and possible association with mitochondrial DNA defects.</gtr:title><gtr:parentPublicationTitle>Journal of hematology &amp; oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bc5bfb0f5b09052c1b7e2aedc539c37"><gtr:id>9bc5bfb0f5b09052c1b7e2aedc539c37</gtr:id><gtr:otherNames>Zamzami MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8722</gtr:issn><gtr:outcomeId>pm_12934_24_23547827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD49BBD7-406E-4DC9-A5BE-03B8821CD7A2</gtr:id><gtr:title>Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aa609930ea18f3e6e37944a61370401"><gtr:id>9aa609930ea18f3e6e37944a61370401</gtr:id><gtr:otherNames>Somers E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56b214a5b2bc93.80532243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6679B765-D116-425C-91F6-1846F808CE8E</gtr:id><gtr:title>Endoplasmic reticulum stress in spinal and bulbar muscular atrophy: a potential target for therapy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9de79d52ebe2e689974c6152448d4281"><gtr:id>9de79d52ebe2e689974c6152448d4281</gtr:id><gtr:otherNames>Montague K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458f6ec6ea556.82262484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AAFC4B9-3CBA-4001-B299-FE3CEF7939BC</gtr:id><gtr:title>Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of a-dystroglycan.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d1a833bc9dcd1dc1ac7f445c0c0796"><gtr:id>07d1a833bc9dcd1dc1ac7f445c0c0796</gtr:id><gtr:otherNames>Stevens E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_12934_24_23453667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12B0A564-277B-4338-9644-D6B74A7FF1C3</gtr:id><gtr:title>Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2* changes.</gtr:title><gtr:parentPublicationTitle>Radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/598061b1fda540f671f267c85097ea19"><gtr:id>598061b1fda540f671f267c85097ea19</gtr:id><gtr:otherNames>Loughran T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-8419</gtr:issn><gtr:outcomeId>56d47a2a5bc252.31774156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D50CDCE-DC2A-4366-93D7-83FC6CD90551</gtr:id><gtr:title>Recessive desmin-null muscular dystrophy with central nuclei and mitochondrial abnormalities.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce705734f3a6f6dee0492b16c25084b9"><gtr:id>ce705734f3a6f6dee0492b16c25084b9</gtr:id><gtr:otherNames>Henderson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_12934_24_23575897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F19C09EE-D799-48C7-8FCB-8F7DD8AD9600</gtr:id><gtr:title>Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0a82c1753617d519e42ca31d6631d0a"><gtr:id>d0a82c1753617d519e42ca31d6631d0a</gtr:id><gtr:otherNames>Dick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>pm_12934_24_23829870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DA22A5B-6DA3-42AD-926B-C7688AFFB271</gtr:id><gtr:title>Sengers syndrome: six novel AGK mutations in seven new families and review of the phenotypic and mutational spectrum of 29 patients.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c0ba259be64b4e48fef84d29a7f796a"><gtr:id>7c0ba259be64b4e48fef84d29a7f796a</gtr:id><gtr:otherNames>Haghighi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>5458bb0b633d12.90702660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21708D81-E203-4834-A64D-A66223A2DEEF</gtr:id><gtr:title>Short stature and pubertal delay in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ce43b3e217926531d4ee964ce527ece"><gtr:id>5ce43b3e217926531d4ee964ce527ece</gtr:id><gtr:otherNames>Wood CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>56d47426683998.07613147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E56A30B-C8F1-4597-9D4C-9F4170D4695E</gtr:id><gtr:title>Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3b1f101fc39803c11f89c7209db490"><gtr:id>8b3b1f101fc39803c11f89c7209db490</gtr:id><gtr:otherNames>Cortese A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23489664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>658759D2-052E-4C1E-ADCC-2A194A04795F</gtr:id><gtr:title>Phenotypic variability of TRPV4 related neuropathies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe8fc4c7a21a2eb5369f6c0eb70d891a"><gtr:id>fe8fc4c7a21a2eb5369f6c0eb70d891a</gtr:id><gtr:otherNames>Evangelista T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b4b3c8ea4350.93586276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F261F55-D9C9-4642-9867-1994B30A159D</gtr:id><gtr:title>Prevalence study of genetically defined skeletal muscle channelopathies in England.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70045987ef050d49a7a1c26b398ecd06"><gtr:id>70045987ef050d49a7a1c26b398ecd06</gtr:id><gtr:otherNames>Horga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>doi_55f98498440ba726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F511A4A9-D72F-4D3B-A225-D51A1825B80C</gtr:id><gtr:title>A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1161dceb49b9031cc5693146e0b920cb"><gtr:id>1161dceb49b9031cc5693146e0b920cb</gtr:id><gtr:otherNames>Lunn MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5697a906c44509.92964387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8619557C-7F0F-4348-A892-2E0F8F7ECF3C</gtr:id><gtr:title>The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51fb847e6a36c4c4664cccb152cf38ba"><gtr:id>51fb847e6a36c4c4664cccb152cf38ba</gtr:id><gtr:otherNames>Kalmar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>pm_12934_24_23978556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C36FB118-70EC-4C30-A6BC-358EE1A2E08D</gtr:id><gtr:title>Design, operation, and safety of single-room interventional MRI suites: practical experience from two centers.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba628a903290c55229e23b5aff5ffe84"><gtr:id>ba628a903290c55229e23b5aff5ffe84</gtr:id><gtr:otherNames>White MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>56c466781cd9a9.81779874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4BC6FF-49CC-4DDE-B082-7726B350140E</gtr:id><gtr:title>Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80583ad27ad24e91c0380658e597d61a"><gtr:id>80583ad27ad24e91c0380658e597d61a</gtr:id><gtr:otherNames>Gonzalez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23729695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76C0987B-E6DB-4E75-AFCF-65B3F7DFDBF0</gtr:id><gtr:title>Reversible infantile mitochondrial diseases.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d75d3b4b9bf032eb6ff10990933d59"><gtr:id>e5d75d3b4b9bf032eb6ff10990933d59</gtr:id><gtr:otherNames>Boczonadi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>56b4b3ca7363f1.82647449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92F8DFC6-B186-43E5-8A54-92BA71CCB6F2</gtr:id><gtr:title>Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12bd802931db2c434b281e1bc64f66fc"><gtr:id>12bd802931db2c434b281e1bc64f66fc</gtr:id><gtr:otherNames>McColgan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5697a76e8dfd17.84087803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>412F9120-D0EA-4DD6-A78B-3154C51F2D0F</gtr:id><gtr:title>Whole-genome sequencing and the clinician: a tale of two cities.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ba297a1edd6970078cb545704ad890"><gtr:id>79ba297a1edd6970078cb545704ad890</gtr:id><gtr:otherNames>Foley AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5458f9098f3817.43082565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B42B000D-65C9-43F9-92C0-22A2562D7300</gtr:id><gtr:title>Hypothermia protects brain mitochondrial function from hypoxemia in a murine model of sepsis.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce614c5704359d54b77cbacc043b17e6"><gtr:id>ce614c5704359d54b77cbacc043b17e6</gtr:id><gtr:otherNames>Chisholm KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>56c32873dd9f81.27777152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77E3F415-FDE4-4161-906A-0A53E390C153</gtr:id><gtr:title>Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b451cb75940c37070ddf29054e4e197"><gtr:id>9b451cb75940c37070ddf29054e4e197</gtr:id><gtr:otherNames>Willis TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_23967145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D06BDDC5-5FA2-471A-84D7-6D6547ABA64E</gtr:id><gtr:title>Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8318fec95991282f2e7ae5a6113e4fc"><gtr:id>a8318fec95991282f2e7ae5a6113e4fc</gtr:id><gtr:otherNames>Kotiadis VN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>5458f4ce7fd2d8.16820365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08407BFA-8B3D-4559-BF95-D8CF785525A2</gtr:id><gtr:title>Regulation of Axonal Transport by Protein Kinases.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4372a19b669f409036e3806c6bf72464"><gtr:id>4372a19b669f409036e3806c6bf72464</gtr:id><gtr:otherNames>Gibbs KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>56b4be11a954a9.64132950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C546C5F-95F0-4B64-824A-37AEB81338DE</gtr:id><gtr:title>Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb0ae33a9cfc00541ab35d881c96b0a0"><gtr:id>eb0ae33a9cfc00541ab35d881c96b0a0</gtr:id><gtr:otherNames>Snowball A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>56c455a45c0132.84736084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F73969F-D077-4D37-9A01-FE109184F73E</gtr:id><gtr:title>The investigation and management of metabolic myopathies.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e46fa9a9d2d3b6ad5fd9d6a99e638480"><gtr:id>e46fa9a9d2d3b6ad5fd9d6a99e638480</gtr:id><gtr:otherNames>Olpin SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>56c3208f721157.88688615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AB9DF86-E872-433C-BC1C-FD2ECD168AAB</gtr:id><gtr:title>Pain and small fiber function in Charcot-Marie-Tooth disease type 1A.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/864491faea7bd8b373d3e523061dadf8"><gtr:id>864491faea7bd8b373d3e523061dadf8</gtr:id><gtr:otherNames>Laur? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>5460bfac44f1c0.85677376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA324D16-408A-43B7-9BA2-CAE874A4FB14</gtr:id><gtr:title>An under-recognised cause of spastic paraparesis in middle-aged women.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c967a786847e7e5db1d802a30f49fbb9"><gtr:id>c967a786847e7e5db1d802a30f49fbb9</gtr:id><gtr:otherNames>Bargiela D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>5458c7e7951b82.87702516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EE26056-A8AD-4C6B-A3EC-1DDF16A5DBFE</gtr:id><gtr:title>COX10 mutations resulting in complex multisystem mitochondrial disease that remains stable into adulthood.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6459db0fb97de13ef30ce2614b06cb4a"><gtr:id>6459db0fb97de13ef30ce2614b06cb4a</gtr:id><gtr:otherNames>Pitceathly RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_12934_24_24100867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0357617-544B-4FB0-BDE2-E4F67A8DDE24</gtr:id><gtr:title>Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9780bba7eb8471c010631ac8d54e6a9"><gtr:id>b9780bba7eb8471c010631ac8d54e6a9</gtr:id><gtr:otherNames>Ayoglu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5458b907974f68.48216134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50ABEEF5-D2E7-4C6D-AC8F-516B10B67087</gtr:id><gtr:title>Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of a-dystroglycan.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61711e17c223459294a27a3946aed64a"><gtr:id>61711e17c223459294a27a3946aed64a</gtr:id><gtr:otherNames>Carss KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_12934_24_23768512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8895025F-AE74-43C7-952C-9447421CBBBF</gtr:id><gtr:title>Topiramate for neuropathic pain and fibromyalgia in adults.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a19302e27b2713e093ea812616e2e"><gtr:id>f67a19302e27b2713e093ea812616e2e</gtr:id><gtr:otherNames>Wiffen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460c2320b8ab0.12093778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F4AF698-9A7D-46C2-A5BF-AC44C6533306</gtr:id><gtr:title>Teaching video neuroimages: muscle cramps and a raised creatine kinase.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5458bda51151c3.77043335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5317516-A6E5-4F03-94DD-0B722FA771A6</gtr:id><gtr:title>Andrew Moore and colleagues reply to Des Spence.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e77f248010c1b434120ad44ce4ec6fd"><gtr:id>6e77f248010c1b434120ad44ce4ec6fd</gtr:id><gtr:otherNames>Moore A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5460c2312b04a6.43680611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDEF0F1B-0D5B-4A91-BAA0-57BB2F862122</gtr:id><gtr:title>Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_12934_24_23945935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>844FCB2A-86B8-4217-9183-411AE7DEBB45</gtr:id><gtr:title>Central nervous system involvement by Waldenstr&amp;ouml;m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3552231620d0eb5642c7bb7e928a11"><gtr:id>4f3552231620d0eb5642c7bb7e928a11</gtr:id><gtr:otherNames>Castillo JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56b8814ed53ed6.71866311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B55311A-CCFA-4A48-AA42-B0FB3876EC6E</gtr:id><gtr:title>Human Auditory Cortex Neurochemistry Reflects the Presence and Severity of Tinnitus.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/749525e103beba2ff85210184829b181"><gtr:id>749525e103beba2ff85210184829b181</gtr:id><gtr:otherNames>Sedley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56c3507d24f043.54621702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CCE3904-30A8-49D9-825C-85F8CC946DDC</gtr:id><gtr:title>Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3b1f101fc39803c11f89c7209db490"><gtr:id>8b3b1f101fc39803c11f89c7209db490</gtr:id><gtr:otherNames>Cortese A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5458f6ebca8af6.63953535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7768DCD-A198-4B01-A76A-24A01E38B784</gtr:id><gtr:title>Diagnosis of muscle diseases presenting with early respiratory failure.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d470ead13e15.31738142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A57AD38-A37D-4DE5-AA09-B6AE91613DE3</gtr:id><gtr:title>Predominantly myalgic phenotype caused by the c.3466G&amp;gt;A p.A1156T mutation ingene.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f4a87b832cb2cc32c28e245fbfc130"><gtr:id>02f4a87b832cb2cc32c28e245fbfc130</gtr:id><gtr:otherNames>Palmio J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a79d625e061b8.58128435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93CD618E-9E8F-4D67-871F-EFF5359D3BA0</gtr:id><gtr:title>In vivo imaging of axonal transport in murine motor and sensory neurons.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4372a19b669f409036e3806c6bf72464"><gtr:id>4372a19b669f409036e3806c6bf72464</gtr:id><gtr:otherNames>Gibbs KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>56b4be12172a29.61117032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05DDF453-9674-41B7-8D47-E95EA09ACF18</gtr:id><gtr:title>Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/230c6ae6cfa4b1a456b4b475e336d4da"><gtr:id>230c6ae6cfa4b1a456b4b475e336d4da</gtr:id><gtr:otherNames>Carr AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5675e1788c0c1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19CAA539-B650-4E50-B7E3-021AB02EB18A</gtr:id><gtr:title>Spectrum of Movement Disorders in Mitochondrial Disorders-Reply.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd55d049dbcc0d328614887ca48f1222"><gtr:id>fd55d049dbcc0d328614887ca48f1222</gtr:id><gtr:otherNames>Martikainen MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>58a71103b53443.34248141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>637197AB-B0E3-4CBD-BB53-775B02B804E7</gtr:id><gtr:title>The Spectrum of Mitochondrial Ultrastructural Defects in Mitochondrial Myopathy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8396e53d2ca82d367005fb41ecc9ac1b"><gtr:id>8396e53d2ca82d367005fb41ecc9ac1b</gtr:id><gtr:otherNames>Vincent AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d6ede37ac01.10383810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C559E9A-F153-4B9D-98E7-9C7009AF8132</gtr:id><gtr:title>Childhood presentation of &amp;quot;adult&amp;quot; polyglucosan body disease: normal GBE1 sequence with no glycogen branching enzyme activity.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cee64f0b98414289e07cdc3fdae9b5c1"><gtr:id>cee64f0b98414289e07cdc3fdae9b5c1</gtr:id><gtr:otherNames>Bathgate D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_12934_24_23526558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A343AFB-5F88-4331-BED8-A1ADF48BC440</gtr:id><gtr:title>Brain. Editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c0709b4926.47104924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>323ACFB9-4FEB-4A76-8750-8588A1DCD12A</gtr:id><gtr:title>The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A&amp;gt;G mutation--implications for diagnosis and management.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f5a64e763cce75d1f562606ee76e5bc"><gtr:id>7f5a64e763cce75d1f562606ee76e5bc</gtr:id><gtr:otherNames>Nesbitt V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12887_27_23355809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45589ECE-0AC1-415E-96DC-746BD116D48B</gtr:id><gtr:title>A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_12934_24_23588557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20D20179-EF91-4C3A-96F0-103138C65EFB</gtr:id><gtr:title>Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc50ac584b098635298c4f9b4186740"><gtr:id>fbc50ac584b098635298c4f9b4186740</gtr:id><gtr:otherNames>Draak TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b888324f67e1.52017480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08991681-4232-45BE-8160-3BD6B31C0D9B</gtr:id><gtr:title>Noncanonical G? Gib2 is a scaffolding protein promoting cAMP signaling through functions of Ras1 and Cac1 proteins in Cryptococcus neoformans.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52542eaf317f347220ec706e5b20b4a1"><gtr:id>52542eaf317f347220ec706e5b20b4a1</gtr:id><gtr:otherNames>Wang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5460c5618086b8.38512548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D11E72C-4EAD-4B86-86AB-9B7C72AED4D2</gtr:id><gtr:title>[Myasthenia gravis].</gtr:title><gtr:parentPublicationTitle>Praxis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1661-8157</gtr:issn><gtr:outcomeId>5460c0725aa0d2.83747316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8E87BE0-B3D7-4980-AEF4-D4445620B58B</gtr:id><gtr:title>A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/230c6ae6cfa4b1a456b4b475e336d4da"><gtr:id>230c6ae6cfa4b1a456b4b475e336d4da</gtr:id><gtr:otherNames>Carr AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5697a8ae5d9234.14740784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A2A6897-0FE9-4934-A6CF-B9CAF0B106E7</gtr:id><gtr:title>Using a quantitative quadruple immunofluorescent assay to diagnose isolated mitochondrial Complex I deficiency.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b9f7ca8bb4df7133446d19983c8f910"><gtr:id>8b9f7ca8bb4df7133446d19983c8f910</gtr:id><gtr:otherNames>Ahmed ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa6a97f678e25.41572169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8408DD40-2870-499C-AE7F-7209165CD719</gtr:id><gtr:title>Recent Advances in Mitochondrial Disease.</gtr:title><gtr:parentPublicationTitle>Annual review of genomics and human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f541a42cba1539f06b619564772e9d9d"><gtr:id>f541a42cba1539f06b619564772e9d9d</gtr:id><gtr:otherNames>Craven L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1527-8204</gtr:issn><gtr:outcomeId>5a5f55794bf251.53039002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD5BA33F-C2FF-4B66-BE44-3E9BA4521EB0</gtr:id><gtr:title>Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1707385a316c35c6294898aff4bc0ae7"><gtr:id>1707385a316c35c6294898aff4bc0ae7</gtr:id><gtr:otherNames>Oates EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_12934_24_23664120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A41F119D-18C0-46E1-8816-3B595CE21779</gtr:id><gtr:title>Whippits, nitrous oxide and the dangers of legal highs.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a31927906cffc4c4cbf31a0c8fd63195"><gtr:id>a31927906cffc4c4cbf31a0c8fd63195</gtr:id><gtr:otherNames>Thompson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56b88833dd9431.02726412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FABE6E00-0050-47E0-80B5-41CEC881874D</gtr:id><gtr:title>Mitochondrial replacement to prevent the transmission of mitochondrial DNA disease.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a341f0d561136c211aae3d422891fb72"><gtr:id>a341f0d561136c211aae3d422891fb72</gtr:id><gtr:otherNames>Herbert M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>56d9b513e2b263.46886554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB901A85-7971-4E6F-9C4D-1156CF084EBF</gtr:id><gtr:title>Conserved and divergent functions of Nfix in skeletal muscle development during vertebrate evolution.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0312ea85ad21c80c3fdad369792b707"><gtr:id>b0312ea85ad21c80c3fdad369792b707</gtr:id><gtr:otherNames>Pistocchi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>pm_12934_24_23482488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF1B6574-D5BD-4061-ACF8-8DE3BD370ED9</gtr:id><gtr:title>Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8f3bb060500a5be403ba0bef3f0811"><gtr:id>9d8f3bb060500a5be403ba0bef3f0811</gtr:id><gtr:otherNames>Ricotti V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23250964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B84F018C-CA04-4418-8A04-8310E7A2387D</gtr:id><gtr:title>Acute exercise remodels mitochondrial membrane interactions in mouse skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Journal of applied physiology (Bethesda, Md. : 1985)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fbb8678528f8cb634deb50d424fecf2"><gtr:id>0fbb8678528f8cb634deb50d424fecf2</gtr:id><gtr:otherNames>Picard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-7567</gtr:issn><gtr:outcomeId>5460caadb0dac8.49521944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA1811D-D56C-45A9-9607-707A6E3CDCE9</gtr:id><gtr:title>Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69719be8c0d997003b15d9b90bc3e6af"><gtr:id>69719be8c0d997003b15d9b90bc3e6af</gtr:id><gtr:otherNames>Logan CV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5460c3ac136fd2.39810193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB1DAF17-0535-42CF-8527-C8DA69FA49E5</gtr:id><gtr:title>188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19b46fb80d2ee74bce746b8e97daa7cf"><gtr:id>19b46fb80d2ee74bce746b8e97daa7cf</gtr:id><gtr:otherNames>Rose MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5458f9093ee178.82984461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8936CA0-C6C7-40AF-9E0F-9A367057F82C</gtr:id><gtr:title>Satellite cells from dystrophic muscle retain regenerative capacity.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89783a5fcb17bacf0fca3ef2fd51289d"><gtr:id>89783a5fcb17bacf0fca3ef2fd51289d</gtr:id><gtr:otherNames>Boldrin L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn><gtr:outcomeId>56b21391e9bd81.10538104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D14665D-751B-4629-8375-EF47220D9DD8</gtr:id><gtr:title>Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ad7ea7b684841e28553167b1157847"><gtr:id>00ad7ea7b684841e28553167b1157847</gtr:id><gtr:otherNames>Voit T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56d47a2b315712.19920574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0473A4F-D86E-44CF-8377-B3C4C773A1DE</gtr:id><gtr:title>Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb8609980b875605d79eaad613f6e13b"><gtr:id>eb8609980b875605d79eaad613f6e13b</gtr:id><gtr:otherNames>St?dberg T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56b2118f3d7088.83674708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28543EE7-2E86-465E-AC04-B0319DDEAF90</gtr:id><gtr:title>Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48214cd8e3234e8568330fdf7a825156"><gtr:id>48214cd8e3234e8568330fdf7a825156</gtr:id><gtr:otherNames>Nicole S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c0c091c4a8.70080359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5098A4F-135A-432D-9043-1E7A29FBBC3B</gtr:id><gtr:title>Clinical and biochemical features associated with BCS1L mutation.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8ca3e688983090ffc5440bb13e4320a"><gtr:id>a8ca3e688983090ffc5440bb13e4320a</gtr:id><gtr:otherNames>Al-Owain M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>pm_12934_24_22991165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80E99EDD-C779-430B-9573-6758EF89CB63</gtr:id><gtr:title>Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31f2ae3b1db951873a152282b9dd26a0"><gtr:id>31f2ae3b1db951873a152282b9dd26a0</gtr:id><gtr:otherNames>Ehinger JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>585d676c2e5364.34364290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40CC2370-F017-4621-99E0-8BAFB7DF982E</gtr:id><gtr:title>Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barr&amp;eacute; syndrome.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a7817537752ee621babf650787e135c"><gtr:id>5a7817537752ee621babf650787e135c</gtr:id><gtr:otherNames>Dujmovic I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23716297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32F8C7BD-A9FE-4797-BA17-52350B9F2CD6</gtr:id><gtr:title>NMDA receptor-dependent function and plasticity in inhibitory circuits.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78bffed74334db2c73b56a94ca9f400"><gtr:id>a78bffed74334db2c73b56a94ca9f400</gtr:id><gtr:otherNames>Moreau AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5460c0728c0234.15281219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26D2B8EC-A4BE-41C0-9805-2680BA8FA474</gtr:id><gtr:title>Genetic neurological channelopathies: molecular genetics and clinical phenotypes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56b2118fc6b7f9.51942341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39433FC2-F7FB-4955-B75D-75B27A40321A</gtr:id><gtr:title>Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7048e1621ef557498f13646f8b99fb"><gtr:id>5e7048e1621ef557498f13646f8b99fb</gtr:id><gtr:otherNames>Anthony K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5458b907c36678.67407544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68EAAD8B-3992-46BB-BBE0-84594DF17287</gtr:id><gtr:title>Neuroferritinopathy.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>5458ca43a01e42.56516957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99B5FDA5-D844-421D-8ED1-9CB401E518B0</gtr:id><gtr:title>Absence of HINT1 mutations in a UK and Spanish cohort of patients with inherited neuropathies.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70045987ef050d49a7a1c26b398ecd06"><gtr:id>70045987ef050d49a7a1c26b398ecd06</gtr:id><gtr:otherNames>Horga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5697a8aeb51739.96584539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BFA2B49-09B2-4EA8-BB6B-7927359395D5</gtr:id><gtr:title>Levetiracetam for neuropathic pain in adults.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a19302e27b2713e093ea812616e2e"><gtr:id>f67a19302e27b2713e093ea812616e2e</gtr:id><gtr:otherNames>Wiffen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460c230c63519.11493623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC5229E-1D99-494C-997D-B77129D2848F</gtr:id><gtr:title>Zonisamide for neuropathic pain in adults.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48df2869b0ba296c7ba8136a5487142b"><gtr:id>48df2869b0ba296c7ba8136a5487142b</gtr:id><gtr:otherNames>Moore RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56b888347c73a3.79534850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBFDA28F-36FF-47D7-9818-38ACA3AB86E9</gtr:id><gtr:title>Role of international registries in enhancing the care of familial hypercholesterolaemia.</gtr:title><gtr:parentPublicationTitle>International journal of evidence-based healthcare</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c63ae96c6b59effa3daac10cc9dd8432"><gtr:id>c63ae96c6b59effa3daac10cc9dd8432</gtr:id><gtr:otherNames>Hammond E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-1595</gtr:issn><gtr:outcomeId>pm_12934_24_23750577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>934FE864-4DA3-4122-B006-630533501317</gtr:id><gtr:title>Exome sequencing: how to understand it.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_12934_24_23727621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB1BEE2-72E0-4F8C-B893-A073B9FA8BB4</gtr:id><gtr:title>The challenges of mitochondrial replacement.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1f4b7c0cf2741f213eff19fe22e37f"><gtr:id>fe1f4b7c0cf2741f213eff19fe22e37f</gtr:id><gtr:otherNames>Chinnery PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5460caac951e60.07870725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3403A85-0323-46DF-A495-032CFB46EA2C</gtr:id><gtr:title>Antisense suppression of donor splice site mutations in the dystrophin gene transcript.</gtr:title><gtr:parentPublicationTitle>Molecular genetics &amp; genomic medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e3c462025b3da12bb065e31c4fdf42b"><gtr:id>2e3c462025b3da12bb065e31c4fdf42b</gtr:id><gtr:otherNames>Fletcher S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2324-9269</gtr:issn><gtr:outcomeId>5460c4b85e5c31.05761264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C431727-C436-40C4-B296-D55B5502B77A</gtr:id><gtr:title>Pathological ribonuclease H1 causes R-loop depletion and aberrant DNA segregation in mitochondria.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0868462ff4eec27e8eea7f7c7c64375"><gtr:id>d0868462ff4eec27e8eea7f7c7c64375</gtr:id><gtr:otherNames>Akman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58a4551b949302.28396865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3674735-F3A0-49F2-BC73-54B3C39326E9</gtr:id><gtr:title>Is SOD1 loss of function involved in amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fd54e97f8d443160f933229c72f332"><gtr:id>03fd54e97f8d443160f933229c72f332</gtr:id><gtr:otherNames>Saccon RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23687121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E30FBE03-197B-461D-88B8-23CE36724774</gtr:id><gtr:title>Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9df8eb0453fc78bce3a4de6720ba8b95"><gtr:id>9df8eb0453fc78bce3a4de6720ba8b95</gtr:id><gtr:otherNames>Connolly AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23726376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08128F61-DAD9-4F5F-BE61-31B7FE988814</gtr:id><gtr:title>The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9abffe3d877c62e1432ee4a5b5d518a8"><gtr:id>9abffe3d877c62e1432ee4a5b5d518a8</gtr:id><gtr:otherNames>Bladen CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12934_24_23913485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>351FF7CF-0D85-4C34-A1F7-AB8994A43BF7</gtr:id><gtr:title>Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1da14bd9205b42d9acd66b016926055c"><gtr:id>1da14bd9205b42d9acd66b016926055c</gtr:id><gtr:otherNames>Sanmaneechai O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5697a8af4625d3.70393708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95195FE8-0F78-4B57-82DD-CBAAFAF93DA2</gtr:id><gtr:title>Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ffcbe5f6fef07cf1358edb003fbe6d5"><gtr:id>9ffcbe5f6fef07cf1358edb003fbe6d5</gtr:id><gtr:otherNames>Vissing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_12934_24_23649721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AACF47F-ECDE-4BBD-A549-F3017971F04C</gtr:id><gtr:title>Heterogeneous abnormalities of in-vivo left ventricular calcium influx and function in mouse models of muscular dystrophy cardiomyopathy.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c653fe8e5141d529e858b620bc408d6"><gtr:id>7c653fe8e5141d529e858b620bc408d6</gtr:id><gtr:otherNames>Greally E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>pm_12934_24_23324314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E824D22D-AFC3-48A9-9308-24D5D6E0B187</gtr:id><gtr:title>Potential compounds for the treatment of mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9bac13cb88cd36c6b6b986ea2e87e04"><gtr:id>b9bac13cb88cd36c6b6b986ea2e87e04</gtr:id><gtr:otherNames>Rai PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>56dee344481951.16627960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B55226EC-3722-48EC-88DA-9B39B162E053</gtr:id><gtr:title>Short peptides from leucyl-tRNA synthetase rescue disease-causing mitochondrial tRNA point mutations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e45ccf4556ac9f2fa83f02f213325f"><gtr:id>51e45ccf4556ac9f2fa83f02f213325f</gtr:id><gtr:otherNames>Perli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56c31f13878717.86419626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12F5B09C-B53B-4CA8-9031-86517117160F</gtr:id><gtr:title>SURF1 deficiency: a multi-centre natural history study.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc83a0dc6efeaca84e86c78b2269d90b"><gtr:id>cc83a0dc6efeaca84e86c78b2269d90b</gtr:id><gtr:otherNames>Wedatilake Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>pm_12934_24_23829769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CD38DDA-C3B4-4BD8-91FD-26BDF4FD575B</gtr:id><gtr:title>DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d7dab9bcd362c812ec7147699561da"><gtr:id>d7d7dab9bcd362c812ec7147699561da</gtr:id><gtr:otherNames>Klein A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23831158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6155CA7-0C32-41E1-A67D-7184016EC83D</gtr:id><gtr:title>Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5b43bd351ce6b17356143743a29b7ba"><gtr:id>b5b43bd351ce6b17356143743a29b7ba</gtr:id><gtr:otherNames>Al-Shammri SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56dd62fd875b61.04533828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>485646D6-0E4C-4C32-A5A8-B13D3DECA967</gtr:id><gtr:title>Visual and psychological morbidity among patients with autosomal dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9722f6428465edb963f5cd639e62f91"><gtr:id>a9722f6428465edb963f5cd639e62f91</gtr:id><gtr:otherNames>Bailie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>pm_12934_24_23452392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C6AB13A-A9D5-4673-80B5-F9C14C446F3B</gtr:id><gtr:title>S151A d-sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d92d9abb4abee50be4f3932ea976ed5d"><gtr:id>d92d9abb4abee50be4f3932ea976ed5d</gtr:id><gtr:otherNames>Rutschow D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>pm_12934_24_23695275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F129AD8-1F43-4FB0-815D-D75DA660B531</gtr:id><gtr:title>Presymptomatic late-onset Pompe disease identified by the dried blood spot test.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7da98262dc441017a1f9a494bb37181"><gtr:id>b7da98262dc441017a1f9a494bb37181</gtr:id><gtr:otherNames>Wagner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23062590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9E7C339-897F-4F3E-A681-84F0E2C9CA94</gtr:id><gtr:title>Muscle proteomics reveals novel insights into the pathophysiological mechanisms of collagen VI myopathies.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14dfb34329a35dbd66b9f7773b403088"><gtr:id>14dfb34329a35dbd66b9f7773b403088</gtr:id><gtr:otherNames>De Palma S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>56d47b0fedd9e0.93643121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD882A58-06E3-4B8F-9BA3-15209E642A61</gtr:id><gtr:title>A pilot study of proximal strength training in Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe8d4bae65c43048e8e437ae0e4fa742"><gtr:id>fe8d4bae65c43048e8e437ae0e4fa742</gtr:id><gtr:otherNames>Ramdharry GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5697a76eb981f4.51952988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F9908D9-6135-449D-A9A3-CEB0D78ADAB0</gtr:id><gtr:title>Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56187dafab4a96aafb1b4e805363d742"><gtr:id>56187dafab4a96aafb1b4e805363d742</gtr:id><gtr:otherNames>Davidson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>56c3287443ec00.89507240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C5E72DC-36B0-4E66-8CA9-4B91D0ECAD02</gtr:id><gtr:title>Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14bd64c16502c520af788739a29cb702"><gtr:id>14bd64c16502c520af788739a29cb702</gtr:id><gtr:otherNames>Lilleker JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a79d6262cdfe0.11126720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D47DC598-3C44-4434-90B7-DBE2BE5299E8</gtr:id><gtr:title>Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fedc4404d626048147a389c1d14ecc32"><gtr:id>fedc4404d626048147a389c1d14ecc32</gtr:id><gtr:otherNames>Bartolome F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_12934_24_23498975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5861F758-AE0A-4F7E-9433-A8FFC0DF7445</gtr:id><gtr:title>Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency.</gtr:title><gtr:parentPublicationTitle>Frontiers in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66d1d9890980f237375baaac3dddc955"><gtr:id>66d1d9890980f237375baaac3dddc955</gtr:id><gtr:otherNames>Ahting U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-8021</gtr:issn><gtr:outcomeId>56c3232e7f4696.55596644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD7E1A0C-F95C-4479-B198-0D76311EFD13</gtr:id><gtr:title>Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/244eef3f0d30408d3aab306f16591521"><gtr:id>244eef3f0d30408d3aab306f16591521</gtr:id><gtr:otherNames>Greggains GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5460caad193689.89870931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0933AD49-A955-44E7-BE7D-4331BA35457D</gtr:id><gtr:title>A novel de novo STXBP1 mutation is associated with mitochondrial complex I deficiency and late-onset juvenile-onset parkinsonism.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>56b4b3c9a89908.43625912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A48027-00A9-4D3F-B129-D5CCEF9E0C89</gtr:id><gtr:title>Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a19302e27b2713e093ea812616e2e"><gtr:id>f67a19302e27b2713e093ea812616e2e</gtr:id><gtr:otherNames>Wiffen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460c231d2b4a1.12738299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD76F218-2DB1-45EC-AE2C-F83ED89A14AD</gtr:id><gtr:title>CGI-58, a key regulator of lipid homeostasis and signaling in plants, also regulates polyamine metabolism.</gtr:title><gtr:parentPublicationTitle>Plant signaling &amp; behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14f9881864726f56fec2e8ffb69e78b1"><gtr:id>14f9881864726f56fec2e8ffb69e78b1</gtr:id><gtr:otherNames>Park S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1559-2316</gtr:issn><gtr:outcomeId>5458b81455f6c4.92281844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E379E1EF-786F-4BEB-8D6B-5353334C0AE4</gtr:id><gtr:title>Gene therapy in status epilepticus.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f13d4d30c5a901bebc5dc995df7dfd5b"><gtr:id>f13d4d30c5a901bebc5dc995df7dfd5b</gtr:id><gtr:otherNames>Walker MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5460c07230d1f2.67737482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B78A134C-14DD-4E70-8BDF-42C06A5B43AE</gtr:id><gtr:title>Mitochondrial DNA deletions and depletion within paraspinal muscles.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72b7092e8b6da59c8d5f3b11ed7d2a72"><gtr:id>72b7092e8b6da59c8d5f3b11ed7d2a72</gtr:id><gtr:otherNames>Campbell GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>pm_12934_24_22762368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD7521EF-1E74-4930-A68C-B35E2DF08207</gtr:id><gtr:title>A Clinical, Neuropathological and Genetic Study of Homozygous A467T POLG-Related Mitochondrial Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56dd6300c01ca9.94490384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78C90C9A-179B-4ACD-AACE-2EC99336DF38</gtr:id><gtr:title>No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72b7092e8b6da59c8d5f3b11ed7d2a72"><gtr:id>72b7092e8b6da59c8d5f3b11ed7d2a72</gtr:id><gtr:otherNames>Campbell GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>5460caad428595.33658734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>442BC9FB-3A49-4E1E-829A-430B6070F002</gtr:id><gtr:title>Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70045987ef050d49a7a1c26b398ecd06"><gtr:id>70045987ef050d49a7a1c26b398ecd06</gtr:id><gtr:otherNames>Horga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>doi_55f9849843d57423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7710E25-D58B-4AFA-BCE4-83B96AB952A4</gtr:id><gtr:title>Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75880868018d92d0b7d54e2c82d1b2bc"><gtr:id>75880868018d92d0b7d54e2c82d1b2bc</gtr:id><gtr:otherNames>Liu YT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_540e151e1514bd255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F9769DF-AA91-4108-ABA3-6A1D91133DC4</gtr:id><gtr:title>Natural history of pulmonary function in collagen VI-related myopathies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ba297a1edd6970078cb545704ad890"><gtr:id>79ba297a1edd6970078cb545704ad890</gtr:id><gtr:otherNames>Foley AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c914aa2385.64295104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2BF44DC-AF0D-4169-9DFC-5AE00D4118D6</gtr:id><gtr:title>Progressive cortical thinning and subcortical atrophy in dementia with Lewy bodies and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b296d4baeb1674602f1bfcb122dc45"><gtr:id>90b296d4baeb1674602f1bfcb122dc45</gtr:id><gtr:otherNames>Mak E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56c3507b930461.81645150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99296722-29D1-4DBB-B6C5-0C5F4AE0EE02</gtr:id><gtr:title>Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21cab1a100cc994e6c9417780528fdde"><gtr:id>21cab1a100cc994e6c9417780528fdde</gtr:id><gtr:otherNames>Ju YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5458bb0add1be9.47766079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>185ACD34-A6C3-40CA-B809-84268832BB9D</gtr:id><gtr:title>Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.</gtr:title><gtr:parentPublicationTitle>PharmaNutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d96adebe1344dd915605897e05fa0dde"><gtr:id>d96adebe1344dd915605897e05fa0dde</gtr:id><gtr:otherNames>Visioli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-4344</gtr:issn><gtr:outcomeId>pm_12934_24_23525455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85E0E18E-6412-4B7D-87DB-1BE5D05BA9B3</gtr:id><gtr:title>Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e84e3707839d90302345838b73f672b7"><gtr:id>e84e3707839d90302345838b73f672b7</gtr:id><gtr:otherNames>Meng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5460c0c0bd14d5.63829073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E33C4D2D-E329-4916-A194-EAC91C4C1FCE</gtr:id><gtr:title>The ARSACS phenotype can include supranuclear gaze palsy and skin lipofuscin deposits.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc3f233f373ed02719f6b6d5e5fa937"><gtr:id>abc3f233f373ed02719f6b6d5e5fa937</gtr:id><gtr:otherNames>Stevens JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23123642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D13EBCD9-CECC-4620-B65E-E4D3B8D357C6</gtr:id><gtr:title>Marketing 'less harmful, low-tar' cigarettes is a key strategy of the industry to counter tobacco control in China.</gtr:title><gtr:parentPublicationTitle>Tobacco control</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ff7b7f7e3fc7d6ec885be1b24ed4c2b"><gtr:id>6ff7b7f7e3fc7d6ec885be1b24ed4c2b</gtr:id><gtr:otherNames>Yang G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-4563</gtr:issn><gtr:outcomeId>pm_12934_24_23349230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>567A66E1-1DFA-4B05-B8C2-75D5454853D8</gtr:id><gtr:title>RyR1 deficiency in congenital myopathies disrupts excitation-contraction coupling.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f290ce49002164ad6a7d750e1563a856"><gtr:id>f290ce49002164ad6a7d750e1563a856</gtr:id><gtr:otherNames>Zhou H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12934_24_23553787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BEB8F75-547D-4ABD-84AE-2B655E45CFD9</gtr:id><gtr:title>Reply: Evaluation of exome sequencing variation in undiagnosed ataxias.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b4b3c884c307.46538258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11AB22D7-CA21-4EDD-8333-ACF58E7B796C</gtr:id><gtr:title>Oscillatory multiplexing of population codes for selective communication in the mammalian brain.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/484faf6aa308846b45079c332380ce6e"><gtr:id>484faf6aa308846b45079c332380ce6e</gtr:id><gtr:otherNames>Akam T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>5460c071d93783.18467249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5628D3C-9AC9-4983-8733-B84400C21D67</gtr:id><gtr:title>Regulatory evaluation of Glybera in Europe - two committees, one mission.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5566928d859554068da4bb7335b56ca5"><gtr:id>5566928d859554068da4bb7335b56ca5</gtr:id><gtr:otherNames>Melchiorri D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_12934_24_23954897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4AF7AF5-48E4-4E5F-8CA0-4EDDC0897E05</gtr:id><gtr:title>Mitochondrial disease: mimics and chameleons.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd55d049dbcc0d328614887ca48f1222"><gtr:id>fd55d049dbcc0d328614887ca48f1222</gtr:id><gtr:otherNames>Martikainen MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56d470e8dfdc27.41786757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0908D1B6-CFA9-4A4D-B339-AD784ACF7D61</gtr:id><gtr:title>Recent advances in the management of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6d89f8465caf79455b6bdd863505384"><gtr:id>c6d89f8465caf79455b6bdd863505384</gtr:id><gtr:otherNames>Strehle EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>56d47a29f13253.20321775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8513A16E-A96E-4A0F-B204-A8849D0BA571</gtr:id><gtr:title>Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd26b1e138b12e934f0f4bc35f2a04be"><gtr:id>cd26b1e138b12e934f0f4bc35f2a04be</gtr:id><gtr:otherNames>Nombela C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458bb0bdbc9c1.92459681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEC211E9-0E29-486D-8054-12BBFE96160A</gtr:id><gtr:title>Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c07a2cd5141499e3dde9061d97e21333"><gtr:id>c07a2cd5141499e3dde9061d97e21333</gtr:id><gtr:otherNames>Zandi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5460c0701ed1f3.81217623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A75CD1B5-97F5-4B94-807C-80432FDC7386</gtr:id><gtr:title>Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations.</gtr:title><gtr:parentPublicationTitle>Blood transfusion = Trasfusione del sangue</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f27a24835e44a8de8dd053d4aca2bf"><gtr:id>d6f27a24835e44a8de8dd053d4aca2bf</gtr:id><gtr:otherNames>Taruscio D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1723-2007</gtr:issn><gtr:outcomeId>5458b8143070c4.38927831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CB3E69C-BEB7-415E-81BA-56F8F611A06B</gtr:id><gtr:title>Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d3a74312ac86d45efc47ac78a3c98c"><gtr:id>35d3a74312ac86d45efc47ac78a3c98c</gtr:id><gtr:otherNames>Haack TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>56c3208f3b4663.97830337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>821D8845-B207-40F0-9F0B-6BE2F3DD4AB4</gtr:id><gtr:title>EUROPLAN: a project to support the development of national plans on rare diseases in Europe.</gtr:title><gtr:parentPublicationTitle>Public health genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f27a24835e44a8de8dd053d4aca2bf"><gtr:id>d6f27a24835e44a8de8dd053d4aca2bf</gtr:id><gtr:otherNames>Taruscio D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1662-4246</gtr:issn><gtr:outcomeId>5458b90828cb12.97371006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76B530BA-765D-460C-BFF3-AF2BB04AC767</gtr:id><gtr:title>EMERGENCY NEUROMUSCULAR ADMISSIONS ARE AVOIDABLE: A REGIONAL AUDIT OF UNPLANNED HOSPITAL ADMISSIONS OF NEUROMUSCULAR PATIENTS 2009-2011: FINAL RESULTS AND RECOMMENDATIONS</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/159c8c7cefbd596fac1d4f5555aa91ee"><gtr:id>159c8c7cefbd596fac1d4f5555aa91ee</gtr:id><gtr:otherNames>Jaffer F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_24109054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D864A28-501B-454F-A3F9-4D35CC964CF8</gtr:id><gtr:title>DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c498c08db8013d31d27379b0a356001"><gtr:id>9c498c08db8013d31d27379b0a356001</gtr:id><gtr:otherNames>Mahjneh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_22884442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8332F30-FA05-4359-B2CA-954218A4536A</gtr:id><gtr:title>Clinical and functional characterisation of the combined respiratory chain defect in two sisters due to autosomal recessive mutations in MTFMT.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d1ffbd27c5115fb37fa981f335d80e"><gtr:id>88d1ffbd27c5115fb37fa981f335d80e</gtr:id><gtr:otherNames>Neeve VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>pm_12934_24_23499752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2911F20C-ADED-4FF5-8807-508F5221E256</gtr:id><gtr:title>Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35673fa19257cbfd66aafd869ca9695e"><gtr:id>35673fa19257cbfd66aafd869ca9695e</gtr:id><gtr:otherNames>English K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>pm_12934_24_22913669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87A6DBE2-3FAC-49BA-AD8E-C11584071F1E</gtr:id><gtr:title>PRUNE is crucial for normal brain development and mutated in microcephaly with neurodevelopmental impairment.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/008714e03cc79922a19d3b457141b891"><gtr:id>008714e03cc79922a19d3b457141b891</gtr:id><gtr:otherNames>Zollo M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a79d625a73141.96953958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CE51E75-CF7B-4AD0-86D2-22553E81B4C2</gtr:id><gtr:title>Mutations causing mitochondrial disease: What is new and what challenges remain?</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee62e53aa807f0b784d06e9a75e65323"><gtr:id>ee62e53aa807f0b784d06e9a75e65323</gtr:id><gtr:otherNames>Lightowlers RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56c31f1559c029.09294613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAAA03C4-98AA-4F0C-9F10-3E34CA01412B</gtr:id><gtr:title>206th ENMC International Workshop: Care for a novel group of patients - adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23-25 May 2014.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bcff2911679f6d1e5b5310afc6259b9"><gtr:id>2bcff2911679f6d1e5b5310afc6259b9</gtr:id><gtr:otherNames>Rahbek J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d474275cbfe4.10171581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BDAE03C-89D5-44A8-99CC-058AE9F186E8</gtr:id><gtr:title>Hydroximic acid derivatives: pleiotropic HSP co-inducers restoring homeostasis and robustness.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/570e80bc07d8261a46f2875b2dcb52dc"><gtr:id>570e80bc07d8261a46f2875b2dcb52dc</gtr:id><gtr:otherNames>Crul T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_12934_24_22920902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEAA16CF-DC16-48CE-98A1-45F3489FA9C3</gtr:id><gtr:title>Targeting protein homeostasis in sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af0707d338e2c1c3c05688ae01f64aed"><gtr:id>af0707d338e2c1c3c05688ae01f64aed</gtr:id><gtr:otherNames>Ahmed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>585d5261421019.24007777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DFBC53E-66DA-41F7-B566-A3A46DD917DC</gtr:id><gtr:title>Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/159c8c7cefbd596fac1d4f5555aa91ee"><gtr:id>159c8c7cefbd596fac1d4f5555aa91ee</gtr:id><gtr:otherNames>Jaffer F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56dd62fe8fd841.08427032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DC73FDD-58E0-428C-969B-871225A16557</gtr:id><gtr:title>Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56b4b3c72759e8.99212661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA5C4862-8FA8-47CA-8ADB-B52B49E47AE5</gtr:id><gtr:title>Skeletal Muscle Channelopathies: Rare Disorders with Common Pediatric Symptoms.</gtr:title><gtr:parentPublicationTitle>The Journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86eb63290fdcd11754a77699cac61733"><gtr:id>86eb63290fdcd11754a77699cac61733</gtr:id><gtr:otherNames>Matthews E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3476</gtr:issn><gtr:outcomeId>5a79d6267fb1c8.06572931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CBA16A8-103F-4326-A01E-4DC0CA965428</gtr:id><gtr:title>Novel mutations in DNAJB6 gene cause a very severe early-onset limb-girdle muscular dystrophy 1D disease.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f4a87b832cb2cc32c28e245fbfc130"><gtr:id>02f4a87b832cb2cc32c28e245fbfc130</gtr:id><gtr:otherNames>Palmio J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d474279359f6.64062372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>890F4CF3-AE69-4455-9781-5349B5C65282</gtr:id><gtr:title>Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure.</gtr:title><gtr:parentPublicationTitle>The Journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcc0ce90a57e6ed2b23d3c4bf2309f3d"><gtr:id>fcc0ce90a57e6ed2b23d3c4bf2309f3d</gtr:id><gtr:otherNames>Al-Hussaini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3476</gtr:issn><gtr:outcomeId>5460c9c43cc908.11235025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCF8E8AE-29DB-458A-A519-A4C6B4F2EF37</gtr:id><gtr:title>SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d88e191d01221f4ad7197d1c7b91f4b"><gtr:id>8d88e191d01221f4ad7197d1c7b91f4b</gtr:id><gtr:otherNames>Yoshida-Moriguchi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_12934_24_23929950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>898AA77A-5533-4D69-8A10-FD581CDC7187</gtr:id><gtr:title>Sympathetic innervation controls homeostasis of neuromuscular junctions in health and disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06b561712784c15d64b1b782c8bb4fe"><gtr:id>d06b561712784c15d64b1b782c8bb4fe</gtr:id><gtr:otherNames>Khan MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d47b0d17be68.58931393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00C58850-D567-481A-B953-2D0081236D36</gtr:id><gtr:title>Mitochondrial genetics.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1f4b7c0cf2741f213eff19fe22e37f"><gtr:id>fe1f4b7c0cf2741f213eff19fe22e37f</gtr:id><gtr:otherNames>Chinnery PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>pm_12934_24_23704099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>123F5ECC-1F19-48D9-9310-93241B3C9BB9</gtr:id><gtr:title>Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f870d8e6a42d39d68ef51eb9a6cfd8c9"><gtr:id>f870d8e6a42d39d68ef51eb9a6cfd8c9</gtr:id><gtr:otherNames>Landfeldt E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d474282ab752.58373938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7223B65B-B273-4055-80FF-E821EBCBD472</gtr:id><gtr:title>Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>5458c7e76b6946.10608476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB421BF2-BE61-44CC-A443-B4B1CC80D045</gtr:id><gtr:title>Modifying mitochondrial tRNAs: delivering what the cell needs.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>56b4b3ca43d413.86974824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB1A579-E29B-4A80-85FC-0610FD997ED9</gtr:id><gtr:title>Testing visual perception in dementia with Lewy bodies and Alzheimer disease.</gtr:title><gtr:parentPublicationTitle>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63046a5d0262bebc3218dc4eeae94210"><gtr:id>63046a5d0262bebc3218dc4eeae94210</gtr:id><gtr:otherNames>Wood JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-7481</gtr:issn><gtr:outcomeId>pm_12934_24_23567415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBE10AFB-B8F9-4C4A-984C-BDCAC0100A0A</gtr:id><gtr:title>Calcineurin-nuclear factor of activated T cells regulation of Krox-20 expression in Schwann cells requires elevation of intracellular cyclic AMP.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5934cecf32a0536013feb021442c8a01"><gtr:id>5934cecf32a0536013feb021442c8a01</gtr:id><gtr:otherNames>Kipanyula MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn><gtr:outcomeId>5460bfabe81d07.72865378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2299883D-9BAC-4C38-B03D-F408A97688EE</gtr:id><gtr:title>Reproducibility, and age, body-weight and gender dependency of candidate skeletal muscle MRI outcome measures in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>pm_540e151e1516f2f9f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>419F79A4-C202-480F-93B4-05BC9753CFB3</gtr:id><gtr:title>Early neuropsychiatry features in neuroferritinopathy.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_12934_24_23436236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11784DF2-E0C3-4C25-8201-7F9A2137CC9B</gtr:id><gtr:title>Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93c560990b9e6d19ab042c298a1f423f"><gtr:id>93c560990b9e6d19ab042c298a1f423f</gtr:id><gtr:otherNames>Mannil M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c5610d7005.18968759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93516DB5-68A9-4792-8E31-A3C3E1537D41</gtr:id><gtr:title>Treatment for IgG and IgA paraproteinaemic neuropathy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e8517ba825cdf5df0b2c4ed86719359"><gtr:id>8e8517ba825cdf5df0b2c4ed86719359</gtr:id><gtr:otherNames>Stork AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56b88834c2be20.35005580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3287710B-728B-4A96-B48E-294D2821CD1B</gtr:id><gtr:title>NDUFA4 mutations underlie dysfunction of a cytochrome c oxidase subunit linked to human neurological disease.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6459db0fb97de13ef30ce2614b06cb4a"><gtr:id>6459db0fb97de13ef30ce2614b06cb4a</gtr:id><gtr:otherNames>Pitceathly RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_23746447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>282B154F-CEDA-4FC0-99BC-9C3DD5E003B8</gtr:id><gtr:title>Recessive and dominant mutations in COL12A1 cause a novel EDS/myopathy overlap syndrome in humans and mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4569c7b2719e7c48c416132d57239bc0"><gtr:id>4569c7b2719e7c48c416132d57239bc0</gtr:id><gtr:otherNames>Zou Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5460c8b5ba8f43.09591568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDCE157F-AE7D-4872-8E38-133D388DFF1A</gtr:id><gtr:title>The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9d388cfe9392142a34e75f477c9b23a"><gtr:id>a9d388cfe9392142a34e75f477c9b23a</gtr:id><gtr:otherNames>Heslop E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>56d47428d22a65.67114019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B4EF18-284D-4EB6-A126-18DFAC5BE432</gtr:id><gtr:title>Brain. Editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c070468c78.92705411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACE1991B-0EF4-40AE-ABFC-5544CA6E9BD1</gtr:id><gtr:title>194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f0682b259759dcbf352bf526183086e"><gtr:id>3f0682b259759dcbf352bf526183086e</gtr:id><gtr:otherNames>Aartsma-Rus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23890933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>373700D3-DF9B-484B-ACCA-C47C9EF7ABF1</gtr:id><gtr:title>Congenital myopathies--clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2b0d170cee684805628038bce1dc048"><gtr:id>d2b0d170cee684805628038bce1dc048</gtr:id><gtr:otherNames>Maggi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23394784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05AB8026-D8D6-46E2-ABE2-43DBB2BAEE02</gtr:id><gtr:title>Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b2f8dfe154301fda0ca7dc5fa167fe8"><gtr:id>9b2f8dfe154301fda0ca7dc5fa167fe8</gtr:id><gtr:otherNames>Ryan NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23539189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A1C392E-B687-4614-85A2-E13E67D553B3</gtr:id><gtr:title>Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06cafa9846d93795ff1a2d7d7ee1b3c"><gtr:id>d06cafa9846d93795ff1a2d7d7ee1b3c</gtr:id><gtr:otherNames>Mazzone E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23809874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C796FC-EE7D-4693-80AD-0E2CCD690297</gtr:id><gtr:title>Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06fb00e3407c420486bc732c34b07c14"><gtr:id>06fb00e3407c420486bc732c34b07c14</gtr:id><gtr:otherNames>Zaharieva IT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458b907ec6455.79625734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>979D9BCF-3958-42D5-B12D-26B88B076565</gtr:id><gtr:title>Mitochondrial Disease Sequence Data Resource (MSeqDR): a global grass-roots consortium to facilitate deposition, curation, annotation, and integrated analysis of genomic data for the mitochondrial disease clinical and research communities.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/768863952a6405f91ae2f03bad3aa5d5"><gtr:id>768863952a6405f91ae2f03bad3aa5d5</gtr:id><gtr:otherNames>Falk MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>56d470e98521e5.63745304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>036C467F-3876-4C67-8E62-5C8D807A8C5A</gtr:id><gtr:title>Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b20a673da2928886a7d7b4747a5253e1"><gtr:id>b20a673da2928886a7d7b4747a5253e1</gtr:id><gtr:otherNames>Huemer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>56d470e73be1f2.71937875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB5D67ED-C90A-4164-BC6F-E7E6F84FC976</gtr:id><gtr:title>Loss of Prox1 in striated muscle causes slow to fast skeletal muscle fiber conversion and dilated cardiomyopathy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a8e4b70d7b86459e295614f5fe89ae5"><gtr:id>7a8e4b70d7b86459e295614f5fe89ae5</gtr:id><gtr:otherNames>Petchey LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5458f6ec97b843.16767462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0A8179D-506A-4825-B0A2-F08F5D421CD7</gtr:id><gtr:title>Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies?</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dac81a37ee1b309119650fc33449ba80"><gtr:id>dac81a37ee1b309119650fc33449ba80</gtr:id><gtr:otherNames>Straub V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47a2a29e259.38549745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>705D30F3-30F8-4BC5-BCEB-DD976FE1387C</gtr:id><gtr:title>Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e1be05bc704191c6d341fabea994683"><gtr:id>0e1be05bc704191c6d341fabea994683</gtr:id><gtr:otherNames>Bercsenyi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56b4be0f6d88a5.23065211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C6F3F1C-90C7-451C-9CBD-DB34CD659794</gtr:id><gtr:title>Exome sequencing in dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>56d470e70baf30.81495967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E494B2E1-647F-456E-B198-58E6B499D606</gtr:id><gtr:title>Novel mutations widen the phenotypic spectrum of slow skeletal/?-cardiac myosin (MYH7) distal myopathy.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0624545369012bdf8b401909e253d03b"><gtr:id>0624545369012bdf8b401909e253d03b</gtr:id><gtr:otherNames>Lamont PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>5458b814b1d297.88164044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD81909-FE3C-4714-938E-3F4AA2467DAF</gtr:id><gtr:title>Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b7a98fbe56cf9ec53af8ad582eedbd6"><gtr:id>7b7a98fbe56cf9ec53af8ad582eedbd6</gtr:id><gtr:otherNames>Burns J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>pm_12934_24_23781965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38E23733-0517-4E32-ABF7-3C42A9F54438</gtr:id><gtr:title>MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b275411489d2e326e8859ee3bae6f17"><gtr:id>4b275411489d2e326e8859ee3bae6f17</gtr:id><gtr:otherNames>Turner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_24054840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01FB6300-BE51-4A7B-9121-A0A60980E4BE</gtr:id><gtr:title>Correlation of clinical and molecular features in spinal bulbar muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5458f6ebf02f00.11806564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBF8143B-CC2E-4D21-97A1-2E1015DB137F</gtr:id><gtr:title>Quantitative magnetic resonance imaging in limb-girdle muscular dystrophy 2I: a multinational cross-sectional study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b451cb75940c37070ddf29054e4e197"><gtr:id>9b451cb75940c37070ddf29054e4e197</gtr:id><gtr:otherNames>Willis TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458f90965f245.31566810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B3C5AAB-6A3E-4D08-97D8-C411F9696FB2</gtr:id><gtr:title>A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b7f1273a72660918c9c8cbbb04b2699"><gtr:id>2b7f1273a72660918c9c8cbbb04b2699</gtr:id><gtr:otherNames>Mestre TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>58a4551bd0e4c4.84588135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EB3073B-9AF7-45E8-976E-AC4692B1D475</gtr:id><gtr:title>Human stem cell aging: do mitochondrial DNA mutations have a causal role?</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bea11a76c679a24a5e90697f3cea608"><gtr:id>6bea11a76c679a24a5e90697f3cea608</gtr:id><gtr:otherNames>Baines HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>5460caace64817.11130752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D25DF77-10A1-4914-BAA2-A4C94382ED37</gtr:id><gtr:title>Muscular dystrophy in dysferlin-deficient mouse models.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/563b74aee8472d139735876bc948832c"><gtr:id>563b74aee8472d139735876bc948832c</gtr:id><gtr:otherNames>Hornsey MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23473732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3DE8C89-D741-4ED9-A7CA-2C1FAEB7982B</gtr:id><gtr:title>Recessive Mutations in RTN4IP1 Cause Isolated and Syndromic Optic Neuropathies.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5372d563a7bb47af0e0d4f7f0e0af9da"><gtr:id>5372d563a7bb47af0e0d4f7f0e0af9da</gtr:id><gtr:otherNames>Angebault C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56d470e83e7bf8.34888478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADBE8761-597C-4235-8185-9E362BB0DD15</gtr:id><gtr:title>Conserved expression of truncated telethonin in a patient with limb-girdle muscular dystrophy 2G.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/266d808f860e3e1d76ce3f3809ed90be"><gtr:id>266d808f860e3e1d76ce3f3809ed90be</gtr:id><gtr:otherNames>Barresi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d4742999e4c7.93554538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4142EFE2-0802-4FB1-93BC-B425BDFE77B5</gtr:id><gtr:title>Hypokalemic periodic paralysis: an omega pore mutation affects inactivation.</gtr:title><gtr:parentPublicationTitle>Channels (Austin, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f9a3247dd1151d4548d2340ae92584"><gtr:id>55f9a3247dd1151d4548d2340ae92584</gtr:id><gtr:otherNames>M?nnikk? R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1933-6950</gtr:issn><gtr:outcomeId>56b2118f0ee088.70519686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F42DDFC7-4716-4588-A964-0A7D6CBC8531</gtr:id><gtr:title>Single-cell analysis of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d470ea039e79.07496153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B43C8FF-0714-45A7-A909-942AACBAD578</gtr:id><gtr:title>Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5740d7dfacf41317fd1190662cfe9c79"><gtr:id>5740d7dfacf41317fd1190662cfe9c79</gtr:id><gtr:otherNames>Gang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>58a4551ceb4a92.15524150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D554559-A762-4ACF-832C-C9AA02E50489</gtr:id><gtr:title>Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cffa34360286141f4e59a95d4f0f2764"><gtr:id>cffa34360286141f4e59a95d4f0f2764</gtr:id><gtr:otherNames>Wallner-Blazek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_23620065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8762B92-E0DF-4ACF-9354-6EA802E57C8E</gtr:id><gtr:title>In vivo impact of presynaptic calcium channel dysfunction on motor axons in episodic ataxia type 2.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56dd63017fb350.73915163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1882C34E-3CDB-4D98-AC07-9BEC9AA24E0B</gtr:id><gtr:title>Repurposing of sodium channel antagonists as potential new anti-myotonic drugs.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86eb63290fdcd11754a77699cac61733"><gtr:id>86eb63290fdcd11754a77699cac61733</gtr:id><gtr:otherNames>Matthews E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>56dd62fb296df8.58497775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>774B98B8-B2CB-4D90-A023-EED62E4AC01C</gtr:id><gtr:title>Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/607ebce6ce7eb094a4edf95a9e722c3a"><gtr:id>607ebce6ce7eb094a4edf95a9e722c3a</gtr:id><gtr:otherNames>Broomfield A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>56dd62fb801195.28158609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEE88A28-1BB7-4D97-B6BC-DB4DF68138E0</gtr:id><gtr:title>200th ENMC International Workshop &amp;quot;European reference networks: recommendations and criteria in the neuromuscular field&amp;quot;, 18-20 October 2013, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe8fc4c7a21a2eb5369f6c0eb70d891a"><gtr:id>fe8fc4c7a21a2eb5369f6c0eb70d891a</gtr:id><gtr:otherNames>Evangelista T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5458b81564fc80.48475216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD941A46-8AD2-4A78-AA98-AF352D5D9CE5</gtr:id><gtr:title>Effects of herbal supplements on the bioactivation of chemotherapeutic agents.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>pm_12934_24_23738729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2A6E971-A146-4C2A-96A4-5DFEAB3F3F95</gtr:id><gtr:title>The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9abffe3d877c62e1432ee4a5b5d518a8"><gtr:id>9abffe3d877c62e1432ee4a5b5d518a8</gtr:id><gtr:otherNames>Bladen CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>56d474294d9467.90357781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26A85136-1E81-4771-B602-0C2FBA7EC0A9</gtr:id><gtr:title>Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc50ac584b098635298c4f9b4186740"><gtr:id>fbc50ac584b098635298c4f9b4186740</gtr:id><gtr:otherNames>Draak TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b888319534e6.67899077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9520DAB8-98BF-4BA6-8F60-55DCA8A43EB8</gtr:id><gtr:title>Brain oxygenation responses to an autonomic challenge: a quantitative fMRI investigation of the Valsalva manoeuvre.</gtr:title><gtr:parentPublicationTitle>Age (Dordrecht, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/954de769cd9e146d51abd7801ded86f3"><gtr:id>954de769cd9e146d51abd7801ded86f3</gtr:id><gtr:otherNames>Bohr I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-9152</gtr:issn><gtr:outcomeId>56c3507cc23299.16656716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA3533DD-1212-4221-9BBD-6AFAB2EC5D70</gtr:id><gtr:title>ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d3a74312ac86d45efc47ac78a3c98c"><gtr:id>35d3a74312ac86d45efc47ac78a3c98c</gtr:id><gtr:otherNames>Haack TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_12934_24_23849775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B3866AC-4245-46D8-ABF5-C79D2F9A42CD</gtr:id><gtr:title>Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d624eb988e061ba80084b6a8f73eeea"><gtr:id>9d624eb988e061ba80084b6a8f73eeea</gtr:id><gtr:otherNames>Paterson RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56b8883084cf54.50557694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DADE276C-5AC2-4F2B-A495-1366476481D8</gtr:id><gtr:title>Reply: Sensorineural hearing loss in OPA1-linked disorders.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458cb0a49ef39.37191599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2145047A-1468-45D0-A155-F8CFE8528B0A</gtr:id><gtr:title>Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>Molecular neurodegeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2db245c76b89ef2ac87eeb7602629d21"><gtr:id>2db245c76b89ef2ac87eeb7602629d21</gtr:id><gtr:otherNames>Chiasserini D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-1326</gtr:issn><gtr:outcomeId>56d470e95192e1.27143977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13BFB327-E414-46E2-942F-95927528BA50</gtr:id><gtr:title>No evidence of an association between mitochondrial DNA variants and osteoarthritis in 7393 cases and 5122 controls.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_12934_24_22984172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2EED19B-AE68-4405-A1CA-D42D73EC79AD</gtr:id><gtr:title>Targeted exon skipping to correct exon duplications in the dystrophin gene.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf3552db267ee5031e31710b23076a7"><gtr:id>ecf3552db267ee5031e31710b23076a7</gtr:id><gtr:otherNames>Greer KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460c189a9bb09.36397165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45C07CEC-C0F3-451D-AC15-13DB2EED0EF4</gtr:id><gtr:title>Identification of an important potential confound in CSF AD studies: aliquot volume.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry and laboratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a896c05ff079b09bbd8b7d45f25746b3"><gtr:id>a896c05ff079b09bbd8b7d45f25746b3</gtr:id><gtr:otherNames>Toombs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1434-6621</gtr:issn><gtr:outcomeId>5460c232311219.06683164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1A7B47B-A808-4D8F-9984-E2C172C708D5</gtr:id><gtr:title>Clinical implications of genetic advances in Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e200f814262dac4d6b88ac30584c047"><gtr:id>8e200f814262dac4d6b88ac30584c047</gtr:id><gtr:otherNames>Rossor AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_12934_24_24018473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9773955-B278-442F-8592-A55B5F4256A5</gtr:id><gtr:title>Intensive blood pressure lowering increases cerebral blood flow in older subjects with hypertension.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04865421c3551c01bbef6ec72aa6b22c"><gtr:id>04865421c3551c01bbef6ec72aa6b22c</gtr:id><gtr:otherNames>Tryambake D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_12934_24_23529166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B34849DF-1630-490D-9CAE-24EBBBE4F3E5</gtr:id><gtr:title>Subepicardial dysfunction leads to global left ventricular systolic impairment in patients with limb girdle muscular dystrophy 2I.</gtr:title><gtr:parentPublicationTitle>European journal of heart failure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf878e42a37a7f62b5e7575b0a3a6e7"><gtr:id>bdf878e42a37a7f62b5e7575b0a3a6e7</gtr:id><gtr:otherNames>Hollingsworth KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1388-9842</gtr:issn><gtr:outcomeId>pm_12934_24_23576288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2A9E72F-C39B-4ECB-8A91-0D316C0BB153</gtr:id><gtr:title>Linking the metabolic state and mitochondrial DNA in chronic disease, health, and aging.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fbb8678528f8cb634deb50d424fecf2"><gtr:id>0fbb8678528f8cb634deb50d424fecf2</gtr:id><gtr:otherNames>Picard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_12934_24_23431006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2715D555-6006-4D6C-86B9-1BB0B179DC63</gtr:id><gtr:title>In Vivo Imaging of Flavoprotein Fluorescence During Hypoxia Reveals the Importance of Direct Arterial Oxygen Supply to Cerebral Cortex Tissue.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce614c5704359d54b77cbacc043b17e6"><gtr:id>ce614c5704359d54b77cbacc043b17e6</gtr:id><gtr:otherNames>Chisholm KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>56c32874e82d38.60000736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F2CE7A9-F043-43EA-B9F5-EB7D40E4F478</gtr:id><gtr:title>Hereditary sensory and autonomic neuropathy type 1 (HSANI) caused by a novel mutation in SPTLC2.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6742175c859dc2842759f84e6dd6f0e6"><gtr:id>6742175c859dc2842759f84e6dd6f0e6</gtr:id><gtr:otherNames>Murphy SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23658386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57377A75-8AAC-4145-8EF8-F07887A13599</gtr:id><gtr:title>Discrete gait characteristics are associated with m.3243A&amp;gt;G and m.8344A&amp;gt;G variants of mitochondrial disease and its pathological consequences.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8894fd431814e7b0d5213d0aae4975a7"><gtr:id>8894fd431814e7b0d5213d0aae4975a7</gtr:id><gtr:otherNames>Galna B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_24150688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12527D07-63D8-498D-AA36-2309AEBF76D6</gtr:id><gtr:title>Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f24c2b492624c48bd8e9c149b9cfbde9"><gtr:id>f24c2b492624c48bd8e9c149b9cfbde9</gtr:id><gtr:otherNames>Oonk S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>56d47b0dc4dea8.39163888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>866C3271-B4E5-4415-89A6-D10F8DD5549D</gtr:id><gtr:title>Zebra body myopathy is caused by a mutation in the skeletal muscle actin gene (ACTA1).</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a3c0657fd1d6eb0111e2f92c5ed8dcd"><gtr:id>3a3c0657fd1d6eb0111e2f92c5ed8dcd</gtr:id><gtr:otherNames>Sewry CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b214a7649f69.22724962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D24924E6-C6EA-4AA9-A57C-BCCC9934ED90</gtr:id><gtr:title>Diagnostic approach to the congenital muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c908c95680291cd2f6373931cd8bb337"><gtr:id>c908c95680291cd2f6373931cd8bb337</gtr:id><gtr:otherNames>B?nnemann CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c3ab6c2f26.43853844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEF903F7-5EA0-4097-9197-8347D50BC34E</gtr:id><gtr:title>Tissue microstructural changes in dementia with Lewy bodies revealed by quantitative MRI.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16c121382f6709092a03a017793856f8"><gtr:id>16c121382f6709092a03a017793856f8</gtr:id><gtr:otherNames>Su L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56c3507b2ce6a3.10857327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3AFC2C6-4BA7-42A9-BA87-1FF57C5CCE6C</gtr:id><gtr:title>Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa4045b0ca26cb93f7e8d0cb42a2d70d"><gtr:id>fa4045b0ca26cb93f7e8d0cb42a2d70d</gtr:id><gtr:otherNames>Trevithick L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>56c44f61f2f0a2.61420911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9C6A3E1-3F90-4C35-972E-8C08A9A2314B</gtr:id><gtr:title>New treatments for mitochondrial disease-no time to drop our standards.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_12934_24_23817350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAA949FB-6005-4709-A833-D8D91AA2DB84</gtr:id><gtr:title>Hypertrophic olivary degeneration on magnetic resonance imaging in mitochondrial syndromes associated with POLG and SURF1 mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da3d30139af2f7d5f115630714930c3a"><gtr:id>da3d30139af2f7d5f115630714930c3a</gtr:id><gtr:otherNames>Kinghorn KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_22729384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FD38E79-213F-4C04-B1A3-89DE9EC15AD5</gtr:id><gtr:title>Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure.</gtr:title><gtr:parentPublicationTitle>Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbf87eabd5322a64bd366c8e3b553b9"><gtr:id>9dbf87eabd5322a64bd366c8e3b553b9</gtr:id><gtr:otherNames>Pisano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1054-8807</gtr:issn><gtr:outcomeId>56c31f13d52665.80048266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9077F04-685E-4F96-B33E-91F8ABEA269A</gtr:id><gtr:title>The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49cc059568c0655a67580b605993419"><gtr:id>a49cc059568c0655a67580b605993419</gtr:id><gtr:otherNames>Mora M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>56b214a7cb9ad1.68227263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543651D6-3B4E-4804-B3FE-5F82F7B337A2</gtr:id><gtr:title>Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/553f7ec4568e90f2c7e4cc3fc62a1bd1"><gtr:id>553f7ec4568e90f2c7e4cc3fc62a1bd1</gtr:id><gtr:otherNames>Carvajal-Gonz?lez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c231059867.86154987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>030E9BBE-D2F7-4360-8542-337ABB93E138</gtr:id><gtr:title>Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62d8f1d9d22814edd5c9efffcb8906b5"><gtr:id>62d8f1d9d22814edd5c9efffcb8906b5</gtr:id><gtr:otherNames>Blain A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1937-5387</gtr:issn><gtr:outcomeId>56d47a2b02b069.58190068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE72443F-116A-4A5F-9BB6-F831D3F042D1</gtr:id><gtr:title>The human desmin promoter drives robust gene expression for skeletal muscle stem cell-mediated gene therapy.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9169c43665936aad66d211d45a2743a9"><gtr:id>9169c43665936aad66d211d45a2743a9</gtr:id><gtr:otherNames>Jonuschies J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn><gtr:outcomeId>56b21392dd9df6.57747213</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDDDF55B-747C-47CE-A416-B6217470DD1D</gtr:id><gtr:title>Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice.</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78e6c0254de4ec7c8cf1f362989d497"><gtr:id>a78e6c0254de4ec7c8cf1f362989d497</gtr:id><gtr:otherNames>Quattrocelli M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>pm_12934_24_23963759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63DDEF26-42FC-49FF-AADB-23411BBB4BF1</gtr:id><gtr:title>Deletion of chromosome 12q21 affecting KCNC2 and ATXN7L3B in a family with neurodevelopmental delay and ataxia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_23475819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C0A85A3-1667-465D-A2F8-6AF41202CC5A</gtr:id><gtr:title>Transcriptional regulator PRDM12 is essential for human pain perception.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25c04fa16b3963d8d32fe758dc53ce3a"><gtr:id>25c04fa16b3963d8d32fe758dc53ce3a</gtr:id><gtr:otherNames>Chen YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5697a8ae320148.73092557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7D06BE4-7D92-4382-A6A3-B219FF9328DF</gtr:id><gtr:title>Cervical transverse myelitis like presentation of cranial dural arteriovenous fistula.</gtr:title><gtr:parentPublicationTitle>Clinical neurology and neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc1ff082016dd34c0b053ded4582c910"><gtr:id>bc1ff082016dd34c0b053ded4582c910</gtr:id><gtr:otherNames>Vivekananda U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0303-8467</gtr:issn><gtr:outcomeId>5460c232e7a056.09134399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17C23037-852B-4839-B33B-5292F911D4C8</gtr:id><gtr:title>Characterisation and evaluation of paramagnetic fluorine labelled glycol chitosan conjugates for (19)F and (1)H magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb4dd889381e6d03613744fb80dd629"><gtr:id>8bb4dd889381e6d03613744fb80dd629</gtr:id><gtr:otherNames>De Luca E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0949-8257</gtr:issn><gtr:outcomeId>pm_12934_24_23955558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20C687C1-FBEC-422E-8473-B1B3ED012503</gtr:id><gtr:title>Raised intraocular pressure as a potential risk factor for visual loss in Leber Hereditary Optic Neuropathy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f66f58488679f6122ce10c4e43a78fd9"><gtr:id>f66f58488679f6122ce10c4e43a78fd9</gtr:id><gtr:otherNames>Thouin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_23667621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AF2ABAD-05BC-4176-8202-F4C44AC87310</gtr:id><gtr:title>Mutational analysis of PMP22, EGR2, LITAF and NEFL in Greek Charcot-Marie-Tooth type 1 patients.</gtr:title><gtr:parentPublicationTitle>Clinical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0141d4dc212d3dc1de00d97ceee75f7"><gtr:id>a0141d4dc212d3dc1de00d97ceee75f7</gtr:id><gtr:otherNames>Koutsis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9163</gtr:issn><gtr:outcomeId>pm_12934_24_22765307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B4C4E85-7150-4A6D-9437-BC48E8DC2869</gtr:id><gtr:title>Altered 2-thiouridylation impairs mitochondrial translation in reversible infantile respiratory chain deficiency.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d75d3b4b9bf032eb6ff10990933d59"><gtr:id>e5d75d3b4b9bf032eb6ff10990933d59</gtr:id><gtr:otherNames>Boczonadi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23814040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7FC14BE-C1B6-403E-AC75-5A04A3591DB4</gtr:id><gtr:title>The burden of Duchenne muscular dystrophy: an international, cross-sectional study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f870d8e6a42d39d68ef51eb9a6cfd8c9"><gtr:id>f870d8e6a42d39d68ef51eb9a6cfd8c9</gtr:id><gtr:otherNames>Landfeldt E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5458b8148009a7.32188458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12ED7EB8-4E25-4EE0-B87C-F2D0C4F8BDB3</gtr:id><gtr:title>Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f870d8e6a42d39d68ef51eb9a6cfd8c9"><gtr:id>f870d8e6a42d39d68ef51eb9a6cfd8c9</gtr:id><gtr:otherNames>Landfeldt E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>56d47428549dc8.68767260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9753B94F-5DB0-4517-B068-4CBACF060F7B</gtr:id><gtr:title>The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89b31b53bd8d22167e3e61b6f878f7e4"><gtr:id>89b31b53bd8d22167e3e61b6f878f7e4</gtr:id><gtr:otherNames>Guthrie G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12934_24_23238845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9AC4F5E-0870-420E-920F-1DEAB7962F20</gtr:id><gtr:title>The genetics and pathology of mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9fed88b0ab0044cbcece97c7fd87c62"><gtr:id>b9fed88b0ab0044cbcece97c7fd87c62</gtr:id><gtr:otherNames>Alston CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5a5f557986e578.13613704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9799A8B-1D04-4A66-945D-ABE50451E12A</gtr:id><gtr:title>Novel HSAN1 mutation in serine palmitoyltransferase resides at a putative phosphorylation site that is involved in regulating substrate specificity.</gtr:title><gtr:parentPublicationTitle>Neuromolecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de2a860f153838d0613290971dc2033"><gtr:id>4de2a860f153838d0613290971dc2033</gtr:id><gtr:otherNames>Ernst D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-1084</gtr:issn><gtr:outcomeId>doi_55f98498435a8dc8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F012094-D3EF-4101-9C95-7FEBDD289458</gtr:id><gtr:title>HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies.</gtr:title><gtr:parentPublicationTitle>Toxicologic pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da7de470552fbe19eaeccb55dde6bf0e"><gtr:id>da7de470552fbe19eaeccb55dde6bf0e</gtr:id><gtr:otherNames>Gardner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0192-6233</gtr:issn><gtr:outcomeId>pm_12934_24_24067671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D206DE32-638D-4754-97BB-2F5433F411A8</gtr:id><gtr:title>197th ENMC international workshop: Neuromuscular disorders of mitochondrial fusion and fission - OPA1 and MFN2 molecular mechanisms and therapeutic strategies: 26-28 April 2013, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5458bda591cfc6.42416072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38D43327-3C45-433F-8D7B-8E3E1186F2D9</gtr:id><gtr:title>A new web-based method for automated analysis of muscle histology.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/917a25e3787b10c39f1e3ac4d4fa352b"><gtr:id>917a25e3787b10c39f1e3ac4d4fa352b</gtr:id><gtr:otherNames>Pertl C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn><gtr:outcomeId>pm_12934_24_23324401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C60D09D4-5EB6-440C-A80E-318F811033BD</gtr:id><gtr:title>Recent progress in satellite cell/myoblast engraftment -- relevance for therapy.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbc8378b3983e19a27ea749757bb61de"><gtr:id>dbc8378b3983e19a27ea749757bb61de</gtr:id><gtr:otherNames>Briggs D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>pm_12934_24_23560812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A29BC22-D9BA-4868-B558-F6D4928088CE</gtr:id><gtr:title>The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e22a3ff7b2f2f08f0e1cfac1e9d3527"><gtr:id>4e22a3ff7b2f2f08f0e1cfac1e9d3527</gtr:id><gtr:otherNames>Whitmore C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5460c3ab91e5c3.57921259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48A72BFE-58B3-48F5-AC94-22AF843D7CA9</gtr:id><gtr:title>Clinical heterogeneity of primary familial brain calcification due to a novel mutation in PDGFB.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b4b3c93b1152.46066328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE1918E3-6420-4A87-835D-8DB96CD8FFBC</gtr:id><gtr:title>A 3'-UTR mutation creates a microRNA target site in the GFPT1 gene of patients with congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53b52465e547418fd22d0bcb2bef6912"><gtr:id>53b52465e547418fd22d0bcb2bef6912</gtr:id><gtr:otherNames>Dusl M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56d47b0eb1e102.61884823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0A12230-BAC6-4515-9873-F86923C32687</gtr:id><gtr:title>Next generation sequencing for neurological diseases: new hope or new hype?</gtr:title><gtr:parentPublicationTitle>Clinical neurology and neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0303-8467</gtr:issn><gtr:outcomeId>pm_12934_24_23200550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C00AA04-7DAA-470C-B01E-9C5AED4DA0A2</gtr:id><gtr:title>Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23645593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD818882-DF73-477F-8D4B-D82E5013D17C</gtr:id><gtr:title>Outcome measures in neuromuscular disease: is the world still flat?</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1161dceb49b9031cc5693146e0b920cb"><gtr:id>1161dceb49b9031cc5693146e0b920cb</gtr:id><gtr:otherNames>Lunn MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b8883224d9b2.58698158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADA6AC9F-F202-4BFF-8348-F1FF2A8F6CF1</gtr:id><gtr:title>Overview of contemporary guidelines in digital pathology: what is available in 2015 and what still needs to be addressed?</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>56dd62fd2277c0.63103063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AED11EF1-9C49-4990-815D-E34791E4D94C</gtr:id><gtr:title>Reply: Hereditary myopathy with early respiratory failure is caused by mutations in the titin FN3 119 domain.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458c7e7e7f484.75623800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4522DB0B-7EF4-46DE-95AF-CC87EBA725C0</gtr:id><gtr:title>Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b09cec3df0253fb5c98e8674910a85a"><gtr:id>3b09cec3df0253fb5c98e8674910a85a</gtr:id><gtr:otherNames>Herrmann DN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5458bb0b1342b1.55922679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B4FB9DD-F8AE-448D-819C-B8FDD1AA4A8C</gtr:id><gtr:title>Old measures and new scores in spinal muscular atrophy patients.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06cafa9846d93795ff1a2d7d7ee1b3c"><gtr:id>d06cafa9846d93795ff1a2d7d7ee1b3c</gtr:id><gtr:otherNames>Mazzone E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>56b214a6966926.32913671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF6D8201-0617-4E3C-862D-4828CABAB541</gtr:id><gtr:title>Brain. Editorial.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5460c0715481b6.45961911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A34B7D56-EA59-443F-B6FD-300E79DA2DE9</gtr:id><gtr:title>A leaky splicing mutation in NFU1 is associated with a particular biochemical phenotype. Consequences for the diagnosis.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945a8a6bc560b4c57b90454e50083ec5"><gtr:id>945a8a6bc560b4c57b90454e50083ec5</gtr:id><gtr:otherNames>Ferrer-Cort?s X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>56c31f147a6b31.21833431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D4C2F99-70CE-47AE-9F89-383C90F60C2B</gtr:id><gtr:title>IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/432a93a0abc1c455d7acbe3bdeeae1de"><gtr:id>432a93a0abc1c455d7acbe3bdeeae1de</gtr:id><gtr:otherNames>Faccenda D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_12934_24_23348567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83D9A9C3-903F-4A23-A783-1E7292660DBC</gtr:id><gtr:title>EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d75d3b4b9bf032eb6ff10990933d59"><gtr:id>e5d75d3b4b9bf032eb6ff10990933d59</gtr:id><gtr:otherNames>Boczonadi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5458bb0bb20919.45578708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5E26229-CF99-46CF-8972-F1B1A3BCB430</gtr:id><gtr:title>ANO10 mutations cause ataxia and coenzyme Q10 deficiency.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bdf1a60ea99c281a61ce794e1157fe6"><gtr:id>5bdf1a60ea99c281a61ce794e1157fe6</gtr:id><gtr:otherNames>Balreira A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5458bb0b3c1de7.85267928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BABA6AC8-9392-49E4-9BA9-E1C8D057ECBA</gtr:id><gtr:title>Pericytes in development and pathology of skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fae8d7e266f179c0d9d26bcf9ebf219"><gtr:id>3fae8d7e266f179c0d9d26bcf9ebf219</gtr:id><gtr:otherNames>Cappellari O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>pm_12934_24_23868830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D427888A-6E7C-49EB-94CE-D33FEF10DF55</gtr:id><gtr:title>Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5523874169f71a476541373c881cf885"><gtr:id>5523874169f71a476541373c881cf885</gtr:id><gtr:otherNames>Piscosquito G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>5697a8ae85e725.96061912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38303F24-2E7D-4E74-85C1-80E3FDEAF86A</gtr:id><gtr:title>Flow cytometry for the analysis of a-dystroglycan glycosylation in fibroblasts from patients with dystroglycanopathies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d1a833bc9dcd1dc1ac7f445c0c0796"><gtr:id>07d1a833bc9dcd1dc1ac7f445c0c0796</gtr:id><gtr:otherNames>Stevens E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_23894383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5456AE0-0486-4141-9C10-DAD0E1E66F1F</gtr:id><gtr:title>Clinical, neuropathological and radiological evidence for a rare complication of rituximab therapy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c493834728363785365027d95f925c69"><gtr:id>c493834728363785365027d95f925c69</gtr:id><gtr:otherNames>Healy EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5697a81a377404.46061092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CA13DE5-AE6E-433C-86AF-DB485917B583</gtr:id><gtr:title>One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.</gtr:title><gtr:parentPublicationTitle>Pediatric neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9df8eb0453fc78bce3a4de6720ba8b95"><gtr:id>9df8eb0453fc78bce3a4de6720ba8b95</gtr:id><gtr:otherNames>Connolly AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-8994</gtr:issn><gtr:outcomeId>5458b8158da4e9.81148618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7501C36D-731B-414B-8925-44C280A53A3C</gtr:id><gtr:title>Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d650d10593bac5fd741f0c8a365fc160"><gtr:id>d650d10593bac5fd741f0c8a365fc160</gtr:id><gtr:otherNames>Rothwell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a79d624f1d887.98711171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42AD9A11-2CCC-4733-BF6A-F6538BB6A801</gtr:id><gtr:title>ELECTROLYTE IMBALANCE TRIGGERING RELAPSE OF INFLAMMATORY NEUROPATHY</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3e20fda70740751de85d30c038b636"><gtr:id>1b3e20fda70740751de85d30c038b636</gtr:id><gtr:otherNames>Keshavan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_24108985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>757398B8-F514-45D3-8576-A9A940CECC4D</gtr:id><gtr:title>Rapidly progressive asymmetrical weakness in Charcot-Marie-Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcb877e01dd9f33040f7fc09646ce4b6"><gtr:id>bcb877e01dd9f33040f7fc09646ce4b6</gtr:id><gtr:otherNames>Cottenie E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23489662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6223D7C-DF47-47FB-A987-C094EF322EEB</gtr:id><gtr:title>A novel prion disease associated with diarrhea and autonomic neuropathy.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5460bfac6cf064.85695481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93CEC22A-791B-42C0-B555-B02F29B975AD</gtr:id><gtr:title>Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c745e5f96e2db4ca9a165bd1a95a4858"><gtr:id>c745e5f96e2db4ca9a165bd1a95a4858</gtr:id><gtr:otherNames>Tremblay JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_12934_24_23369965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76A42CAF-3B1D-44F1-B4EB-5D24E6CE5FE4</gtr:id><gtr:title>Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_12934_24_23818065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>586F9D84-B7BC-4E5C-A776-E3EB753242D6</gtr:id><gtr:title>A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b4be0f384821.55993569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86BCEC1C-2796-4030-8E42-2AB589FEC714</gtr:id><gtr:title>RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research.</gtr:title><gtr:parentPublicationTitle>Journal of general internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d271ce2c041617a84324295cdfebb33"><gtr:id>6d271ce2c041617a84324295cdfebb33</gtr:id><gtr:otherNames>Thompson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0884-8734</gtr:issn><gtr:outcomeId>5458b81408faa7.96971161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>641282A8-2E1D-4A4D-ADA4-CA9757A4B591</gtr:id><gtr:title>Nitric oxide synthesis and cGMP production is important for neurite growth and synapse remodeling after axotomy.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebf7247303ae034067f93a0a46ca600f"><gtr:id>ebf7247303ae034067f93a0a46ca600f</gtr:id><gtr:otherNames>Cooke RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>5460c914d88692.48314097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C7A541D-EB3C-4BA7-8BD4-472048B810AB</gtr:id><gtr:title>Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378141bd5d0e9dda40dc02234cae0d5b"><gtr:id>378141bd5d0e9dda40dc02234cae0d5b</gtr:id><gtr:otherNames>Bonnen PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_12934_24_23993193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7579D915-6EB5-47C4-B3BB-452E11E4D431</gtr:id><gtr:title>Loss of dermatan sulfate epimerase (DSE) function results in musculocontractural Ehlers-Danlos syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49567818545b5e0f8f503e0ceda45947"><gtr:id>49567818545b5e0f8f503e0ceda45947</gtr:id><gtr:otherNames>M?ller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23704329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAD202F4-69DA-42C2-AA5A-10B7ABDAD774</gtr:id><gtr:title>Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d98ce90f1474e2079d539e21d06cdca"><gtr:id>6d98ce90f1474e2079d539e21d06cdca</gtr:id><gtr:otherNames>van den Bergen JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56b214a811f633.18592605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF696955-3ED9-4AD0-9904-80DB28CC625E</gtr:id><gtr:title>Muscle MRI in Bethlem myopathy.</gtr:title><gtr:parentPublicationTitle>BMJ case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1757-790X</gtr:issn><gtr:outcomeId>pm_12934_24_23595177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF749C7C-4DF0-4A7C-AD5B-142E95A30E10</gtr:id><gtr:title>Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51cba051719f81ef2c20624dca20d9fa"><gtr:id>51cba051719f81ef2c20624dca20d9fa</gtr:id><gtr:otherNames>Cossins J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12934_24_23404334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B773704C-9122-4FF9-BD1F-A419000D9800</gtr:id><gtr:title>Grafting of a single donor myofibre promotes hypertrophy in dystrophic mouse muscle.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89783a5fcb17bacf0fca3ef2fd51289d"><gtr:id>89783a5fcb17bacf0fca3ef2fd51289d</gtr:id><gtr:otherNames>Boldrin L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_23349935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCA01CD3-D045-44B0-AAB1-54ACF57017C6</gtr:id><gtr:title>Severe toxicity and polymerase-? gene abnormalities in Malawian adults on stavudine-based antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf045c357cab93673df461672ada7234"><gtr:id>cf045c357cab93673df461672ada7234</gtr:id><gtr:otherNames>van Oosterhout JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12934_24_23962909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>579B5D34-A42E-482C-9A4A-99EFBDB6C16A</gtr:id><gtr:title>Founder p.Arg 446* mutation in the PDHX gene explains over half of cases with congenital lactic acidosis in Roma children.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de3b7b49c613ac5b0744f18e7f01e49b"><gtr:id>de3b7b49c613ac5b0744f18e7f01e49b</gtr:id><gtr:otherNames>Ivanov IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>56b4b3ca08bee9.28993445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B3A4F09-611D-4AE1-B47D-61E872C629A7</gtr:id><gtr:title>Adenovirus-mediated expression of myogenic differentiation factor 1 (MyoD) in equine and human dermal fibroblasts enables their conversion to caffeine-sensitive myotubes.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88c97d6ebfa4c0932dde8dec53ddcebc"><gtr:id>88c97d6ebfa4c0932dde8dec53ddcebc</gtr:id><gtr:otherNames>Fernandez-Fuente M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c3abe0ae37.98390531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89436954-0359-4F28-873F-68A2A07CE838</gtr:id><gtr:title>Hereditary mtDNA heteroplasmy: a baseline for aging?</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e7376f3d3701a7844fa1c1d8c9a39c7"><gtr:id>9e7376f3d3701a7844fa1c1d8c9a39c7</gtr:id><gtr:otherNames>Keogh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>pm_12934_24_24093673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD7ADD68-8D7C-4B34-949E-91D3044D622B</gtr:id><gtr:title>Differential triggering of spontaneous glutamate release by P/Q-, N- and R-type Ca2+ channels.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dee3b9490f57d9ac4d64b01c8d5be195"><gtr:id>dee3b9490f57d9ac4d64b01c8d5be195</gtr:id><gtr:otherNames>Ermolyuk YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>pm_12934_24_24185424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>309DE5D6-CB85-45DF-B1FD-236072D4094B</gtr:id><gtr:title>Dystrophin quantification: Biological and translational research implications.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7048e1621ef557498f13646f8b99fb"><gtr:id>5e7048e1621ef557498f13646f8b99fb</gtr:id><gtr:otherNames>Anthony K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b213924213f3.39799139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D0761F4-4FE0-43EC-B4D5-AD2FCCE7747B</gtr:id><gtr:title>Adult-onset myoclonus ataxia associated with the mitochondrial m.8993T&amp;gt;C &amp;quot;NARP&amp;quot; mutation.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd55d049dbcc0d328614887ca48f1222"><gtr:id>fd55d049dbcc0d328614887ca48f1222</gtr:id><gtr:otherNames>Martikainen MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>56c46eac4a20e9.67047761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F440CE-ADA6-483E-B090-1A8E2609C39F</gtr:id><gtr:title>Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa72e1487b5c9616d7251983f1a41ed9"><gtr:id>aa72e1487b5c9616d7251983f1a41ed9</gtr:id><gtr:otherNames>Natera-de Benito D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56d47b0df0a118.60494968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84DB9866-016C-464C-A142-A1FB9DD776F2</gtr:id><gtr:title>Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).</gtr:title><gtr:parentPublicationTitle>Biomolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87baae63149e8384883159bbff301f14"><gtr:id>87baae63149e8384883159bbff301f14</gtr:id><gtr:otherNames>Chen Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2218-273X</gtr:issn><gtr:outcomeId>56d47b0f26a096.73192648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA77645C-8F68-4C0E-98D1-87C995DD4470</gtr:id><gtr:title>Distal myopathy with cachexia: an unrecognised phenotype caused by dominantly-inherited mitochondrial polymerase ? mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6459db0fb97de13ef30ce2614b06cb4a"><gtr:id>6459db0fb97de13ef30ce2614b06cb4a</gtr:id><gtr:otherNames>Pitceathly RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_22933815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D869FFAF-C6F9-4A7C-9A48-8835AC066088</gtr:id><gtr:title>Modulation of the host skeletal muscle niche for donor satellite cell grafting.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89783a5fcb17bacf0fca3ef2fd51289d"><gtr:id>89783a5fcb17bacf0fca3ef2fd51289d</gtr:id><gtr:otherNames>Boldrin L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_12934_24_23959991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8D355E5-E683-42C1-8033-01134B53B480</gtr:id><gtr:title>Pathogenic mitochondrial mt-tRNA(Ala) variants are uniquely associated with isolated myopathy.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce0a0e0400ee574b2ff1f4f75d7e293"><gtr:id>1ce0a0e0400ee574b2ff1f4f75d7e293</gtr:id><gtr:otherNames>Lehmann D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>56c3232dd6da71.54117427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FE0090E-1AAA-469A-9EEC-D0A9D4F7E1DB</gtr:id><gtr:title>Biallelic Mutations in NBAS Cause Recurrent Acute Liver Failure with Onset in Infancy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d3a74312ac86d45efc47ac78a3c98c"><gtr:id>35d3a74312ac86d45efc47ac78a3c98c</gtr:id><gtr:otherNames>Haack TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56c3208e9fcf08.75145587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72A241EF-C6E3-46BF-B669-6404B81BD972</gtr:id><gtr:title>Universal heteroplasmy of human mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23077218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA9CE4CF-5333-4AD1-878C-2EDAC2D48037</gtr:id><gtr:title>HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb9c5d48c8dcf4897e3817b8dc39687d"><gtr:id>eb9c5d48c8dcf4897e3817b8dc39687d</gtr:id><gtr:otherNames>Mielcarek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56b4be10a47b34.28221965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF8A10B7-E7B6-4964-9E45-991DDA6697A7</gtr:id><gtr:title>Gene therapy in epilepsy-is it time for clinical trials?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>5460c071847f26.10585722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7580B9AD-C86A-4A0D-BA30-021B167B6428</gtr:id><gtr:title>One contact for every twelve residues allows robust and accurate topology-level protein structure modeling.</gtr:title><gtr:parentPublicationTitle>Proteins</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/683219b49dae18c6a120fd7d069274fb"><gtr:id>683219b49dae18c6a120fd7d069274fb</gtr:id><gtr:otherNames>Kim DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-3585</gtr:issn><gtr:outcomeId>5460c4b8053091.75607531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99B6A0DF-F9B9-4832-8452-10BE3C82CABD</gtr:id><gtr:title>Strictly lobar microbleeds are associated with executive impairment in patients with ischemic stroke or transient ischemic attack.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba9d68534dd470811270aaaefa44e903"><gtr:id>ba9d68534dd470811270aaaefa44e903</gtr:id><gtr:otherNames>Gregoire SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_12934_24_23482601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CBDC7A9-E149-41CE-8FCE-943AF750BAD1</gtr:id><gtr:title>Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5268921a2133166b5abb02286a543bce"><gtr:id>5268921a2133166b5abb02286a543bce</gtr:id><gtr:otherNames>Sadjadi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5697a819bf8cb8.58760635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D53FADC2-301A-435C-BF63-EB047BA7ECB6</gtr:id><gtr:title>Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110e3dc589769ce84dec29b85162fcd3"><gtr:id>110e3dc589769ce84dec29b85162fcd3</gtr:id><gtr:otherNames>Sitarz KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>5458bda5def466.84863785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3874F52D-744E-4502-81A1-70CD88A551F4</gtr:id><gtr:title>Undiagnosed genetic muscle disease in the north of England: an in depth phenotype analysis.</gtr:title><gtr:parentPublicationTitle>PLoS currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b5de1d981332a350b2c81c56a19507c"><gtr:id>4b5de1d981332a350b2c81c56a19507c</gtr:id><gtr:otherNames>Harris E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-3999</gtr:issn><gtr:outcomeId>pm_12934_24_23788081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B758D21-3366-4898-B7FF-C6B9A055F8CC</gtr:id><gtr:title>Novel MTND1 mutations cause isolated exercise intolerance, complex I deficiency and increased assembly factor expression.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>56c46e04057842.46163072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44509EA3-2FFA-4128-88D4-753E0B390794</gtr:id><gtr:title>LRPPRC mutations cause early-onset multisystem mitochondrial disease outside of the French-Canadian population.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcd740097cdb9f5d82285952eb54e32e"><gtr:id>dcd740097cdb9f5d82285952eb54e32e</gtr:id><gtr:otherNames>Ol?hov? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56c31f14bfd253.04939879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44C45D3E-18FF-46BC-B060-476A00738727</gtr:id><gtr:title>MPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in Mitochondria.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca3c3837edc29825f95fc70a324f122a"><gtr:id>ca3c3837edc29825f95fc70a324f122a</gtr:id><gtr:otherNames>Dalla Rosa I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56c31f143e8981.52632989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52D2C6E8-E9B2-41EC-BB43-DA37AE08F152</gtr:id><gtr:title>Tackling obstacles for gene therapy targeting neurons: disrupting perineural nets with hyaluronidase improves transduction.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/823ca74e9959990c065d8bada97e6f01"><gtr:id>823ca74e9959990c065d8bada97e6f01</gtr:id><gtr:otherNames>Wanisch K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460c7e0bebb24.23043222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24E2CB59-C36C-40F1-BE4D-B5D9C3C91C36</gtr:id><gtr:title>Long-term survival in a child with severe encephalopathy, multiple respiratory chain deficiency and GFM1 mutations.</gtr:title><gtr:parentPublicationTitle>Frontiers in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0ca88c2a9b4a93b445d496f296fc137"><gtr:id>e0ca88c2a9b4a93b445d496f296fc137</gtr:id><gtr:otherNames>Brito S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-8021</gtr:issn><gtr:outcomeId>56c3232ee0b303.52075127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC519491-E14B-4F56-8562-F522C55ACCF9</gtr:id><gtr:title>De novo KCNA2 mutations cause hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ffda67425e994f02c670de63593986"><gtr:id>c9ffda67425e994f02c670de63593986</gtr:id><gtr:otherNames>Manole A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5a79d6252bfca2.11252337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>796FE4C7-BFB7-423A-8894-700E0177BEA7</gtr:id><gtr:title>Mitochondrial Donation - Clearing the Final Regulatory Hurdle in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a341f0d561136c211aae3d422891fb72"><gtr:id>a341f0d561136c211aae3d422891fb72</gtr:id><gtr:otherNames>Herbert M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a5f5578674750.83640193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60A74FD6-CBBD-49E3-9F04-38E19389BD39</gtr:id><gtr:title>Rasch-ionale for neurologists.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12cffd5a1b1a9a5423d7304520481af6"><gtr:id>12cffd5a1b1a9a5423d7304520481af6</gtr:id><gtr:otherNames>Vanhoutte EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>56b88830d77b28.80253556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364DD2F9-7B9C-4357-8DEA-FDD7A54C0B87</gtr:id><gtr:title>DNA testing in hereditary neuropathies.</gtr:title><gtr:parentPublicationTitle>Handbook of clinical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6742175c859dc2842759f84e6dd6f0e6"><gtr:id>6742175c859dc2842759f84e6dd6f0e6</gtr:id><gtr:otherNames>Murphy SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0072-9752</gtr:issn><gtr:outcomeId>pm_12934_24_23931782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F7298E0-1B73-42BB-A962-0D43D890E49F</gtr:id><gtr:title>Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuropediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ce43b3e217926531d4ee964ce527ece"><gtr:id>5ce43b3e217926531d4ee964ce527ece</gtr:id><gtr:otherNames>Wood CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0174-304X</gtr:issn><gtr:outcomeId>56d47426c64dc3.32447773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>854B2A19-5071-4BA7-89F9-F184714A299D</gtr:id><gtr:title>Investigating the role of the physiological isoform switch of cytochrome c oxidase subunits in reversible mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d75d3b4b9bf032eb6ff10990933d59"><gtr:id>e5d75d3b4b9bf032eb6ff10990933d59</gtr:id><gtr:otherNames>Boczonadi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>56b4b3c8b74d10.95171257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2555FB4-31F5-4DC1-90B1-8BD12BD9624E</gtr:id><gtr:title>Rodent models of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52d08fa06edfabbc102dfeef4a0e4f35"><gtr:id>52d08fa06edfabbc102dfeef4a0e4f35</gtr:id><gtr:otherNames>McGoldrick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_12934_24_23524377</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62D696B8-3BE7-45B0-A4FF-8FF012DD1A6F</gtr:id><gtr:title>Reply: Early-onset Behr syndrome due to compound heterozygous mutations in OPA1.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458bb0c3a4e85.44823568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0947E332-4074-476F-BE9E-C3108600B00C</gtr:id><gtr:title>A novel mitochondrial DNA m.7507A&amp;gt;G mutation is only pathogenic at high levels of heteroplasmy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/927b9eac65caf659704ceb26544a39cd"><gtr:id>927b9eac65caf659704ceb26544a39cd</gtr:id><gtr:otherNames>McCann BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56c3232f87a8d1.42417319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3044581-4C15-4410-B312-61DAC1233BCB</gtr:id><gtr:title>The Role of Calcium Channels in Epilepsy.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>56dd6300a2b1c0.92235475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BA6C9DE-605B-4276-965E-1AE9A798D409</gtr:id><gtr:title>Detrusor overactivity in Becker muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76afd7de3dc2cce787bb9810fab22a5c"><gtr:id>76afd7de3dc2cce787bb9810fab22a5c</gtr:id><gtr:otherNames>Smith MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23382079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3632625B-FFB9-4A1E-9F31-B1AA2AE9FEA0</gtr:id><gtr:title>Erratum to: Charcot-Marie-Tooth disease type 2C and scapuloperoneal muscular atrophy overlap syndrome in a patient with the R232C TRPV4 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0141d4dc212d3dc1de00d97ceee75f7"><gtr:id>a0141d4dc212d3dc1de00d97ceee75f7</gtr:id><gtr:otherNames>Koutsis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5697a8af19ce60.26733150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C18DB346-52C1-488E-8DAD-E7C83E35688E</gtr:id><gtr:title>Review of the Diagnosis and Treatment of Periodic Paralysis.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298bb180e38e48cf69bf03d814af75c8"><gtr:id>298bb180e38e48cf69bf03d814af75c8</gtr:id><gtr:otherNames>Statland JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>5a79d62733df07.69494916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCBFE59F-8274-4EAA-B9F1-17DD32486E0C</gtr:id><gtr:title>A multicentre postal survey investigating the contribution of illness perceptions, coping and optimism to quality of life and mood in adults with muscle disease.</gtr:title><gtr:parentPublicationTitle>Clinical rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01b4347d360aba57a8c1c4ced2e3873c"><gtr:id>01b4347d360aba57a8c1c4ced2e3873c</gtr:id><gtr:otherNames>Graham CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-2155</gtr:issn><gtr:outcomeId>5458b815363f37.26861051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2089BF9E-9D9D-45C1-93C6-9E4C7CCB5423</gtr:id><gtr:title>Aggregated a-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/698dce08335e33c54f81143559203d23"><gtr:id>698dce08335e33c54f81143559203d23</gtr:id><gtr:otherNames>Reeve AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dee34482fbc3.02655429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1CD6E22-8EBA-4230-AECF-473EEBDA3D66</gtr:id><gtr:title>Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Child: care, health and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25aec2e2ccedc799abc36f4ac2f05229"><gtr:id>25aec2e2ccedc799abc36f4ac2f05229</gtr:id><gtr:otherNames>Garralda ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1862</gtr:issn><gtr:outcomeId>pm_12934_24_22676208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A8DB244-13F6-4169-94DB-93499601D976</gtr:id><gtr:title>Accurate measurement of mitochondrial DNA deletion level and copy number differences in human skeletal muscle.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74f2fa9963b7ec34c3908d8b43ff9534"><gtr:id>74f2fa9963b7ec34c3908d8b43ff9534</gtr:id><gtr:otherNames>Grady JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d9b513b57ae4.09915764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4341723E-E773-400C-B7B7-5C1754425BFF</gtr:id><gtr:title>Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18692bc909f1f653c05eed67803ff70d"><gtr:id>18692bc909f1f653c05eed67803ff70d</gtr:id><gtr:otherNames>Lorenzoni PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>pm_12934_24_23790237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B24071-0EFD-497C-994F-1CA4C8D98869</gtr:id><gtr:title>Late-onset sacsinopathy diagnosed by exome sequencing and comparative genomic hybridization.</gtr:title><gtr:parentPublicationTitle>Journal of neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec7e888ca27cb54fb6a199e4662974"><gtr:id>6aec7e888ca27cb54fb6a199e4662974</gtr:id><gtr:otherNames>Pyle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-7063</gtr:issn><gtr:outcomeId>5458ca437749c8.55978159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>304BF68C-650F-4C9A-A628-E161862AE28B</gtr:id><gtr:title>Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6eb36c645750836ba7b7fb501797c8d9"><gtr:id>6eb36c645750836ba7b7fb501797c8d9</gtr:id><gtr:otherNames>Klopstock T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458d3bfba4158.81793050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55861358-513D-43DD-8327-6CB22DBDC3A6</gtr:id><gtr:title>Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/666c1bca35822325694519446dc7f903"><gtr:id>666c1bca35822325694519446dc7f903</gtr:id><gtr:otherNames>Weckhuysen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_24107868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42662222-AFA2-4DE2-806A-67863F21B745</gtr:id><gtr:title>Lithium, gray matter, and magnetic resonance imaging signal.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/461cea49c6f21c2dac4c71e5676fb433"><gtr:id>461cea49c6f21c2dac4c71e5676fb433</gtr:id><gtr:otherNames>Cousins DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_12934_24_23158114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36737045-6011-4128-9449-A39016D671AA</gtr:id><gtr:title>Gene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5264b9f5894cbb82c704238d5daf5d9e"><gtr:id>5264b9f5894cbb82c704238d5daf5d9e</gtr:id><gtr:otherNames>Paco S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460c4b8329d97.62545542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CA37127-C5C2-4001-967A-5D849FE04767</gtr:id><gtr:title>Long-term follow-up in patients with CCFDN syndrome.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d77f4a974d7dca691474e7790a715fd2"><gtr:id>d77f4a974d7dca691474e7790a715fd2</gtr:id><gtr:otherNames>Walter MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56d47b0f9a4526.44592638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43D4B461-F0FC-473C-8798-03202BCB673C</gtr:id><gtr:title>Midbrain encephalitis associated with neoplasia.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d4e75b0b24c77827977eb5ea7014ffb"><gtr:id>1d4e75b0b24c77827977eb5ea7014ffb</gtr:id><gtr:otherNames>Nitkunan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>5460c2327b22e8.56432578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97B10A1B-882D-45B0-9A03-5044573A4554</gtr:id><gtr:title>Endocrine disorders in mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31c1147d31fcaeb7a6be3151b14a7bc9"><gtr:id>31c1147d31fcaeb7a6be3151b14a7bc9</gtr:id><gtr:otherNames>Schaefer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>pm_12934_24_23769710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C75D417-EDCC-4FEE-A927-56270849D976</gtr:id><gtr:title>Erratum to: Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ade32be540517fb772d6b8c51f53d7fd"><gtr:id>ade32be540517fb772d6b8c51f53d7fd</gtr:id><gtr:otherNames>Nisar R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>56c3232e240276.68552581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>919D43DD-1782-4E8F-9033-14F9F7AB0A31</gtr:id><gtr:title>Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c7b8d6c569bacbc7eda897c0862fd62"><gtr:id>1c7b8d6c569bacbc7eda897c0862fd62</gtr:id><gtr:otherNames>Dlamini N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_12934_24_23628358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57640902-FF68-4F99-9AE7-9645370991E3</gtr:id><gtr:title>Does posterior cortical atrophy on MRI discriminate between Alzheimer's disease, dementia with Lewy bodies, and normal aging?</gtr:title><gtr:parentPublicationTitle>International psychogeriatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b58169927dd8191c54379c43c071a533"><gtr:id>b58169927dd8191c54379c43c071a533</gtr:id><gtr:otherNames>O'Donovan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1041-6102</gtr:issn><gtr:outcomeId>pm_12934_24_22809815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0AE1A7F-80E9-4C53-AADF-7BB58A4D5053</gtr:id><gtr:title>Neurological manifestations of influenza infection in children and adults: results of a National British Surveillance Study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e27e90e3a34fb56c841c712dd8e066"><gtr:id>66e27e90e3a34fb56c841c712dd8e066</gtr:id><gtr:otherNames>Goenka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5460c231af27a4.71462233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23401CE9-B65C-4569-AC02-282996AD5A66</gtr:id><gtr:title>Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62d8f1d9d22814edd5c9efffcb8906b5"><gtr:id>62d8f1d9d22814edd5c9efffcb8906b5</gtr:id><gtr:otherNames>Blain A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12934_24_23437355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DC64E9C-E052-496C-8529-E5D1FFB49428</gtr:id><gtr:title>Early detection of nerve injury in transthyretin-related familial amyloid polyneuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81487feecd00f449b4f5dac70d19f178"><gtr:id>81487feecd00f449b4f5dac70d19f178</gtr:id><gtr:otherNames>Morrow JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5697a819e9a8a4.73330410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0D3E2FC-6C2B-4EB2-B2F9-2353A37D900D</gtr:id><gtr:title>An unusual presentation for SOD1-ALS: isolated facial diplegia.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23873540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CFD59B2-B86B-4831-84BC-4C2E3F2E38BC</gtr:id><gtr:title>Corticosteroids in Duchenne muscular dystrophy: major variations in practice.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76024b6c132434b2fa75d24fc6457614"><gtr:id>76024b6c132434b2fa75d24fc6457614</gtr:id><gtr:otherNames>Griggs RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23483575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D20B4D-648C-4DE1-8A66-312617DD6D9C</gtr:id><gtr:title>The clinical, biochemical and genetic features associated with RMND1-related mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4767d613694b160a2224099a0d07c0e9"><gtr:id>4767d613694b160a2224099a0d07c0e9</gtr:id><gtr:otherNames>Ng YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>5a35e49ead6b00.23069463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F6240D-C543-4388-95DB-6ADB092F9863</gtr:id><gtr:title>Reply: Parsing the differences in affected with LHON: genetic versus environmental triggers of disease conversion.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56d470e80f1870.60487081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9013DF3D-DD76-459D-B795-1B5FC6274A11</gtr:id><gtr:title>Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/825d0259f7e674c13c04db9eecf8d8a6"><gtr:id>825d0259f7e674c13c04db9eecf8d8a6</gtr:id><gtr:otherNames>Rolfs A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_12934_24_23306324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08BFD8CA-E989-4753-8471-5770BE03D2BF</gtr:id><gtr:title>Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fac2bf702bb6fab99707746dd8dc925a"><gtr:id>fac2bf702bb6fab99707746dd8dc925a</gtr:id><gtr:otherNames>Sansone VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56dd63015b2288.07554226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA694451-D1D5-4C0E-9A24-AC4B970A18C1</gtr:id><gtr:title>Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af0b91a7a22116e669645bb3d679ca44"><gtr:id>af0b91a7a22116e669645bb3d679ca44</gtr:id><gtr:otherNames>Bros-Facer V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5458f6ec47b2d3.35702636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5413459B-956E-4D4B-BC2F-D781707644BB</gtr:id><gtr:title>Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2037935ce06a692140907215e31999d"><gtr:id>d2037935ce06a692140907215e31999d</gtr:id><gtr:otherNames>Naccache SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56b8883446def3.22220326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B7CA13E-BAF8-4A51-9F51-8DEE368283C5</gtr:id><gtr:title>Triplex real-time PCR--an improved method to detect a wide spectrum of mitochondrial DNA deletions in single cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbb354db3fe15f02e9119f525c22a31a"><gtr:id>dbb354db3fe15f02e9119f525c22a31a</gtr:id><gtr:otherNames>Rygiel KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56c3208ed4e6c3.22039750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9D2E030-F22F-438F-8B24-4B8714688A2E</gtr:id><gtr:title>Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d77f4a974d7dca691474e7790a715fd2"><gtr:id>d77f4a974d7dca691474e7790a715fd2</gtr:id><gtr:otherNames>Walter MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>pm_12934_24_23406536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49DD5362-C14E-4DF3-811F-71019CF8C774</gtr:id><gtr:title>ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3594f340e4a1627490ba4eeba3e02389"><gtr:id>3594f340e4a1627490ba4eeba3e02389</gtr:id><gtr:otherNames>Sarkozy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>doi_12934_humu_22342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F83B9318-35D6-4D7C-BD70-9EA269D5E0A5</gtr:id><gtr:title>Sar1 GTPase Activity Is Regulated by Membrane Curvature.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6245cdf1f398ae02b2a5aeee3d80c215"><gtr:id>6245cdf1f398ae02b2a5aeee3d80c215</gtr:id><gtr:otherNames>Hanna MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56dd62ffb86b50.22032001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91353F4D-8DFB-415A-BCDD-4FC208A31725</gtr:id><gtr:title>The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fadb846c4bf0f743bd514b4d59eb4741"><gtr:id>fadb846c4bf0f743bd514b4d59eb4741</gtr:id><gtr:otherNames>Massey LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23616165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A524470-C6F3-4671-8C49-034C996C27AF</gtr:id><gtr:title>The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82f3f1ff420153814bc3aa407bed051"><gtr:id>f82f3f1ff420153814bc3aa407bed051</gtr:id><gtr:otherNames>Rodger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>pm_12934_24_24148153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17BF145B-841B-40D6-B1CE-9327E1F53163</gtr:id><gtr:title>Late-onset respiratory failure due to TK2 mutations causing multiple mtDNA deletions.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9fed88b0ab0044cbcece97c7fd87c62"><gtr:id>b9fed88b0ab0044cbcece97c7fd87c62</gtr:id><gtr:otherNames>Alston CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_24198295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9FA3345-A70C-4C6E-BA53-107CCD4D7683</gtr:id><gtr:title>Disease progression in patients with single, large-scale mitochondrial DNA deletions.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74f2fa9963b7ec34c3908d8b43ff9534"><gtr:id>74f2fa9963b7ec34c3908d8b43ff9534</gtr:id><gtr:otherNames>Grady JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458f4cef25cf7.76590473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7B8FFEC-1422-4D9C-83EE-D075384D5B8C</gtr:id><gtr:title>Cortical and Subcortical Changes in Alzheimer's Disease: A Longitudinal and Quantitative MRI Study.</gtr:title><gtr:parentPublicationTitle>Current Alzheimer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16c121382f6709092a03a017793856f8"><gtr:id>16c121382f6709092a03a017793856f8</gtr:id><gtr:otherNames>Su L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1567-2050</gtr:issn><gtr:outcomeId>56c3507bea7672.99154774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56F38506-C31B-4365-B2D2-3303D69A4D6B</gtr:id><gtr:title>Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or 'classical' congenital myopathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06fb00e3407c420486bc732c34b07c14"><gtr:id>06fb00e3407c420486bc732c34b07c14</gtr:id><gtr:otherNames>Zaharieva IT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56dd6300771797.55970658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC24E6A8-4B9A-41C5-9B6E-573630CA8D4B</gtr:id><gtr:title>SIL1-related Marinesco-Sjoegren syndrome (MSS) with associated motor neuronopathy and bradykinetic movement disorder.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d17c7bc339ab8d1e53a665e22a4f259"><gtr:id>9d17c7bc339ab8d1e53a665e22a4f259</gtr:id><gtr:otherNames>Byrne S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56b214a7388211.27404308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>466959F4-EBC3-4E75-AEAA-F6A6DCCBD988</gtr:id><gtr:title>Mitochondrial morphology, topology, and membrane interactions in skeletal muscle: a quantitative three-dimensional electron microscopy study.</gtr:title><gtr:parentPublicationTitle>Journal of applied physiology (Bethesda, Md. : 1985)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fbb8678528f8cb634deb50d424fecf2"><gtr:id>0fbb8678528f8cb634deb50d424fecf2</gtr:id><gtr:otherNames>Picard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-7567</gtr:issn><gtr:outcomeId>pm_12934_24_23104694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>144072D1-F8B6-4D13-8FB6-1770A59DE56A</gtr:id><gtr:title>Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4767d613694b160a2224099a0d07c0e9"><gtr:id>4767d613694b160a2224099a0d07c0e9</gtr:id><gtr:otherNames>Ng YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>58a7110608c3c0.92938339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>703706AA-87BC-450B-A828-B9B7AF69CA08</gtr:id><gtr:title>Improved anatomical reproducibility in quantitative lower-limb muscle MRI.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77c9184fe547f4504dc1a1a7ed3f5944"><gtr:id>77c9184fe547f4504dc1a1a7ed3f5944</gtr:id><gtr:otherNames>Fischmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>pm_12934_24_24123788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96A9FBB4-685A-4479-AAB0-7D6B749C033F</gtr:id><gtr:title>Objective Bayesian fMRI analysis-a pilot study in different clinical environments.</gtr:title><gtr:parentPublicationTitle>Frontiers in neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a3f3c454c52de2dc96bb28ab5c336a0"><gtr:id>6a3f3c454c52de2dc96bb28ab5c336a0</gtr:id><gtr:otherNames>Magerkurth J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-453X</gtr:issn><gtr:outcomeId>56c46678516b85.12018360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77787B82-19E3-47FF-972A-017E6450066B</gtr:id><gtr:title>Rare disease centers for periodic paralysis: China versus the United States and United Kingdom.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2cdbe57f47f9e20614d40c1e2df895e"><gtr:id>e2cdbe57f47f9e20614d40c1e2df895e</gtr:id><gtr:otherNames>Ke Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>5458f7d370bbd4.77151365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF8FB293-9B10-4AE7-B0B9-E9E16215CA15</gtr:id><gtr:title>Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd1178cb31862466822a3cecfd2c7d08"><gtr:id>dd1178cb31862466822a3cecfd2c7d08</gtr:id><gtr:otherNames>Kmoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d470ea8fedf7.19090034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F174E8FE-361F-4AF7-9402-FF7A31EE6272</gtr:id><gtr:title>Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcb877e01dd9f33040f7fc09646ce4b6"><gtr:id>bcb877e01dd9f33040f7fc09646ce4b6</gtr:id><gtr:otherNames>Cottenie E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>doi_55f98498437608b5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B9D201-2D15-4A4D-B52E-DE183FC54A4A</gtr:id><gtr:title>Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/002dc518113cfcd49df817b7f8935a46"><gtr:id>002dc518113cfcd49df817b7f8935a46</gtr:id><gtr:otherNames>Scoto M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>doi_55f984984403a692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C701A4FC-C13F-4D11-953A-4D012DDAE357</gtr:id><gtr:title>Re-evaluation of the phenotype caused by the common MATR3 p.Ser85Cys mutation in a new family.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f4a87b832cb2cc32c28e245fbfc130"><gtr:id>02f4a87b832cb2cc32c28e245fbfc130</gtr:id><gtr:otherNames>Palmio J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d47427c80374.75664059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC709628-D097-4E7C-959E-EB4E1A5F5214</gtr:id><gtr:title>Diagnosis of skeletal muscle channelopathies.</gtr:title><gtr:parentPublicationTitle>Expert opinion on medical diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1753-0059</gtr:issn><gtr:outcomeId>pm_12934_24_24066928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ADC2B32-C91A-4418-8CC9-8C992FF34404</gtr:id><gtr:title>Clinical reasoning: a 39-year-old man with abdominal cramps.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9467e3f5cdd5f25380938d6a1a35daa0"><gtr:id>9467e3f5cdd5f25380938d6a1a35daa0</gtr:id><gtr:otherNames>Jaiser SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12934_24_23836948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2B9E4C6-9DB1-4F15-9827-3D0AEEF82DCB</gtr:id><gtr:title>Mitochondrial DNA and traumatic brain injury.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdfbfb91a7b47bc5eee1c33f01a89c8d"><gtr:id>cdfbfb91a7b47bc5eee1c33f01a89c8d</gtr:id><gtr:otherNames>Bulstrode H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5458bda6886031.07329766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5F7D14A-683C-4FB3-9131-3BB76664172E</gtr:id><gtr:title>KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa72e1487b5c9616d7251983f1a41ed9"><gtr:id>aa72e1487b5c9616d7251983f1a41ed9</gtr:id><gtr:otherNames>Natera-de Benito D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d47b0ce3dc38.44979794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5603B496-8E9D-47B6-ABB4-46135F64FAA8</gtr:id><gtr:title>In vivo mitochondrial function in HIV-infected persons treated with contemporary anti-retroviral therapy: a magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458bda6af4698.40822647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B9BCAE6-0F15-4F19-801B-5C1B3E174CF1</gtr:id><gtr:title>Mitochondrial dynamics and quality control in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ab95560c5f1e023382cb34f11fcc3c"><gtr:id>d4ab95560c5f1e023382cb34f11fcc3c</gtr:id><gtr:otherNames>Guedes-Dias P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>56c328748a3e65.34242857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1A6B53C-2986-4D12-A621-D1955841DDD4</gtr:id><gtr:title>Congenital myasthenic syndrome due to choline acetyltransferase mutations in infants: clinical suspicion and comprehensive electrophysiological assessment are important for early diagnosis.</gtr:title><gtr:parentPublicationTitle>Journal of child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04410a162d08784a75b26f90f55df43c"><gtr:id>04410a162d08784a75b26f90f55df43c</gtr:id><gtr:otherNames>Dilena R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0883-0738</gtr:issn><gtr:outcomeId>pm_12934_24_23292760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B5286DC-6E51-441F-BA98-B06DE3716BF3</gtr:id><gtr:title>Naked mole-rats maintain healthy skeletal muscle and Complex IV mitochondrial enzyme function into old age.</gtr:title><gtr:parentPublicationTitle>Aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e474c1b9f4c9752681f2586b35687d7b"><gtr:id>e474c1b9f4c9752681f2586b35687d7b</gtr:id><gtr:otherNames>Stoll EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-4589</gtr:issn><gtr:outcomeId>58a71105caf005.83244147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82C31A42-21E7-43A5-A0C4-09E9DF9684DB</gtr:id><gtr:title>From treatment to cure: stopping seizures, preventing seizures, and reducing brain propensity to seize.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>5460c7e0335a93.84843750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C714ED30-B927-4A96-ACD4-A3A4A70B013D</gtr:id><gtr:title>A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92036d9b29125add13836e8d7b90148b"><gtr:id>92036d9b29125add13836e8d7b90148b</gtr:id><gtr:otherNames>Rocha MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56c31f14ed4cf1.36519175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE1C1382-B7BE-41FC-8F51-2431953D16AD</gtr:id><gtr:title>Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5458f56e8b1b48.76719747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>398545E0-DCE9-4B7B-AF3F-05806A20E1B7</gtr:id><gtr:title>Use of stereotypical mutational motifs to define resolution limits for the ultra-deep resequencing of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da7de470552fbe19eaeccb55dde6bf0e"><gtr:id>da7de470552fbe19eaeccb55dde6bf0e</gtr:id><gtr:otherNames>Gardner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>5458bda5b76eb5.21502625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>430D07B1-6695-4157-AECD-F70F70FB6864</gtr:id><gtr:title>LOBAR DISTRIBUTION OF CORTICAL GREY MATTER LESIONS IN MULTIPLE SCLEROSIS CLINICAL SUBGROUPS</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc8c731efc252ae7b6b32a34775a2159"><gtr:id>fc8c731efc252ae7b6b32a34775a2159</gtr:id><gtr:otherNames>Sethi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12934_24_24108965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6D9FE34-7E3F-48AF-B83D-7B0DE5217E98</gtr:id><gtr:title>Tremor in inflammatory neuropathies.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f175735d8ce083c048d9ac312841f7d2"><gtr:id>f175735d8ce083c048d9ac312841f7d2</gtr:id><gtr:otherNames>Saifee TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12934_24_22952325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>949E2AA3-7FA0-4675-89BF-C465CB68B6F7</gtr:id><gtr:title>Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b4b3c6527439.42013996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7582757C-A50E-421E-A357-D820C7CAADBA</gtr:id><gtr:title>A national perspective on prenatal testing for mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f5a64e763cce75d1f562606ee76e5bc"><gtr:id>7f5a64e763cce75d1f562606ee76e5bc</gtr:id><gtr:otherNames>Nesbitt V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>5460c33d22dc04.45858672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9762747-4FAC-431B-AD99-82E21F3742B2</gtr:id><gtr:title>Reply: Hereditary myopathy with early respiratory failure is caused by mutations in the titin FN3 119 domain.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5458c7e81ba487.86054770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8A02E99-45E2-469A-B2C8-06550111299E</gtr:id><gtr:title>Clinicopathologic and molecular spectrum of-related mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Neurology. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d1503307a90897a52487453a039bddd"><gtr:id>1d1503307a90897a52487453a039bddd</gtr:id><gtr:otherNames>Bugiardini E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2376-7839</gtr:issn><gtr:outcomeId>5a79d62659d931.44884005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8741B5D-F774-4ED8-88BD-05935F44852D</gtr:id><gtr:title>Defective i6A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic mutations in TRIT1 and its substrate tRNA.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_540e151e15192c06c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3200E6D-9727-4759-AD8F-8B86A9AD806B</gtr:id><gtr:title>Levothyroxine improves abnormal cardiac bioenergetics in subclinical hypothyroidism: a cardiac magnetic resonance spectroscopic study.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2ac7ea64a259779a38f305d4ec1eae8"><gtr:id>e2ac7ea64a259779a38f305d4ec1eae8</gtr:id><gtr:otherNames>Madathil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56c3507b5b5240.02835443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A19825-F274-4F13-A2BA-418A1806432A</gtr:id><gtr:title>Global opportunities and challenges for clinical neuroscience.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e574c13fe259a2453673d93c0c7c323e"><gtr:id>e574c13fe259a2453673d93c0c7c323e</gtr:id><gtr:otherNames>Birbeck GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>5458f909b72fc4.41310251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1C0B904-D8B8-4258-9A0C-10B31463C004</gtr:id><gtr:title>Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf878e42a37a7f62b5e7575b0a3a6e7"><gtr:id>bdf878e42a37a7f62b5e7575b0a3a6e7</gtr:id><gtr:otherNames>Hollingsworth KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_12934_24_23620230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E75A64A-3D24-44C3-B4C1-B4AD53B9D692</gtr:id><gtr:title>Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef1daab582c85c7641d8fd3dea00cc9e"><gtr:id>ef1daab582c85c7641d8fd3dea00cc9e</gtr:id><gtr:otherNames>Belaya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b214a6658296.20567142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23401C3B-D047-4999-9BB2-91C32FAB07F2</gtr:id><gtr:title>Structural connectivity in a paediatric case of anarchic hand syndrome.</gtr:title><gtr:parentPublicationTitle>BMC neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bbf817451900ead5c3e735b21e08a1e"><gtr:id>6bbf817451900ead5c3e735b21e08a1e</gtr:id><gtr:otherNames>Basu AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2377</gtr:issn><gtr:outcomeId>56c3507cec51b4.72408993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D55F104A-EFFE-4E49-9906-0437C90958B6</gtr:id><gtr:title>Expression of a pathogenic mutation of SOD1 sensitizes aprataxin-deficient cells and mice to oxidative stress and triggers hallmarks of premature ageing.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e3148d9ca42535ad1aa4cb73cd446de"><gtr:id>7e3148d9ca42535ad1aa4cb73cd446de</gtr:id><gtr:otherNames>Carroll J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56b4be10715804.78515932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A120EC6-7B16-4EFF-A008-5EC161DE12A8</gtr:id><gtr:title>How to spot mitochondrial disease in adults.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>pm_12934_24_23472503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70D681ED-2905-47E8-8CFA-C9CE48634F27</gtr:id><gtr:title>The m.3291T&amp;gt;C mt-tRNA(Leu(UUR)) mutation is definitely pathogenic and causes multisystem mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>pm_12934_24_23273904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73A84725-4195-40B7-8019-D7B60BA561F3</gtr:id><gtr:title>Molecular pathogenesis of polymerase ?-related neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ad31ee1a86f6ba14e92eb598b85fe9e"><gtr:id>3ad31ee1a86f6ba14e92eb598b85fe9e</gtr:id><gtr:otherNames>Tzoulis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5458bda53d22b2.99168763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E908E21-9D74-45CA-BA6B-8CD2B9F96A81</gtr:id><gtr:title>Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d665eeb541ee7870a0c405ab2dbaeb9"><gtr:id>7d665eeb541ee7870a0c405ab2dbaeb9</gtr:id><gtr:otherNames>Srinivasan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>56d47426f289a1.92870703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C9463B3-7B9D-4972-AD19-DA3CD6BB485B</gtr:id><gtr:title>No effect of AR polyG polymorphism on spinal and bulbar muscular atrophy phenotype.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0da5205014189b24ef547ea463228b"><gtr:id>0f0da5205014189b24ef547ea463228b</gtr:id><gtr:otherNames>Bertolin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>58a4551c35c9f7.93923471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B813E757-0613-471A-810E-C6D65CD02D1D</gtr:id><gtr:title>Recessive mutations in the a3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c1441f518485287ff8eac8491c7ae01"><gtr:id>6c1441f518485287ff8eac8491c7ae01</gtr:id><gtr:otherNames>Zech M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56d47b0d5dcea2.86661701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12FF56AB-6794-43D8-BD9A-D95C1E45016B</gtr:id><gtr:title>Assessment of regional gray matter loss in dementia with Lewy bodies: a surface-based MRI analysis.</gtr:title><gtr:parentPublicationTitle>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b129def860af32798ebfc1f9871af800"><gtr:id>b129def860af32798ebfc1f9871af800</gtr:id><gtr:otherNames>Watson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-7481</gtr:issn><gtr:outcomeId>56c3507aeeb124.55389466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90374043-A623-457C-B3EE-CC4C37058123</gtr:id><gtr:title>Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b20a673da2928886a7d7b4747a5253e1"><gtr:id>b20a673da2928886a7d7b4747a5253e1</gtr:id><gtr:otherNames>Huemer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>56c3208f9f1267.76896805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84D08210-C4CC-40E4-97EF-3B55616B1471</gtr:id><gtr:title>Extra-ocular muscle MRI in genetically-defined mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6459db0fb97de13ef30ce2614b06cb4a"><gtr:id>6459db0fb97de13ef30ce2614b06cb4a</gtr:id><gtr:otherNames>Pitceathly RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>56c4667778b402.84006603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EB9840B-5033-4BE5-A23B-3F024B501835</gtr:id><gtr:title>Ageing and Parkinson's disease: why is advancing age the biggest risk factor?</gtr:title><gtr:parentPublicationTitle>Ageing research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94d51a03b4c263995449304602baa470"><gtr:id>94d51a03b4c263995449304602baa470</gtr:id><gtr:otherNames>Reeve A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1568-1637</gtr:issn><gtr:outcomeId>5460caacbdf290.23735008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9342A73-A049-48D5-A478-593CAD7482AE</gtr:id><gtr:title>Ataluren treatment of patients with nonsense mutation dystrophinopathy.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f80ea9d5dda7d9892b34764e9832dc19"><gtr:id>f80ea9d5dda7d9892b34764e9832dc19</gtr:id><gtr:otherNames>Bushby K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>56d4742a2f38c3.88926452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CD425AF-C9C5-4586-937F-7E40B8CE4C7C</gtr:id><gtr:title>Treatment strategies for inherited optic neuropathies: past, present and future.</gtr:title><gtr:parentPublicationTitle>Eye (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-222X</gtr:issn><gtr:outcomeId>5458bda6355934.89518503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F90A196-34F5-407C-A195-B96DB672E139</gtr:id><gtr:title>Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a90a82436eee8eb4a9a25f757756064"><gtr:id>5a90a82436eee8eb4a9a25f757756064</gtr:id><gtr:otherNames>Sinha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5460bfab9d2d38.63662424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487A17A9-6795-4CEE-8FCC-2AFC474E2E42</gtr:id><gtr:title>Congenital myopathies: Natural history of a large pediatric cohort.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbdd9378b809ca153d26f98d44e292ef"><gtr:id>fbdd9378b809ca153d26f98d44e292ef</gtr:id><gtr:otherNames>Colombo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56b214a894f291.54573289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22418270-585B-41A7-8BEF-6FD038798368</gtr:id><gtr:title>Cytoplasmic dynein heavy chain: the servant of many masters.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c944bcf656a481a3b947faf567b80d7"><gtr:id>5c944bcf656a481a3b947faf567b80d7</gtr:id><gtr:otherNames>Schiavo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>pm_12934_24_24035135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08572876-80E6-469D-B708-F3CDBFCF2E20</gtr:id><gtr:title>Reply to: effects of lithium on magnetic resonance imaging signal might not preclude increases in brain volume after chronic lithium treatment.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8acaa87c16a6eab77b2261c478d85d4a"><gtr:id>8acaa87c16a6eab77b2261c478d85d4a</gtr:id><gtr:otherNames>Ferrier NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_12934_24_23993640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79B8625A-8A69-499C-AC88-89D37A3F5C71</gtr:id><gtr:title>Recent advances in the genetic neuropathies.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e200f814262dac4d6b88ac30584c047"><gtr:id>8e200f814262dac4d6b88ac30584c047</gtr:id><gtr:otherNames>Rossor AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>585d668886a411.58542127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A359426A-B796-4A0A-8D2A-022D4CCF8892</gtr:id><gtr:title>Congenital myopathy with &amp;quot;corona&amp;quot; fibres, selective muscle atrophy, and craniosynostosis associated with novel recessive mutations in SCN4A.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fdb992791004919fc73ebf904c4d7fb"><gtr:id>8fdb992791004919fc73ebf904c4d7fb</gtr:id><gtr:otherNames>Gonorazky HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5a79d6255326d7.84899453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2B6A20C-E9E3-4B00-AB39-D172FF283322</gtr:id><gtr:title>Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f46ce8597d265963cae03471c26f8e21"><gtr:id>f46ce8597d265963cae03471c26f8e21</gtr:id><gtr:otherNames>Zoltowska K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12934_24_23569079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA2EDF61-C3FF-41EB-8898-A4515FDA960A</gtr:id><gtr:title>The compound BTB06584 is an IF1 -dependent selective inhibitor of the mitochondrial F1 Fo-ATPase.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e61f06daff385c3ca0667886a18ea7"><gtr:id>01e61f06daff385c3ca0667886a18ea7</gtr:id><gtr:otherNames>Ivanes F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5458d3c0153fa6.48467670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3143C09F-AA01-4D8B-B498-C2A0BAFD08D5</gtr:id><gtr:title>Early neurodevelopmental assessment in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a07700458597bb17074c545f65ae73a"><gtr:id>9a07700458597bb17074c545f65ae73a</gtr:id><gtr:otherNames>Pane M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5460c4b8b3fb25.85749371</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000608/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>